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Some of your hurts you have cured, 
And the sharpest you still have survived, 
But what torments of grief you endured 
From the evil which never arrived. 
~Ralph Waldo Emerson (1803 – 1882) 
 
Never bear more than one kind of trouble at a time.  Some 
people bear three - all they have had, all they have now, and all 
they expect to have.   
~Edward Everett Hale (1822 – 1909) 
 
The greatest mistake you can make in life is to continually fear 
you will make one.   
~Elbert Hubbard (1856 – 1915) 
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ABSTRACT 
 
Anxiety disorders are psychiatric disorders, characterized by exaggerated, 
prolonged and debilitating levels of anxiety. Disorder-specific clinical 
characteristics of the anxiety are the basis for their subdivision into diseases 
such as panic disorder (PD), obsessive-compulsive disorder (OCD), post-
traumatic stress disorder (PTSD), generalized anxiety disorder (GAD), and 
phobias. Collectively, anxiety disorders form the most common group of 
mental disorders, annually affecting 14% of Europeans. Together with other 
mental disorders, they cause significant work disability and loss of quality of 
life, and are therefore of great importance for public health. 
Anxiety disorders are complex diseases with onset influenced by both 
environmental and genetic factors. Although susceptibility to anxiety 
disorders is clearly heritable, so far little progress has been made in 
identifying solid genetic susceptibility factors for them. The main aim of this 
study was to shed light on the genetic basis of human anxiety disorders by 
genetic association analyses of selected novel and previously implicated 
candidate genes in the Finnish population. 
Altogether, 333 single nucleotide polymorphism (SNP) markers from 30 
genes were tested for genetic association to anxiety disorders. The studied 
genes were 1) 13 genes selected based on expression levels correlating with 
anxiety-like behavior in a mouse model of inbred strains with differential 
innate anxiety; 2) an asthma-linked G-protein coupled receptor 
(neuropeptide S receptor 1; NPSR1) and its neuropeptide ligand 
(neuropeptide S; NPS); and 3) 15 putative anxiety susceptibility genes 
selected based on previously published associations with anxiety disorders or 
anxiety-related personality traits. All genes were initially studied in an 
anxiety disorder sample (N = 974) derived from the Finnish population-
based Health 2000 cohort. In this sample, we also evaluated gene-
environment interactions by examining whether any of the genotyped SNPs 
modulate probability for anxiety disorders in interaction with childhood 
adverse life events, one of the strongest known environmental risk factors for 
anxiety disorders. In addition to the Health 2000 sample, three other case-
control samples from Spain (N = 503), Sweden (N = 2020) and USA (N = 
1128) were used for replication attempts or meta-analyses. 
First, taking a cross-species approach, we discovered that six of the 
murine candidate genes (delta-aminolevulinate dehydratase [ALAD], 
cadherin 2 [CDH2], erythrocyte membrane protein band 4.1 like 4a 
[EPB41L4A], dynein light chain LC8-type 2 [DYNLL2], prosaposin [PSAP] 
and prostaglandin D2 synthase [PTGDS]) showed evidence for association 
with specific anxiety disorders in the Health 2000 sample. The six implicated 
genes link novel biochemical pathways to influencing anxiety susceptibility, 
but our findings should be replicated in independent samples as a next step. 
Second, both NPS and NPSR1 showed evidence for association with PD in 
the Health 2000 sample. SNPs in NPSR1 were further associated with 
6 
symptoms of anxiety/depression in 8-year children of a Swedish birth cohort. 
We further demonstrated that some of the most significantly associated SNPs 
in NPSR1 may alter transcription factor binding, and thereby influence the 
expression level of the gene. We also found that Npsr1-deficient mice (Npsr1-
/-) differ from wild types regarding at least some gene expression responses 
to acute stress. The neurotrophic factor neurotrophin 3 was downregulated 
in brains of stressed Npsr1-/- mice, whereas the stress-related 
immunotransmitter interleukin-1 beta was upregulated. Taken together, our 
findings suggest that NPS-NPSR1 signaling modulates predisposition not 
only to asthma, but also to anxiety disorders. 
Third, of the putative anxiety susceptibility genes examined based on 
previously published human association studies, the gene showing the 
strongest evidence for association in the Health 2000 sample was glutamate 
decarboxylase 1 (GAD1). This gene encodes the enzyme synthesizing the 
neurotransmitter gamma-aminobutyric acid (GABA) from glutamate. One 
specific common risk haplotype spanning the locus of the gene increased risk 
for phobias. As the identified haplotype was the same as implicated in a prior 
study, we performed a meta-analysis (N = 1985) incorporating our findings 
with the published ones. This analysis further supported the role of GAD1 as 
a joint risk factor for anxiety- and mood disorders, and neuroticism. 
Fourth, SNPs from the neuropeptide Y (NPY) gene, accounting for two 
phylogenetically related risk haplotypes, modulated the effects of the number 
of experienced childhood adversities on anxiety susceptibility in the Health 
2000 sample. Based on previous animal and human studies, NPY is a 
particularly good candidate for influencing individual variation in stress 
resilience. 
In conclusion, altogether ten potential susceptibility genes for anxiety 
disorders were identified in this study at the P ≤ 0.01 significance level. The 
identified genes illustrate the genetic and functional heterogeneity that likely 
underlies anxiety disorders, as they encode either enzymes, neuropeptides or 
their receptors, or structural proteins important for synapse formation. Our 
findings also support the notion that knowledge of the interplay between well 
established environmental risk factors and genetic variants is of great 
importance for understanding predisposition to psychiatric disorders. 
 We suggest that the top candidate genes based on this work be further 
evaluated in independent study samples, and studied functionally to 
understand how genetic variation in them influences their transcription, 
protein properties and ultimately the function of neural circuitry that 
regulates behavior. Such future studies will be essential for evaluating the 
therapeutic potential of targeting their biological pathways in treatment of 
anxiety disorders.   
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TIIVISTELMÄ 
 
Ahdistuneisuushäiriöt ovat psykiatrisia häiriöitä, joiden tunnusmerkki on 
liiallinen, pitkittynyt ja toimintakykyä alentava ahdistuneisuustaso. 
Tautispesifisten kliinisten ahdistuneisuusoireiden perusteella ne jaotellaan 
useampiin häiriöihin kuten paniikkihäiriö, pakko-oireinen häiriö, 
traumaperäinen stressihäiriö, yleistynyt ahdistuneisuushäiriö ja fobiat. 
Ryhmänä ahdistuneisuushäiriöt ovat yleisimpiä mielenterveyshäiriöitämme, 
joista kärsii 14% eurooppalaisista vuosittain. Yhdessä muiden 
mielenterveyshäiriöiden kanssa ne ovat merkittävä syy työkyvyttömyyteen ja 
heikentyneeseen elämänlaatuun. Näistä syistä ahdistuneisuushäiriöiden 
kansanterveydellinen merkitys on suuri. 
Ahdistuneisuushäiriöt ovat monitekijäisiä tauteja, joiden puhkeamiseen 
vaikuttavat sekä ympäristö- että geneettiset tekijät. Huolimatta siitä, että 
alttius ahdistuneisuushäiriöille on perinnöllinen, vankkoja geneettisiä 
alttiustekijöitä tunnetaan toistaiseksi heikosti. Tämän tutkimuksen 
päätavoitteena oli selvittää ahdistuneisuushäiriöiden perinnöllistä taustaa 
geneettisillä assosiaatioanalyyseillä, joissa tutkittiin sekä uusia että aiemmin 
ahdistuneisuuteen yhdistettyjä ehdokasgeenejä suomalaisväestössä.   
Arvioimme yhteensä 333 SNP:n eli yhden nukleotidin polymorfismin (30 
eri geenistä) mahdollista geneettistä assosiaatiota ahdistuneisuushäiriöihin. 
Tutkitut geenit olivat: 1) 13 geeniä joiden ilmenemistaso korreloi 
ahdistuneisuuskäyttäytymisen kanssa sisäsiittoisissa hiirikannoissa, joilla 
synnynnäinen ahdistuneisuustaso eroaa toisistaan; 2) astmaan yhdistetty G-
proteiinikytkentäinen reseptori (neuropeptidi S reseptori 1; NPSR1) ja sen 
ligandi, neuropeptidi S (NPS); sekä 3) 15 ehdokasgeeniä, jotka valittiin 
perustuen aikaisempiin assosiaatiolöydöksiin ahdistuneisuushäiriöissä tai 
ahdistuneisuutta mittaavissa persoonallisuuspiirteissä. Kaikkia geenejä 
tutkittiin ensin ahdistuneisuushäiriöaineistossa (N = 974), joka oli peräisin 
suomalaisesta Terveys 2000 (T2000) väestötutkimuksesta. Kyseisessä 
aineistossa tutkimme myös geeni-ympäristövuorovaikutuksia selvittämällä 
muokkaavatko jotkut SNP:stä alttiutta ahdistuneisuushäiriöille yhdessä 
lapsuusiän vastoinkäymisten kanssa. Lapsuusiän vastoinkäymiset ovat 
vahvimpia tunnettuja ympäristöllisiä riskitekijöitä ahdistuneisuushäiriöille. 
T2000 näytteen lisäksi käytimme kolmea muuta tapaus-verrokkiaineistoa 
Espanjasta (N = 503), Ruotsista (N = 2020) ja Yhdysvalloista (N = 1128) 
replikaatioaineistona tai meta-analyyseissä. 
Lajeja yhdistävän lähestymistavan avulla havaitsimme, että kuusi 
hiirimallien perusteella valittua ehdokasgeeniä (delta-aminolevulinaatti 
dehydrataasi [ALAD], kadheriini 2 [CDH2], erytrosyyttikalvoproteiinibändi  
4.1 kuten 4a [EPB41L4A], dyneiinin kevyt ketju LC8-tyyypi 2 [DYNLL2], 
prosaposiini [PSAP] ja prostaglandiini D2 syntaasi [PTGDS]) assosioituivat 
spesifisiin ahdistuneisuushäiriöihin T2000-aineistossa. Nämä kuusi geeniä 
yhdistävät uusia biologisia reittejä ahdistuneisuusalttiuteen, mutta 
löydöksemme tulee seuraavaksi toistaa riippumattomissa aineistoissa. 
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Sekä NPS että NPSR1 assosioituivat paniikkihäiriöön T2000-aineistossa. 
SNPt NPSR1:stä assosioituivat myös ahdistuneisuuden/masennuksen 
oireisiin 8-vuotiailla lapsilla ruotsalaisessa syntymäkohortissa. Osa 
merkitsevimmin assosioituvista SNP:stä NPSR1-geenissä saattavat vaikuttaa 
transkriptiofaktoreiden sitoutumiseen ja siten geenin ilmenemistasoon. 
Havaitsimme myös, että hiirillä joilta Npsr1 puuttuu (Npsr1-/-), on ainakin 
osittain poikkeava geenien ilmenemisvaste akuuttiin stressiin. Neurotrofinen 
tekijä neurotrofïini 3 ilmentyi alhaisemmalla tasolla stressattujen Npsr1-/- 
hiirten aivoissa, kun taas stressivasteeseen yhdistetyn immunovälittäjän 
interleukini-1 betan ilmentyminen oli korkeammalla tasolla. Löydöksemme 
viittaavat siihen, että NPS-NPSR1 signalointi muuntelee altiutta paitsi 
astmalle myös ahdistuneisuushäiriöille. 
Aikaisemmissa tutkimuksissa ahdistuneisuuteen assosiaatioanalyysein 
yhdistetyistä geeneistä merkitsevimmät löydöksemme T2000-aineistossa 
olivat glutamaattidekarboksylaasi 1 (GAD1) geenistä. Tämä geeni koodittaa 
entsyymiä, joka syntetisoi hermovälittäjäaine gamma-aminovoihappoa 
(GABA) glutamaatista. Tutkimuksessamme yksi yleinen koko geenilokuksen 
kattava riskihaplotyyppi lisäsi riskiä sairastua fobioihin. Tunnistettu 
riskhaplotyyppi oli sama kuin aikaisemmassa amerikkalaisaineistossa, joten 
teimme meta-analyysiin (N = 1985) jossa yhdistimme aineistomme siihen. 
Myös tämä analyysi tuki GAD1:n merkitystä jaettuna riskitekijänä 
ahdistuneisuus- ja mielialahäiriöille sekä neuroottisuudelle. 
SNP:t neuropeptidi Y (NPY)-geenistä, edustaen kahta fylogeneettisesti 
sukua olevaa riskihaplotyyppiä, muuntelivat koettujen lapsuusiän 
vastoinkäymisten määrän vaikutusta ahdistuneisuusaltiuteen T2000-
aineistossa. Aikaisemmat eläin- ja ihmistutkimukset tukevat NPY:n roolia 
yksilöllisen stressinsietokyvyn muuntelussa. 
Yhteenvetona tunnistimme tässä tutkimuksessa yhteensä kymmenen 
potentiaalista alttiusgeeniä ahdistuneisuushäiriöille merkitsevyystasolla P ≤ 
0.01. Tunnistetut geenit havainnollistavat ahdistuneisuushäiriöihin 
vaikuttavaa geneettistä ja toiminnallista monimuotoisuutta, sillä ne 
koodittavat joko entsyymejä, neuropeptidejä tai synapsien muodostumiselle 
tärkeitä rakenneproteiineja. Löydöksemme tukevat myös käsitystä, että 
vakiintuneiden ympäristöllisten riskitekijöiden ja geneettisten varianttien 
vuorovaikutusten tunteminen on tärkeää psykiatristen tautien alttiuden 
ymmärtämisessä.  
Ehdotamme, että parhaimpia tässä työssä tunnistettuja ehdokasgeenejä 
tutkitaan jatkossa riippumattomissa näytteissä sekä toiminnallisin kokein. 
Näin voimme ymmärtää, miten geneettinen variaatio vaikuttaa näiden 
geenien ilmenemiseen, proteiinien ominaisuuksiin ja lopulta käyttäytymistä 
säätelevien hermoverkkojen toimintaan. Tämänkaltaisia tutkimuksia 
tarvitaan jatkossa, jotta voidaan arvioida voisivatko tässä tutkimuksessa 
tunnistettujen geenien biologiset reitit olla sopivia kohteita 
ahdistuneisuushäiriöiden lääkehoidossa.  
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1 INTRODUCTION 
Anxiety and fear are a part of life. Whereas we fear an immediate and 
definite threat, such as an approaching stranger in a dark alley, we feel 
anxious in anticipation of future possible dangers and intangible threats. 
Anxiety is accompanied by emotional manifestations of uneasiness, worry, 
restlessness, despair, horror and panic. Somatically, anxiety is distinguished 
by a fight-or-flight response triggered by activation of the sympathetic 
nervous system. Increased heart rate, accelerated breathing, and sweating 
are meant to help the body perform better under threat. However, this comes 
with downsides like dizziness, choking sensations, tightness in the chest, 
chills, and dry mouth.  
Thus, normal anxiety is an adaptive response to potentially harmful 
situations. On the other hand, exaggerated anxiety may manifest as clinically 
diagnosable anxiety disorders, such as panic disorder, obsessive-compulsive 
disorder, post-traumatic stress disorder, generalized anxiety disorder, and 
phobias (American Psychiatric Association, 2000). The core feature of these 
mental disorders is excessive, prolonged and debilitating anxiety. Other 
specific features regarding focus, course, and onset of the anxiety are the 
basis for the clinical subdivision. A recent large cross-European study 
reported that 14.0% of Europeans annually suffer from anxiety disorders 
(Wittchen et al., 2011), making them not only detrimental to the individual, 
but also a common and costly burden for society via health care costs and 
work disability (Sillanpää et al., 2008).  
Evidence from twin- and family studies indicate a heritable, partially 
genetic basis for anxiety disorders (Hettema et al., 2001). Consequently, 
much effort has been put into identifying the specific genetic determinants of 
these complex disorders with the aim to obtain a better understanding of 
their biology and discover new potential targets for safer and more efficient 
anxiolytics. Although a great deal of knowledge has been gained regarding 
specific brain regions and neurotransmitter systems regulating anxiety, only 
a handful of solid susceptibility genes have been identified thus far. The main 
aim of this study was to investigate whether genetic variation in several 
putative candidate genes, both unexamined and previously implicated ones, 
predisposes to human anxiety disorders in the Finnish population.  
The following review of the literature describes the origins of human 
genetic variation and how it may manifest as disease phenotypes. Genetic 
mapping methods for identification of genes predisposing to complex 
disorders are reviewed, followed by a summary of the characteristics and 
genetics of anxiety disorders with a special emphasis on work that has lead to 
the identification of novel potential susceptibility genes for anxiety-related 
phenotypes.    
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2 REVIEW OF THE LITERATURE 
2.1 GENETICS OF DISEASES 
2.1.1 THE HUMAN GENOME 
 
Genetic information is stored in the base sequence of DNA, a linear double 
helical molecule composed of a sugar-phosphate backbone and the bases 
adenine (A), cytosine (C), guanine (G) and thymine (T). The sequence of the 
bases contains hereditary genetic instructions for the construction of 
proteins, and functional ribonucleic acid molecules.  
The human genome consists of around 3 billion base pairs (bp) of DNA, 
carried by 22 autosomal chromosome pairs and the sex-determining X and Y 
chromosomes in each cellular nucleus. In addition to the nuclear linear 
chromosomes, all mitochondria carry their own genome on a small 16.6 
kilobase (kb) circular DNA molecule. While inheritance of the nuclear 
genome is mediated by transmission of one copy of each homologous 
chromosome from the mother, and another copy from the father, inheritance 
of the mitochondrial genome is maternal. 
Both publically and privately funded consortia raced to sequence the 
human genome, with draft versions from both projects published 
simultaneously ahead of schedule in 2001 (Lander et al., 2001; Venter et al., 
2001). Availability of the sequence, and subsequent work, has lead to major 
insights regarding the organization of the human genome. We now know that 
it contains an estimated 20000 genes (Clamp et al., 2007), i.e. much less 
than previously thought. The complexity of humans and other vertebrates 
compared to worms or flies is rather the result of more complex gene 
structure and regulation, and alternative splicing of gene products. In fact, 
only around 2% of the genome encodes for protein-coding genes. Another 2% 
represents evolutionarily conserved non-coding regions that might be of 
functional importance (Dermitzakis et al., 2005). A large proportion of what 
was previously called non-coding “junk” DNA is now thought to encode 
functionally important non-protein coding RNA molecules (Wright and 
Bruford, 2011). Our genome is also rich in repeat sequences of varying 
length, and about half of it consists of sequences derived from transposable 
elements (Lander, 2011).  
Review of the literature 
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2.1.2 HUMAN GENETIC VARIATION 
 
The genome sequence of any two individuals is identical to 99.9%. The 
remaining varying 0.1% must thus be of particular importance in that it, 
together with environmental factors, determines individual variation in 
disease susceptibility.  
Genetic variation between individuals arises through three main 
mechanisms: random combination of male and female gametes during 
fertilization, independent assortment of chromosomes with crossovers 
during meiosis, and mutations. Of these mechanisms, mutations create novel 
alleles, whereas the others create unique combinations of alleles. 
Mutations, or changes in the base sequence of DNA, are the ultimate 
introducers of novel genetic variation into a population, and the raw material 
of evolution. It was estimated that each parent passes on an average of 30 de 
novo germline mutations to their offspring, although great variability exists 
(Conrad et al., 2011). Mutations can be the result of intracellular events such 
as errors in DNA replication and repair, or caused by external factors such as 
radiation or mutagenic chemicals. All mutations are originally rare, and most 
are neutral or deleterious in effect rather than beneficial. However, novel 
alleles can increase in frequency and even eventually become fixed in a 
population by evolutionary processes such as natural selection and genetic 
drift. When the least common allele of a mutation has a frequency of more 
than 1% in the population, it is no longer considered as an abnormal 
deviation from the normal DNA sequence. It is then called a polymorphism, a 
variant of the standard DNA sequence. 
Mutations range in type from point mutations affecting only a single base 
pair in the genome, to larger chromosomal rearrangements and polyploidy of 
entire chromosome sets. Point mutations can be classified as substitutions, 
insertions or deletions of single base pairs, whereas larger chromosomal 
alterations are typically duplications, deletions, inversions or translocations 
of larger genomic segments. 
It has become apparent that the human genome is rich in both sequence 
(e.g., single nucleotide polymorphisms; SNPs) and structural genetic 
variation (e.g., copy number variations; CNVs) originally created by 
mutations and shaped by evolutionary processes. Although we call most of it 
normal polymorphic genetic variation between populations and individuals, 
its potential importance for disease predisposition is evident. Although most 
genetic variation is not disease-causing in itself, it represents a valuable tool 
for genetic mapping of actual disease-predisposing variants as variant alleles 
can be used as genetic markers representing their surrounding genomic 
region (discussed in section 2.2.1). 
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2.1.3 THE GENETIC BASIS OF HUMAN DISEASE 
 
Gregor Mendel (1822-1884), an Austrian monk often called the father of 
genetics, was the first one to form and document descriptive laws explaining 
how traits are inherited from parents to offspring. His studies were limited to 
traits regulated by one or a few genes that follow basic genetic rules of what 
we now call, in his honour, Mendelian inheritance. Today diseases are 
classified as either monogenic (Mendelian), or complex, based on their 
pattern of inheritance (Figure 1).  
 
Monogenic disorders 
 
Monogenic disorders are caused by defects in single genes. In general, they 
can be classified as either dominant or recessive, depending on whether one 
or two copies of the mutated gene are required to cause the disease. 
Monogenic disorders are also classified as either autosomal or X-linked, 
based on the chromosomal location of the causal gene. Examples of recessive 
disorders include the well studied cystic fibrosis, phenylketonuria and sickle 
cell anemia, and many of the disorders of the Finnish disease heritage such 
as aspartylglucosaminuria (AGU), Salla disease, and RAPADILINO 
syndrome (Online Mendelian Inheritance in Man [OMIM], 
www.ncbi.nlm.nih.gov/omim). Examples of dominantly inherited disorders 
include Huntington’s disease, neurofibromatosis, and Marfan syndrome. 
Diseases caused by mutations in mitochondrial DNA display 
mitochondrial inheritance. As only maternal mitochondria are transmitted to 
the embryo, only females pass on mitochondrial diseases, whereas affected 
males do not. The clinical phenotype of mitochondrial diseases varies 
depending on the percentage of cellular mitochondria that carry mutated 
DNA. Examples of mitochondrially inherited disorders are MELAS 
(mitochondrial encephalomyopathy, lactic acidosis, and stroke-like 
syndrome) and CPEO (chronic progressive external ophthalmoplegia). 
 
Complex disorders 
 
In contrast to monogenic disorders, complex (multifactorial) diseases are 
caused by the joint effects of genetic variants in multiple genes combined 
with lifestyle and environmental factors. On a population level, they are 
significantly more common than monogenic ones, and therefore of great 
socioeconomical importance. Examples include well known diseases such as 
asthma, diabetes, cardiovascular diseases, cancers, and psychiatric disorders.  
Complex diseases do not follow simple Mendelian patters of inheritance, 
although they are often described to run in families. Instead, rules of 
polygenic inheritance first proposed by Ronald Fisher may more accurately 
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describe their genetics (Fisher, 1918). According to his polygenic theory, 
quantitative variation in a human trait could be explained by a large number 
of disease risk loci, each contributing minorly to the phenotype and segrating 
according to the laws of Mendel. When the number of loci influencing the 
trait is large, the trait will appear continous and normally distributed (Figure 
2A). However, the clinical disease phenotypes of complex diseases that we 
use are often dichotomous (i.e., affected/healthy) rather than quantitative. 
The liability-threshold model proposed by Karl Pearson is then useful for 
understanding disease predisposition from a genetic perspective (Pearson, 
1900). According to this theory, genetic liability to a disease follows a normal 
distribution (Figure 2B). The disease would then manifest when a certain 
liability-threshold is exceeded, i.e. when an individual carries a large enough 
number of disease risk alleles.  
 
 
Figure 1 Modes of disease inheritance in pedigrees showing monogenic or complex 
inheritance. Typically, either one (dominant inheritance) or two (recessive inheritance) 
copies of a mutated gene are required for disease manifestation. Onset of complex disorders 
is triggered by multiple genetic variants interacting with environmental factors. In reality, also 
monogenic diseases show incomplete penetrance, and their course and form is shaped by 
environmental factors and other genes. There are also rare monogenic forms of some 
complex diseases (e.g., Alzheimer’s disease and familial combined hyperlipidemia) that may 
provide important clues about specific biological pathways that are important also for the 
forms showing complex inheritance (Peltonen et al., 2006).  
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Figure 2 Models explaining quantitative variation in a human trait, and genetic 
predisposition to a dichotomous phenotype. (A) Fisher’s polygenic theory shows that a 
trait will appear continuosly distributed, when a sufficient number of equally common loci of 
small and equal effect influence the trait. In reality, alleles at each locus are not equally 
frequent or of equal effect, e.g. due to dominance or epistasis. (B) Pearson’s liability-
threshold model suggests that genetic liability to a disease follows a normal distribution in the 
population. The disease manifests only when an individual carries enough genetic risk 
variants to exceed the liability threshold. 
There is an ongoing debate whether genetic susceptibility to complex 
diseases is better explained by the additive effects of a large number of 
common risk alleles (minor allele frequency [MAF] typically > 5%) with 
modest effects (odds ratios [ORs] mostly = 1.2 - 1.5), or by fewer rarer risk 
alleles (MAF typically 0.1 – 3%) conferring higher disease risk (OR usually 
>2) (Bodmer and Bonilla, 2008; Pritchard and Cox, 2002). The former 
theory is referred to as the common disease – common variant (CD-CV) 
hypothesis, and the latter one as the common disease – rare variant (CD-CR) 
hypothesis. Most likely, both theories hold true to some extent and no 
universal explanation for complex disease predisposition is to be found. For 
example, common variants in the apolipoprotein E gene increase the risk for 
Alzheimer’s disease (Coon et al., 2007), whereas rare copy number variants 
are thought to be a major risk factor for autism spectrum disorders (Pinto et 
al., 2010).  
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2.2 GENETIC MAPPING 
 
After a genetic basis for a disease has been established by family, twin, 
and/or adoption studies, attempts to identify or “map” the specific genetic 
factors involved in determining predisposition are warranted. Two 
complementary types of methodologies for mapping, each with their specific 
areas of utility as well as their respective advantages and disadvantages, are 
commonly used: linkage- and association studies. Both rely on the use of 
genetic markers to represent the variation of specific chromosomal positions.  
2.2.1 GENETIC MARKERS 
 
A genetic marker can be any polymorphic variant showing Mendelian 
inheritance, and having a known chromosomal location. A genetic marker 
acts as a flag of its position, and it can be used to follow the inheritance of its 
surrounding chromosomal segment through a pedigree (Elston and Spence, 
2006). Genetic markers can both be examined for co-inheritance with 
disease phenotypes in pedigrees (linkage studies), or tested for statistical 
association to disease phenotypes in populations of unrelated individuals 
(association studies), as described in sections 2.2.2 and 2.2.3.  
There are several different types of genetic markers. In general, shifts in 
contemporary markers of choice have followed advances in molecular 
technology. The general trend over the past 25 years has been that the 
number of markers that can be feasibly genotyped has increased, whereas the 
cost and amount of work per marker has decreased (Elston and Spence, 
2006; Schork et al., 2000). The first commonly used markers (prior to the 
1980s) were the physiological and biochemical properties of blood group 
antigens and protein isoforms. These were followed by restriction fragment 
length polymorphisms (RFLPs), point mutations that altered restriction 
enzyme digestion sites, in the 1970-1980s (Botstein et al., 1980). After 
polymerase chain reaction (PCR) technology became commonplace from the 
1980s onward, microsatellites became the tools of choice (Weber and May, 
1989). Microsatellites are DNA repeat sequences with alleles of varying 
repeat length. Microsatellites are particularly suitable for linkage studies as 
they typically are highly polymorphic, easing identification of a specific allele 
that uniquely co-segregates with a disease phenotype. 
Today, the most commonly used genetic markers for gene mapping 
studies are SNPs (Collins et al., 1997). Their utility is explained by a number 
of reasons (Schork et al., 2000). They are the most abundant type of genetic 
polymorphism, dispersed throughout the genome with estimated 
occurrences of, on average, one SNP every 100 – 300 bp in the human 
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genome (www.ncbi.nlm.nih.gov/snp). With current technology, up to a 
million SNPs can be genotyped simultaneously on microarrays, making their 
high-throughput genotyping a cost-efficient and fairly easy undertaking. 
They are more stable, i.e. less mutable, than microsatellites. The benefits of 
SNPs thus compensate for the disadvantage, namely that they are usually 
only biallelic with two of the four possible alleles A, C, G and T, and therefore 
less informative than microsatellites. 
One further benefit of using SNPs as genetic markers is that they 
themselves are potential candidates for conferring disease risk (Schork et al., 
2000). For instance, exonic SNPs could cause functionally relevant amino 
acid changes in the encoded protein. SNPs in non-coding regions could alter 
gene function by either disrupting transcript splice sites or influencing gene 
expression. SNPs could modulate gene expression by altering transcription 
factor binding to promoters or regulatory elements, or microRNA (miRNA) 
binding to target sites in the transcript.    
After the human genome sequencing project was completed, 
interindividual variation in genome sequence has been the focus of major 
international research ventures. Projects such as the International HapMap 
Project aim to characterize dense maps of SNP markers across the genome, 
and determine their allele frequencies and correlation patterns for various 
populations (The International HapMap Consortium, 2003; 
www.ornl.gov/sci/techresources/Human_Genome/home.shtml). The 
information is then made available to researchers to ease the selection of 
optimal sets of SNPs for use as genetic markers in disease gene mapping 
studies. Taken together, the Human Genome Project, the SNP consortium, 
and the HapMap Project have identified close to 10 million common (MAF > 
5%) SNPs (International HapMap 3 Consortium, 2010; 
http://hapmap.ncbi.nlm.nih.gov). Recently, after the advent of next-
generation sequencing technologies made it possible, focus has turned to rare 
SNPs (MAF < 5%). Ventures such as the 1000 Genomes Project aim to 
catalogue these rarer variants by resequencing of individuals from several 
populations (1000 Genomes Project Consortium, 2010). 
2.2.2 LINKAGE ANALYSIS 
 
Linkage analysis-based methods for positional cloning of disease 
susceptibility genes are most commonly used for initial genome-wide scans 
over long chromosomal ranges in pedigrees of affected individuals (Figure 
3A). In conventional linkage analysis, the aim is to discover genetic marker 
alleles that co-segregate with the disease alleles (Terwilliger and Ott, 1994). 
Markers close to a risk variant will be most strongly “linked”, i.e. inherited 
together with it, but recombination events between marker and disease 
alleles within the pedigree further narrow down the chromosomal region 
containing potential candidate genes.  
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Figure 3 Methods for genetic mapping of disease genes. (A) Linkage analyses examine 
coinheritance of genetic markers with disease in pedigrees of affected individuals. In this 
hypothetical example showing two homologous chromosomes with four microsatellite 
markers, the allele combination 4-2-2-2 is always coinherited with the disease phenotype, 
suggesting that a disease mutation is located somewhere on that specific haplotype. Further 
fine mapping is needed to narrow down the interval containing possible candidate genes. (B) 
Association studies examine the correlation of genetic marker alleles and trait phenotypes in 
unrelated individuals. In this example, all carriers of at least one copy of a G-allele at one 
hypothetical SNP have been shaded grey. The G-allele is significantly more frequent among 
cases than controls, suggesting that it may influence disease onset or be in linkage 
disequilibrium with a causal variant.  
The probability for two loci to be linked is directly related to their 
genomic distance. The probability for recombination to break up the linkage 
of two loci is expressed by the recombination fraction (θ), which ranges from 
0 (always inherited together) to 0.5 (the loci segregate as being on two 
independent chromosomes). A test statistic called the LOD-score (logarithm 
of the odds) is used to evaluate whether a genetic marker co-segregates with 
a disease phenotype (Morton, 1955). For each marker, it compares the 
likelihood of the observed data in the pedigree if there is linkage between 
marker and disease allele, to the null hypothesis that the observations are 
due to chance. The final LOD-score is given for the most likely recombination 
fraction between marker and disease allele. A LOD score of ≥ 3 is generally 
considered as evidence for linkage, as it corresponds to 1000:1 odds in favour 
that the observed linkage was not due to chance. However, when analyzing a 
large number of markers in a genome-wide scan, a more appropriate LOD 
score threshold for genome-wide significance would be 3.3, corresponding to 
statistical evidence expected to be found by chance with a 5% probability in 
such an effort (Lander and Kruglyak, 1995). 
In more detail, linkage analyses can be classified as either parametric or 
non-parametric. Parametric analyses require knowledge about the mode of 
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inheritance, and estimates of disease allele frequencies and penetrance. Such 
analyses have been successfully applied for identification of genes underlying 
monogenic disorders that follow simple Mendelian inheritance patterns. In 
contrast, non-parametric (i.e., model-free) analyses are more suitable for 
complex diseases that lack a clear model of inheritance, and have more 
uncertain risk allele frequencies and incomplete penetrance. The non-
parametric analyses aim to identify alleles or chromosomal regions that are 
shared by affected individuals. 
Linkage-based approaches have been very successful in identifying the 
genes responsible for Mendelian disorders, sometimes even in studies 
including only a few affecteds and families (Risch, 2000). Linkage studies 
can be useful for the mapping of complex disease genes as well, especially if 
one has large, well-characterized families to study. However, the track record 
of linkage in complex diseases is not as convincing. Complex diseases show 
greater allelic and locus heterogeneity, and one can expect such genetic 
heterogeneity even within a family. Each individual gene likely contributes 
only minorly to the phenotype, and environmental factors also influence the 
trait. The consequence of all of the above is that much larger samples are 
needed to identify predisposing variants. However, the collection of large 
family samples is a labor-intensive and time-consuming task. Moreover, the 
final chromosomal region identified in linkage studies is usually large and 
containing several potential candidate disease genes, as the resolution of the 
approach is limited by the number of recombination events between markers 
and disease alleles (Cardon and Bell, 2001). Therefore, a complementary and 
refining methodology, association-based mapping, is in use, and it is 
discussed in the following section.  
2.2.3 ASSOCIATION-BASED METHODS 
 
Association analysis 
 
Whereas linkage analyses evaluate the relationship between loci (marker and 
disease gene), genetic association studies examine the statistical correlation 
between genetic variants and trait differences, such as disease phenotypes 
(Cardon and Bell, 2001); Figure 3B. A highly influential paper by Risch and 
Merikangas suggested that association studies have more power than linkage 
studies to identify common risk variants with small effect sizes, and that 
association-based approaches may therefore provide a means of overcoming 
some of the limitations of linkage analyses in studies of complex diseases 
(Risch and Merikangas, 1996). This has inspired much of the development 
during the past 15 years, from small association studies examing specific 
candidate genes, or fine mapping of linkage regions, to the large scale 
genome-wide association studies of today. The advantages and disadvantages 
of linkage and association studies are summarized in Figure 4. 
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Figure 4 Advantages and disadvantages of linkage- and association-based methods 
for identification of human disease genes. 
The most common association study design is the classical case-control 
study, in which allele frequencies at genetic marker (usually SNPs) loci are 
determined in a group of unrelated affected individuals and compared to 
those in a population of unrelated unaffected control subjects. Likelihood-
ratio tests (LRT) or chi-square (χ2) tests are then used to statistically evaluate 
whether there are significant differences in allele or genotype distributions 
between cases and controls. The aim is to identify alleles that are more 
frequent among cases than controls, and thereby “associated” with the 
disease. Although one appeal of the association approach is that collection of 
large samples of unrelated individuals is relatively easy, there is also one 
major pitfall to it. Any systematic difference in allele frequencies between 
cases and controls will apperar as a spurious disease association, even though 
it in reality is the result of evolutionary or migratory history (ethnicity), 
gender differences, or non-random mating (Cardon and Bell, 2001). Such an 
effect, the presence of multiple subgroups with different allele frequencies 
within the study sample, is called population stratification, and it was 
suggested to be one major reason behind discrepant association findings in 
the literature (Risch, 2000). Therefore, well characterized and 
geographically/ethnically matched control samples, or statistical methods to 
control for ancestry in population controls (Tian et al., 2008) are key 
elements of a well designed association study. 
In addition to case-control studies, there are also family-based association 
study designs for constellations of parents and affected offspring (Laird and 
Lange, 2006). The statistical tests used in family-based designs are the 
transmission disequilibrium test (TDT) and its extension FBAT (family-
based association test). The principle of these tests is to consider the alleles 
not transmitted to affected children as control alleles, and evaluate whether 
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there is significant overtransmission (deviation from Mendelian 
transmission) of other alleles to affected children. 
Typically, a marker found to be associated in an association study is not 
necessarily the causal variant itself, but rather a variant in linkage 
disequilibrium (LD) with the risk variant. This important concept is 
described next. 
 
Linkage disequilibrium 
 
The concept of LD is the foundation that association studies rely on. It can be 
defined as non-random association of alleles, or the tendency for specific 
alleles to be inherited together, coupled as a unit (Ardlie et al., 2002). LD is 
best understood by considering it from a population-historical perspective. 
When a mutation increasing the risk for disease first arises and enters a 
population, it does so on a haplotype background of other pre-existing DNA 
variants. Subsequently, the mutation will be transmitted together with these 
other variants as a unit in the population; that is, it will be in LD with other 
variants nearby. Over time, historical recombination events during meioses 
in the population will reduce LD by breaking up associations between the 
mutation and other alleles of the ancestral haplotype. Eventually, only 
specific variants very close to the mutation will still be co-inherited with it. 
Thus, combinations of marker alleles represent the recombinatorial history 
of the chromosomal region they are located in. This is the genetic basis of 
why alleles of genetic markers provide information about, or capture, other 
surrounding genetic variation, including potential disease susceptibility 
mutations. In essence, linkage and association studies are thus both based on 
the same principle, the co-inheritance of adjacent variants. However, linkage 
is found and studied in recent pedigrees with known patterns of ancestry, 
with few recombination events, whereas association reflects long-term, 
historic recombination in the population that can be inferred to have the 
properties of an enormous hypothetical pedigree (Cardon and Bell, 2001). 
Two different measures are used to quantify the extent of LD between 
loci: D’ and r2 (Wall and Pritchard, 2003; Ardlie et al., 2002). D’ is obtained 
by dividing D (the difference between the observed frequency of a two locus 
haplotype and its expected frequency assuming random segregation of 
alleles), with its maximum possible value given the allele frequencies of the 
two loci. The value of D’ ranges from 0 to 1, with 1 designating complete LD, 
i.e. no recombination between the two loci. However, low D’ values cannot be 
clearly interpreted in relation to each other, and therefore the variable r2 is 
often preferred, as it takes differences in allele frequencies between the loci 
into account. The r2 coefficient represents the statistical correlation between 
two loci, and it is thus a measure of how complete information the loci 
provide about each other. r2 values also range from 0 to 1, but a value of 1 is 
only obtained when there has been no recombination between the loci, and 
their allele frequencies are equal. 
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Genome-wide association studies 
 
Traditionally, association studies were focused on specific candidate genes, 
based on a priori hypotheses justified by previous linkage findings, animal 
models, and prior knowledge about the function of the gene in biological 
processes relevant for the disease. Nowadays, hypotheses-free, genome-wide 
association (GWA) studies examining up to a million SNPs in large samples 
are technologically and economically feasible and commonplace. Thus, the 
popularity of the association study approach in recent years is due to a 
combination of factors, such as development of dense genome-wide SNP 
maps for use as reference markers, high-throughput genotyping technology 
on microarrays, and increase in computing power that is necessary for the 
data analysis. To put GWA studies into the context of genetic theories for 
explaining disease susceptibility, they were designed to evaluate genetic 
variation with MAFs > 0.05, and therefore detect any so called common risk 
variants for complex disease (CD-CV hypothesis). 
However, GWA-studies come with an enormous multiple testing penalty, 
as the number of potential spurious false positive associations increases 
along with the number of statistical tests performed. It was suggested that an 
appropriate threshold for a genome-wide significant finding is P < 5 x 10-8 
(Risch and Merikangas, 1996), an approximation still considered reasonably 
accurate today. The need to have sufficient power to reach such thresholds 
has, together with the very modest effect sizes currently thought to be 
conferred by individual risk variants, lead to studies with enormous study 
samples (10 000 – 100 000 individuals). This trend has lead to the formation 
of numerous international consortia focusing on the study of specific 
complex disease phenotypes, as these efforts are no longer possible for 
individual research groups to carry out.  
Through the extensive work done across a wide range of phenotypes, the 
emerging consensus from the GWA studies performed to date is that the CD-
CV hypothesis alone is not sufficient to explain the genetic predisposition to 
complex disorders (Manolio et al., 2009). Rather, the effect sizes of the 
identified common risk variants are generally small, and they collectively 
only explain a fraction of the heritability of complex disorders. This seems to 
be particularly true for psychiatric disorders. Thus, depending on one’s point 
of view, some might call the GWA studies performed to data a success, 
whereas others remain more hesitant regarding their actual practical utility 
(Weiss and Terwilliger, 2000). Therefore, the field is currently moving (via 
exome sequencing) towards performing genome-wide resequencing studies 
for the detection of any possible rare risk variants for complex disease. Again, 
this development is fuelled by concurrent development in next-generation 
sequencing technologies, computing power and statistical and 
bioinformatical advances. 
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2.3 ANXIETY DISORDERS 
2.3.1 CLINICAL FEATURES 
 
Anxiety as a universal phenomenon has been discussed for ages. Originally, it 
was not included as a mental illness in disease descriptions made by ancient 
Greek physicians (Stone, 2009). The focus on anxiety in the medical 
literature has shifted from treatment of the somatic (objective) 
manifestations related to activation of the sympathetic nervous system to 
treatment of the emotional (subjective) manifestations pioneered by 
psychoanalysts (Table 1). Today, we acknowledge that “normal” anxiety is an 
adaptive response to potentially harmful situations, but consider it a 
diagnosable mental disorder when exaggerated. The main criteria for 
classifying anxiety as pathological are that is excessive and prolonged such 
that it leads to considerable disability and distress. Disorder subtypes are 
further identified based on other disorder-specific features regarding the 
course and onset of the anxiety, and the focus of the anxiety-associated 
avoidance behavior. The most common classification instrument of mental 
disorders for research purposes, the Diagnostic and Statistical Manual of 
Mental Disorders (currently DSM-IV), recognizes the following anxiety 
disorders: acute stress disorder, agoraphobia (without a history of panic 
disorder [PD]), generalized anxiety disorder (GAD), obsessive-compulsive 
disorder (OCD), PD (with or without agoraphobia), phobias (e.g., social 
phobia and specific phobias), and post-traumatic stress disorder (PTSD) 
(American Psychiatric Association, 2000). Diagnostic criteria for the major 
anxiety disorders are summarized in Table 2. Clinicians also commonly use 
the International Classification of Diseases (currently ICD-10) to classify 
anxiety disorders (World Health Organization, 1993). It groups anxiety 
disorders under the neurotic, stress-related, and somatoform disorders. 
Table 1. Symptoms of anxiety 
 
 
 
 
 
 
 
 
Emotional manifestations Somatic manifestations 
Uncertainty Heart palpitations
Despair Chest pain
Uneasiness Sweating
Tension Increased blood pressure 
Restlessness Dizziness
Horror Dry mouth
Panic Lump in the throat
Agitation Tremor
Nightmares Chills or hot flushes
Flashbacks Shortness of breath
Obsessive thoughts Suffocation
Avoidance behavior Nausea
Fear of losing control of life Diarrhea
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Table 2. Diagnostic criteria for selected anxiety disorders adapted from the 
Diagnostic and Statistical Manual of Mental Disorders, 4
th
 edition (DSM-IV-TR) 
Panic disorder
A. Both (1) and (2)
(1) Recurrent unexpected panic attacks. 
(2) At least one of the attacks has been followed by at least 1 month of one or more of the following:
Persistent concern about having additional panic attacks 
Worry about the implications of the attack or its consequences 
A significant change in behavior related to the attacks 
B. Presence or absence of agoraphobia.
C. The panic attacks are not due to the direct physiologic effects of a substance (e.g., a drug of abuse, a medication) 
or a general medical condition (e.g., hyperthyroidism). 
D. The panic attacks are not better accounted for by another mental disorder. 
Generalized anxiety disorder
A. Excessive anxiety about a number of events or activities, occurring more days than not, for at least 6 months. 
B. The person finds it difficult to control the worry. 
C. The anxiety and worry are associated with at least three of the following six symptoms (with at least some
symptoms present for more days than not, for the past 6 months):
Restlessness or feeling keyed up or on edge 
Being easily fatigued 
Difficulty concentrating or mind going blank 
Irritability 
Muscle tension 
Sleep disturbance 
D. The focus of the anxiety and worry is not confined to features of an Axis I disorder, being embarrassed in public
(as in social phobia), being contaminated (as in obsessive-compulsive disorder), being away from home or close
relatives (as in separation anxiety disorder), gaining weight (as in anorexia nervosa), having multiple physical
complaints (as in somatization disorder), or having a serious illness (as in hypochondriasis), and the anxiety and
worry do not occur exclusively during posttraumatic stress disorder. 
E. The anxiety, worry, or physical symptoms cause clinically significant distress or impairment in social or
occupational functioning. 
F. The disturbance does not occur exclusively during a mood disorder, a psychotic disorder, pervasive
developmental disorder, substance use, or general medical condition. 
Agoraphobia
A. Fear of being in places or situations from which escape might be difficult (or embarrassing) or in which help
might not be available in the event of having unexpected panic-like symptoms. 
B. The situations are typically avoided or require the presence of a companion. 
C. The condition is not better accounted for by another mental disorder. 
Social phobia
A. A fear of one or more social or performance situations in which the person is exposed to unfamiliar people or to
possible scrutiny by others and feels he or she will act in an embarrassing manner. 
B. Exposure to the feared social situation provokes anxiety, which can take the form of a panic attack. 
C. The person recognizes that the fear is excessive or unreasonable. 
D. The feared social or performance situations are avoided or are endured with distress. 
E. The avoidance, anxious anticipation, or distress in the feared situation interferes significantly with the person's
normal routine, occupational functioning, or social activities or relationships. 
F. The condition is not better accounted for by another mental disorder, substance use, or general medical
condition. 
G. If a general medical condition or another mental disorder is present, the fear is unrelated to it. 
H. The phobia may be considered generalized if fears include most social situations.  
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Specific phobia
A. Persistent fear that is excessive or unreasonable, cued by the presence or anticipation of a specific object or
situation. 
B. Exposure provokes immediate anxiety, which can take the form of a situationally predisposed panic attack. 
C. Patients recognize that the fear is excessive or unreasonable. 
D. Patients avoid the phobic situation or else endure it with intense anxiety or distress. 
E. The distress in the feared situation interferes significantly with the person's normal routine, occupational
functioning, or social activities or relationships. 
F. In persons younger than 18 years, the duration is at least 6 months. 
G. The fear is not better accounted for by another mental disorder. 
Post-traumatic stress disorder
A. The person has been exposed to a traumatic event in which both of the following were present:
(1) The person experienced, witnessed, or was confronted with an event that involved actual or threatened 
death or serious injury or a threat to the physical integrity of others. 
(2) The person's response involved intense fear, helplessness, or horror. 
B. The traumatic event is persistently re-experienced in at least one of the following ways:
Recurrent and intrusive distressing recollections of the event, including images, thoughts, or perceptions. 
Recurrent distressing dreams of the event. 
Acting or feeling as if the traumatic event were recurring, including a sense of reliving the experience, 
illusions, hallucinations, and flashback episodes. 
Intense psychological distress at exposure to cues that symbolize an aspect of the traumatic event. 
Physiologic reactivity on exposure to cues that symbolize or resemble an aspect of the traumatic event. 
C. The person persistently avoids stimuli associated with the trauma and has numbing of general responsiveness 
including at least three of the following:
Efforts to avoid thoughts, feelings, or conversations associated with the trauma 
Efforts to avoid activities, places, or people that arouse recollections of the trauma 
Inability to recall an important aspect of the trauma 
Markedly diminished interest or participation in significant activities 
Feeling of detachment or estrangement from others 
Restricted range of affect 
D. Persistent symptoms of increased arousal are indicated by at least two of the following:
Difficulty falling or staying asleep 
Irritability or outbursts of anger 
Difficulty concentrating 
Hypervigilance 
Exaggerated startle response 
E. Duration of the disturbance is more than 1 month. 
F. The disturbance causes clinically significant distress or impairment in social, occupational, or other important 
areas of functioning. 
Obsessive-Compulsive Disorder 
A. Either obsessions or compulsions (or both) are present on most days for a period of at least 2 weeks.
(1) Obsessions
Recurrent and persistent thoughts, impulses, or images that are experienced as intrusive and 
inappropriate, causing anxiety or distress. 
The thoughts, impulses, or images are not simply excessive worries about real-life problems. 
The person attempts to ignore or suppress such thoughts, impulses, or images or to neutralize them with 
some other thought or action. 
The person recognizes that the obsessional thoughts, impulses, or images are a product of his or her own 
(2) Compulsions 
Repetitive behaviors or mental acts that the person feels driven to perform in response to an obsession or 
according to rules that must be applied rigidly. 
The behaviors or mental acts are aimed at preventing or reducing distress or preventing some dreaded 
event or situation. 
These behaviors or mental acts either are not connected in a realistic way with what they are designed to 
neutralize or prevent, or they are clearly excessive. 
B. At some point during the course of the disorder, the person has recognized that the obsessions or compulsions 
are excessive or unreasonable. 
C. The obsessions or compulsions cause marked distress, take up more than 1 hour a day, or significantly interfere 
with the person's normal routine, occupation, or usual social activities. 
D. If another Axis I disorder, substance use, or general medical condition is present, the content of the obsessions 
or compulsions is not restricted to it. 
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2.3.2 ANXIETY-RELATED PERSONALITY TRAITS 
 
In one of the fundamental principles of the integrative science of personality, 
human personality is defined as an individual’s unique variation on the 
general evolutionary design of human nature (McAdams and Pals, 2006). In 
addition to defining anxiety by the use of clinical anxiety disorder diagnoses, 
human anxiety is commonly assessed by quantitative measurement of a 
number of human personality traits. These are assessed with psychological 
personality inventories, such as the NEO-PI-R (Neuroticism-Extraversion-
Openness Personality Inventory Revised; Costa and McCrae, 1992), EPQ 
(Eysenck Personality Questionnaire; Eysenck and Eysenck, 1975), or the 
TPQ/TCI (Tridimensional Personality Questionnaire/Temperament and 
Character Inventory; Cloninger, 1994). From a research point of view, 
personality traits offer the benefit that they can relatively easily be assessed 
in large samples using self-report questionnaires. Moreover, they are 
measured on a continuous quantitative scale, offering more power for 
statistical analyses than dichotomous clinical diagnoses.  
In particular, personality traits such as high neuroticism, low 
extraversion, high harm avoidance, low novelty seeking, or high behavioral 
inhibition are related to anxiety disorders. They are heritable characteristics, 
and aggregate in families with anxiety disorders (Smoller et al., 2008a). 
Personality traits may relate to clinical anxiety disorders either by being 
susceptibility factors themselves or by being consequences of the disease 
(Brandes and Bienvenu, 2006). Personality traits may also share etiology 
with anxiety disorders, or shape the course of the disease. It is thought that 
some personality traits, such as the ones listed above, are risk markers for 
anxiety disorders, but also that remission may result in at least partial 
“improvement” in personality measures. It is also known that anxiety 
disorders in early life shape personality (Brandes and Bienvenu, 2006). 
Taken together, anxiety disorders and personality traits likely represent an 
overlapping spectrum of behavior. Moreover, also from a genetic perspective, 
anxiety disorders and personality traits represent overlapping entities, as 
correlation models based on twin studies suggest that they share genetic risk 
factors to a large extent. For instance, the genetic risk factors influencing 
variation in neuroticism and extraversion entirely account for genetic liability 
to social phobia and agoraphobia (Bienvenu et al., 2007). The factors 
modulating variation in neuroticism further show substantial overlap with 
those influencing PD and GAD (Hettema et al., 2006). 
 31 
2.3.3 EPIDEMIOLOGY 
 
Prevalence 
 
The prevalence of anxiety disorders shows large variability between 
populations. Rather than being mostly due to true underlying reasons, the 
large variations in estimates across studies are accounted for by factors such 
as diagnostic criteria, diagnostic instrument, sample size, study country, and 
response rate (Somers et al., 2006). A recent large cross-European study 
reported that 14.0% of Europeans annually suffer from anxiety disorders 
(Wittchen et al., 2011). The corresponding figure from an American 
nationwide study was 18.1% (Kessler et al., 2005b). A systematic review of 41 
anxiety disorder prevalence studies estimated pooled rates of 11% for 12-
month prevalence, and 17% for lifetime prevalence (Somers et al., 2006). In 
Finland, the 12-month prevalence of anxiety disorders was 4.1% in the 
general adult (age ≥ 30 years) population (Pirkola et al., 2005b). However, 
this is an underestimate, as OCD and PTSD were not assessed. A 
supplementing examination of Finnish young adults (aged 19-34) that 
included those diagnoses reported a lifetime prevalence of 12.6% for anxiety 
disorders (Suvisaari et al., 2009). 
A general pattern that emerges from the lifetime prevalence studies 
performed to date is that as a group anxiety disorders are always the most 
common type of mental disorders (Kessler et al., 2009). Among the anxiety 
disorders, specific phobias are typically the most common disorders 
(prevalence usually 6-12%), followed by social phobia (up to 10%), and PTSD 
(1% - more than 10%, depending on the population); Table 3. The other 
anxiety disorders usually have lower lifetime prevalences around 2-4%. 
Table 3. Summary of epidemiological measures of the major anxiety disorders. 
Estimates based on (Kessler et al., 2009; Smoller et al., 2008a; Somers et al., 2006; Kessler 
et al., 2005a; Kessler et al., 2005b; Pirkola et al., 2005b; Hettema et al., 2001; Kendler et al., 
1999) are presented to give a general, albeit not all-encompassing, idea.  
12-month 
prevalence 
(%)
Lifetime 
prevalence 
(%)
Median 
age-of-
onset (yrs)
Odds ratio for 1st 
degree relatives 
of probands  
Heritability 
(h 2)
Panic disorder 1-3 2-5 24 5 48
Generalized anxiety disorder 1-3 3-6 31 6 32
Obsessive-compulsive disorder 0.5-1 1-3 19 4 30–45
Post-traumatic stress disorder 1-4 1-10 23 - 30
Social phobia 1-7 4-10 13 3–10 51
Specific phobia 3-9 5-12 7 3–4 30
Agoraphobia 1-2 2-4 20 3-4 61  
Review of the literature 
32 
Comorbidities 
 
Anxiety disorders frequently co-occur with each other, and with other 
psychiatric and physical disorders. In fact, the majority of anxiety disorder 
subjects will meet the criteria for another psychiatric disorder during their 
lifetime (Kessler et al., 2005b). It is not uncommon to meet criteria for two 
or more anxiety disorders. In the Finnish nationally representative Health 
2000 sample, the most common comorbidity among the anxiety disorders 
was between PD and social phobia (6.4% of all anxiety disorder subjects), 
and 14.5% met the criteria for more than one anxiety disorder (Pirkola et al., 
2005b). 
Two major classes of mental disorders are often comorbid with anxiety 
disorders: mood and substance use disorders. In the Finnish Health 2000 
sample, the annual prevalences of anxiety, depressive, and alcohol use 
disorders were 4.1%, 6.5%, 4.5%, respectively (Pirkola et al., 2005b). Of 
subjects with anxiety disorders in that study, 35.9% met criteria for a 
comorbid depressive disorder (major depressive disorder [MDD] and/or 
dysthymia), and 22.4% for a comorbid alcohol use disorder (alcohol abuse 
and/or dependence). In the American National Comorbidity Survey 
Replication, estimates of ORs for concomitant co-occurrence of anxiety 
disorders with MDD, dysthymia, and bipolar disorder ranged from 2.3–12.3, 
with lifetime estimates being even higher (Merikangas and Swanson, 2009). 
The corresponding figures for any alcohol use disorder were 1.5–4.7, and 1.1–
3.5 for any drug abuse disorder. There is a general trend that substance 
dependence is more highly comorbid with anxiety disorders than substance 
abuse (Merikangas and Swanson, 2009).  
A variety of physical conditions also co-occur with anxiety disorders in 
epidemiological studies, either in general or with specific anxiety disorder 
subdiagnoses. Examples include respiratory conditions like asthma with PD 
and phobias (Goodwin et al., 2003), gastrointestinal diseases like ulcer with 
PD/GAD (Sareen et al., 2005), brain injuries with any anxiety disorder (Luis 
and Mittenberg, 2002), and cardiovascular diseases and migraine with any 
anxiety disorders (Harter et al., 2003). 
While the epidemiological evidence for comorbidity between anxiety 
disorders and the other conditions described is clear, the underlying reasons 
and causal relationships between the observations are not. There might be 
shared biological and genetic mechanisms that account for some of the co-
occurences. Family and twin studies  suggest that anxiety and depression are 
distinct disorders, but that they partially share underlying risk factors, 
including genetic ones (Merikangas and Swanson, 2009; Middeldorp et al., 
2005). On the other hand, a consensus from family studies seems to be that 
substance use disorders are transmitted independently of anxiety disorders, 
and are not caused by the same familial risk factors. Use of alcohol for self-
medication purposes of anxiety disorders is known to directly increase the 
risk for subsequent substance use disorders, and may represent one 
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explanation for the high comorbodity (Robinson et al., 2011). The causal 
relationships between physical- and anxiety disorders remain unclear, but 
they likely provide clues about biological processes that are relevant for 
anxiety.  
 
Risk factors 
 
Acknowledged risk factors for anxiety disorder onset include gender, age, 
family history and genetic factors, traumatic or stressful life events 
(particularly in childhood), socioeconomical factors, and certain medical 
conditions. The main risk factors are discussed in the following sections.  
 
Gender 
 
In general, anxiety disorders are about 1.7-2.0 times more common in 
women than men (McLean et al., 2011). However, this is not true for all 
anxiety disorder subtypes, as for instance social phobia is equally common in 
men and women. Anxiety disorders may also be more debilitating in women 
than men, as women with a lifetime diagnosis of anxiety disorder have 
greater illness burden, and are more likely to have psychiatric comorbidities, 
such as another anxiety disorder, MDD, or bulimia nervosa (McLean et al., 
2011). However, epidemiological models suggest that the environmental and 
genetic factors that underlie anxiety disorders are similar between men and 
women (Hettema et al., 2005). 
 
Age 
 
A general pattern from age-of-onset studies of anxiety disorders is that they 
usually have much earlier onset than other common mental disorders like 
mood disorders, disruptive behavior disorders, nonaffective psychoses, and 
substance use disorders (Kessler et al., 2009). Both across Europe and in the 
USA, the onset of anxiety disorders is typically in childhood, adolescence, or 
early adulthood, with one estimate of the median age of onset being 11 years 
(Goodwin et al., 2005; Kessler et al., 2005a). However, different anxiety 
disorder subtypes show considerable variability. For instance, specific 
phobias and separation anxiety have very early median onset (7 years), social 
phobia intermediate onset (13 years), and other anxiety disorders (in 
ascending order of median age of onset: OCD, agoraphobia, PTSD, PD and 
GAD) relatively late onset (19-31 years). Despite the early age of onset, most 
subjects receive their first treatment in adulthood, even more than a decade 
later (Christiana et al., 2000). Anxiety disorders are typically persistent 
throughout life, often with a recurrent-intermittent course featuring episodes 
of different comorbid anxiety disorders (Kessler et al., 2009). 
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Family history 
 
Family studies assess to what extent a disorder aggregates in a family (i.e., is 
familial). This is an indice of the total contribution of both genetic and 
environmental factors that the family shares. Anxiety disorders clearly 
aggregate in families. Odds ratios predicting disease risk for first-degree 
relatives of affected individuals typically range from 4-6 in family studies, 
and are similar across PD, GAD, OCD, and phobias (Smoller et al., 2008a; 
Hettema et al., 2001); Table 3, page 31. The contribution of genetics to 
anxiety disorder susceptibility is discussed in more detail in section 2.3.4. 
 
Stressful life events and childhood adversities 
 
One view explaining anxiety disorder onset is that environmental factors, 
such as traumatic life events, trigger them in individuals that are susceptible 
due to genetic, biochemical, or psychological factors. The clearest example of 
this is PTSD, where a single major traumatic life event (such as experience of 
combat, natural disasters, or sexual abuse) triggers an anxiety disorder in 
specific individuals, whereas others remain stress-resilient (Koenen et al., 
2009). In general, even any milder life events that require adaptation, and 
involve change and uncertainty, can be emotional triggers of clinical anxiety 
disorders. Examples include financial difficulties, illness and lack of a social 
network.  
Childhood is a particularly sensitive developmental period in life, and 
early experiences can have profound and persistent biobehavioral effects 
(Bale et al., 2010). Childhood adversities, in particular ones related to 
maladaptive family functioning (parental mental illness, substance abuse 
disorder, criminality, violence, physical/sexual abuse, and neglect) represent 
some of the strongest known risk factors for anxiety disorder onset and 
persistence (Green et al., 2010; McLaughlin et al., 2010). It is thought that 
traumatic events during childhood can influence later behaviour in 
interaction with genetic variants during development of the neurocircuitry 
that regulates emotional states (Gillespie et al., 2009). Therefore, analyses of 
predictors of anxiety disorder onset that have the possibility to take both 
genetic variation and childhood adversities into account might be 
advantageous. 
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2.3.4 GENETIC EPIDEMIOLOGY 
 
Heritability 
 
As noted above, family studies indicate that anxiety disorders “run in the 
family”. However, family studies do not provide an answer to whether this is 
due to the genes, or the environment that relatives share. Twin studies that 
compare the concordance rate of a disorder in monozygous twins to that in 
dizygous twins make it possible to estimate the relative contribution of 
genetic and environmental factors to a phenotype. The proportion of total 
phenotypic variability in a trait that can be explained by additive genetic 
variation is called heritability. Twin studies suggest that anxiety disorders 
typically have moderate (30-40%) heritability (Hettema et al., 2001); Table 
3, page 31. Although the major source of familiar risk is thought to be due to 
genetic factors, the major part of the overall variability in susceptibility to 
anxiety disorders seems to be explained by individual-specific environmental 
factors. 
The heritabilities estimated for anxiety disorders are lower than for most 
other psychiatric disorders. However, they are likely no less genetically 
complex than other psychiatric disorders. Rather, the environment may play 
a relatively larger role in triggering onset of anxiety disorders than in other 
psychiatric disorders. Moreover, heritability is informative in that it tells us 
that genetics are involved, but not about how many variants influence a trait, 
or what their frequencies and relative effect sizes are. One should also 
remember that heritability estimates only apply to the specific population 
they were measured in, in its specific environment at that time.  
 
Genetic architecture 
 
The genetic architecture, or the structure of genetic determinants underlying 
of anxiety disorders, is unknown. Family studies suggest that the clinical 
disorders are not inherited as distinct entities, as relatives of affected 
individuals are at increased risk not only for the anxiety disorder of the 
proband, but also for other anxiety disorders (Smoller et al., 2008a). 
Multivariate models suggest that the genetic risk factors for different anxiety 
disorders overlap, and that they further cluster together with those of other 
major internalizing mental disorders of the DSM-IV axis I (MDD, eating 
disorders and somatoform disorders), forming a group distinct from the axis 
I externalizing disorders (e.g., substance abuse/dependence and conduct 
disorder) and the axis II personality disorders (Kendler et al., 2011). More 
specifically, within the anxiety disorders, PD, agoraphobia, and GAD seem to 
be influenced by one genetic risk factor, whereas another one mainly 
influenced specific phobias (Hettema et al., 2005). Social phobia was 
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influenced by both genetic risk factors. The consensus seems to be that genes 
do not know DSM-IV boundaries, and what is inherited might for instance be 
a type of quantitative anxiety proneness, or anxiety-predisposing changes in 
brain function and neurocircuitry (Smoller et al., 2008a). As noted above, 
genetic risk factors for anxiety disorders overlap with those influencing 
anxiety-related personality traits (Bienvenu et al., 2007; Hettema et al., 
2006). One plausible consensus is that there are genes that are specific for 
some anxiety disorder-subtypes, some that increase anxiety susceptibility in 
general, and yet others that are shared risk genes with other psychiatric 
disorders. This hypothetical view of the genetic architecture of anxiety 
disorders in illustrated in Figure 5. 
 
 
 
Figure 5 A hypothetical view of the genetic architecture of anxiety disorders. Twin- and 
family studies suggest that some genes increase susceptibility to anxiety in general, that 
other genes are shared susceptibility factors with other anxiety disorders or psychiatric 
disorders and that some may be specific for certain subtypes of anxiety. There is also 
considerable overlap between the genes influencing anxiety-related personality traits, and 
those influencing clinical anxiety disorders. Figure adapted based on an idea from (Smoller 
et al., 2008a). 
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2.3.5 NEUROBIOLOGY 
 
Brain regions regulating anxiety 
 
A vast body of research from both animal models and humans has aimed at 
identifying brain circuitry involved in anxiety regulation. This research is 
rooted in animal models of or human observations of the consequences of 
specific brain lesions, electrical stimulation work, animal paradigms of 
conditioned fear responses, and in neuroimaging studies of brain responses 
to emotional stimuli in humans (Shin and Liberzon, 2010). Imaging studies 
of subjects with specific anxiety disorders have also been carried out. 
Ivan Pavlov’s studies on conditioned responses in dogs in the 1920s laid 
the foundation for later research into mechanisms of fear conditioning, and 
coined the terminology still used today (Pavlov, 1927). Classical Pavlovian 
fear conditioning is based on repeatedly presenting a neutral stimulus like a 
tone together with an unpleasant stimulus (the unconditioned stimulus, US) 
such as an electrical shock that elicits an unconditioned response (UR) such 
as increased freezing. After repeating this for a number of times, presenting 
the originally neutral stimulus alone is sufficient to elicit a fear response. 
Once this has occurred, the neutral stimulus is called a conditioned stimulus 
(CS), as it has been coupled to a conditioned response (CR; increased fear 
response in this case). As anxiety is an evolutionarily conserved response, 
animal models of conditioned fear responses offer important insight into 
biology relevant also for human anxiety. In addition, distorted or 
overinterpreted conditioned fear reactions are directly thought to be involved 
in the pathogenesis of PD and other anxiety disorders (Gorman et al., 2000). 
Animal models aiming to identify neural circuitry relevant for anxiety offer 
the additional advantage that specific lesions or transgenic and 
pharmacological manipulations can be combined with neuroimaging, in vivo 
electrophysiological recordings, and behavioral testing. The effects of 
stimulating specific circuitry can also be evaluated.  
Rodent behavioral paradigms of Pavlovian fear conditioning, inhibitory 
avoidance, and fear-potentiated startle have identified key components of the 
neurocircuitry of fear. These include the amygdala, nucleus accumbens 
including the bed nucleus of the stria terminalis, hippocampus, 
hypothalamus, periaqueductal grey, insular cortex, parts of the prefrontal 
cortex, and nuclei from the thalamus and brain stem (Maren, 2008; Quirk 
and Mueller, 2008; Davis, 2006). These regions appear to have their own 
specific roles in fear processing, such as threat perception, coupling of a 
neutral stimulus to a conditioned response, execution of the fear response, 
and modulation of the fear response (Shin and Liberzon, 2010). However, as 
a whole, anxiety is likely an emerging property of interacting brain regions 
(Morgane et al., 2005). An overview of the most relevant neuroanatomical 
pathways for fear processing is shown in Figure 6.  
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Figure 6 Simplified view of major neural circuits relevant for anxiety and fear 
response. The central co-ordinator of the fear response is the amygdala. Its lateral or basal 
nucleus receives input from three major sources: the thalamus, cortical pathways, and the 
hippocampus. The direct link between the thalamus and the amygdala enables fast, reflex-
like response to stimuli predicting threat. The amygdala also receives processed and 
modulated neurocognitive information from the cortex, enabling more complex and 
appropriate reaction to the threat, depending on its extent and type. The hippocampus is 
thought to be responsible for fear memory, allowing for contextual processing of threat based 
on previous experiences. There are three major efferent pathways from the central nucleus 
of the amygdala that execute the fear response via the hypothalamus, locus coeruleus and 
periaqueductal grey. The hypothalamus activates the HPA (hypothalamus-pituitary-adrenal)- 
axis that leads to metabolic and behavioral changes crucial for the stress response. The key 
players of this pathway are the neuropeptides CRH (corticotropin-releasing hormone), AVP 
(arginine vasopressin) and ACTH (adrenocorticotropic hormone). The hypothalamus is also 
critical for inducing the symphatetic nervous system-mediated physiological changes that 
accompany the fight-or-flight response. Similarly, the locus coeruleus is responsible for stong 
physiological arousal induced by norepinephrine release. The periaqueductal grey dampens 
the conscious perception of pain. Figure based on (Finn et al., 2003; Gorman et al., 2000). 
One of the most solid rodent findings is the involvement of the amygdala 
in fear acquisition and expression of the fear response. This is also supported 
by studies of Pavlovian fear conditioning and pharmacologically induced fear 
in non-human primates (LeDoux, 2000), and functional neuroimaging of 
responses to emotional stimuli and facial expressions in humans (Alvarez et 
al., 2008). Taken together, these studies suggest that the amygdala responds 
to threat-predicting stimuli, and mediates states of fear and anxiety. This has 
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formed the hypothesis that amygdalar responses are hyperreactive in anxiety 
disorder patients, which is supported by studies of subjects with e.g. PTSD, 
social phobia and specific phobias (Dilger et al., 2003; Tillfors et al., 2001; 
Shin et al., 1997). 
Other key brain structures important for fear processing are the 
hippocampus and the ventromedial prefrontal cortex (vmPFC). The 
hippocampus has been implicated in contextual processing of fear, and the 
infralimbic cortex in extinction recall, which means recall of an extincted fear 
(Shin and Liberzon, 2010). These structures appear important for fear 
memory, or learning and remembering that a stimulus that used to predict 
threat no longer does so. This has lead to the hypothesis that exaggerated 
fear and worry in anxiety disorder patients is due to impaired ability to 
context-dependently quench anxiety responses when they are unnecessary, 
or recall that a specific stimulus no longer predicts threat. Such impaired fear 
extinction was observed e.g. in PTSD patients (Blechert et al., 2007b). 
 
Neurochemistry of anxiety: Neurotransmitter systems and neuropeptides 
 
Specific neurotransmitter- and neuropeptide signaling systems mediate the 
anxiety-regulating actions of the brain regions described above. Their release 
and signaling during stress has both central and peripheral functions in 
preparing the body for threat and coping with it. The central functions 
include increased attention and vigilance, modulation of memory to make 
use of prior experience and planning and preparation for action (Garakani et 
al., 2009). The peripheral effects include increased heart rate and blood 
pressure, and the modulation of the organism’s allocation of energy. 
Neurotransmitters and neuropeptides thus have evolutionarily important 
adaptive functions with regard to fear responses, but their dysfunction could 
be an important factor underlying pathological anxiety. Therefore, current 
pharmacological treatment of anxiety disorders is based on targeting specific 
components of relevant neurotransmitter signaling systems, which has 
behavioral consequences. Pharmacological or genetic manipulation of 
neurotransmitters or their receptors in animals create models of anxiety-like 
behavioral, enabling functional studies of the underlying neural circuits. In 
humans, methods combining use of pharmacological agonists and 
antagonists of specific neurotransmitters with behavioral challenge tests and 
functional neuroimaging help to understand the function of neurotransmitter 
systems relevant for anxiety. 
The four main neurotransmitter systems implicated and studied in 
anxiety disorders are the GABA (γ-aminobutyric acid)ergic, serotonergic, 
noradrenergic and dopaminergic systems (Durant et al., 2010). 
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γ-aminobutyric acid (GABA) 
 
GABA is the major inhibitory neurotransmitter in the central nervous system 
(CNS), and thereby the principal regulator of the excitability of neurons and 
ongoing neural activity (Nutt, 2006). It is synthesized from glutamate by the 
glutamate decarboxylase enzymes. GABAergic neurons are widespread 
throughout the brain, and GABA has at least three main receptor types 
(Bormann, 2000). The most widely studied GABA receptor in the context of 
anxiety is the most common one, GABAA, as subtypes of it are targeted by the 
benzodiazepine class of anxiolytics. Enhancing GABA signaling with GABAA 
–agonists has anxiolytic and sedative effects, while attenuating it with 
inverse agonists increases anxiety, arousal and restlessness (Durant et al., 
2010). Consistently, there is clinical evidence supporting that subjects with 
PD and social phobia have lower brain GABA levels (Pollack et al., 2008; 
Chang et al., 2003). 
 
Serotonin (5HT) 
 
Serotonergic neurons arise from the so called raphe nuclei in the brainstem, 
and project throughout the forebrain (Durant et al., 2010). Serotonin (5HT; 
5-hydroxytryptamine) is synthesized from the amino acid tryptophan. In 
general, serotonin influences central processing of emotional information 
(Harmer, 2008). Its release can have both anxiolytic and anxiogenic effects, 
depending on which region of the forebrain is involved, and which receptor 
subtype is activated (Garakani et al., 2009). One theory proposes that 5HT 
has dual roles in anxiety regulation: on one hand, it increases defensive 
responses and anticipatory anxiety by activating the amygdala and PFC, on 
the other hand, it inhibits the fight-or-flight response by activating the 
periaqueductal grey. This may explain why no simple relationships between 
the serotonergic system and anxiety have been established, and there is 
evidence supporting both a 5HT excess, and 5HT deficiency theory in anxiety 
predisposition (Durant et al., 2010). The serotonergic system components 
most relevant for anxiety are the 5HT1A receptor (one of 13 identified 
receptors) and the serotonin transporter (5HTT). In particular, selective 
serotonin reuptake inhibitors (SSRIs) are the most common group of 
anxiolytics used today, and they block the uptake of 5HT from the synaptic 
cleft by the 5HTT. Particularly relevant from a genetic perspective is the 
existence of a length repeat in the promoter region of the 5HTT encoding 
gene SLC6A4, which influences its expression level and thereby 5HT uptake. 
This repeat has been extensively evaluated for association to mood and 
anxiety disorder phenotypes since it was first shown to interact with stressful 
life events in influencing depression (Caspi et al., 2003). Although some 
smaller negative meta-analyses of the interaction exist (Munafo et al., 2009a; 
Risch et al., 2009), the largest one to date supports that the functional repeat 
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sequence in 5HTT moderates the relationship between childhood/life stress 
and depression (Karg et al., 2011). 
 
Norepinephrine (NE) 
 
Norepinephrine, also called noradrenaline, levels are increased in the brain 
in response to stress and modulate behavioral components of the stress 
response (Garakani et al., 2009). Most noradrenergic neurons arise in the 
locus coeruleus, and project from there throughout the forebrain (Durant et 
al., 2010). There are two main types of NE adrenoreceptors, α and β, with the 
α2-receptor subtype appearing to be the most relevant one for anxiety 
disorders. Generally, agonists of adrenoreceptors have anxiolytic effects, 
whereas antagonists are anxiogens that may e.g. induce panic attacks. 
Activation of adrenoreceptors mediates many of the autonomous nervous 
system-dependent effects of anxiety that underlie the fight-or-flight 
response, such as increased heart rate, blood pressure and sweating. 
 
Dopamine (DA) 
 
Dopamine is synthesized from the amino acid tyrosine, and it is used as a 
neurotransmitter in several brain regions important for anxiety behavior. 
The main dopaminergic pathways include the nigrostriatal, mesolimbic and 
mesocortical ones (Durant et al., 2010). These are important for, among 
other things, stress responsiveness and reward behavior in brain regions 
such as the ventral tegmental area. There are clinical observations, and 
imaging studies suggesting that there might be a link between dopamine 
deficiency and social phobia (Tiihonen et al., 1997; Berrios et al., 1995). 
 
Neuropeptides 
 
Neuropeptides are small polypeptide signaling molecules that act as 
neurotransmitters or hormones and modulate neuronal function by binding 
to their specific receptors. They are involved in a wide variety of functions, 
such as regulation of feeding behavior, arousal and wakefulness, anxiety, 
learning and memory, lactation, pain and inflammatory responses (Hokfelt 
et al., 2000). The behavioral effect of some neuropeptides is to increase 
anxiety, whereas others are anxiolytic. Examples of neuropeptides that are 
particularly relevant for the regulation of anxiety are corticotropin-releasing 
hormone, neuropeptide Y, neuropeptide S, oxytocin, cholecystokinin, galanin 
and arginine vasopressin (Garakani et al., 2009; Madaan and Wilson, 2009; 
Thorsell, 2008; Xu et al., 2004; Bradwejn et al., 1991). Whereas NPY is an 
example of a ubiquous anxiolytic neuropeptide (Wu et al., 2011), injections of 
cholecystokinin tetrapeptide (CCK-4) can be used to induce panic attacks for 
experimental purposes (Bradwejn et al., 1991). In general, neuropeptides 
thus represent promising, and as of yet underexplored, targets for novel 
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anxiolytics (Madaan and Wilson, 2009). However, given that they usually 
have widespread behavioral and physiological effects, questions regarding 
their specificity and safety still remain to be resolved. 
Many neuropeptides participate in the function of, or interact with, the 
hypothalamic-pituitary-adrenal (HPA) axis that controls stress responses 
and homeostatic processes related to digestion, energy allocation, sexuality, 
and mood or emotions. The relevance of this axis for anxiety is described 
next.    
 
Hypothalamic-pituitary-adrenal (HPA) -axis  
 
The neurocircuitry of anxiety overlaps and interacts with that of the stress 
response, of which the HPA-axis is an important component. The HPA-axis 
is a neuroendocrine system that consists of a set of interactions and feedback 
regulation between mainly the paraventricular nucleus of the hypothalamus, 
the anterior lobe of the pituitary gland, and the adrenal cortices (Figure 6, 
page 38). Upon a stressful stimulus, the neuropeptides corticorticotropin-
releasing hormone (CRH) and arginine vasopressin (AVP) are synthesized 
and secreted from the paraventricular nucleus (Pego et al., 2010). They in 
turn stimulate the release of adrenocorticotropic hormone (ACTH) from the 
pituitary. It is transported by the blood to the adrenal cortex, where it 
stimulates the production of glucocorticoids such as the stress hormone 
cortisol. The glucocorticoids are important for the adaptive response to 
stress, as they dampen the immune and inflammatory responses, and 
influence energy metabolism by stimulating gluconeogenesis and release of 
substrates for energy production (Tsigos and Chrousos, 2002). Cortisol also 
has important central effects relevant for anxiety behavior, as it modulates 
the function of the amygdala, hippocampus, and PFC (Garakani et al., 2009). 
These actions are mainly mediated by binding of glucorticoids to the 
ubiquously distributed glucocorticoid receptor (Tsigos and Chrousos, 2002). 
Dysregulation of the HPA-axis has been observed in several mood- and 
anxiety disorders. One consensus interpretation suggests that HPA-
hyperreactivity is consistenly seen in depression, while the more 
heterogeneous anxiety disorder classes show a wider spectrum of HPA-
alterations (Pego et al., 2010). As examples, PD subjects may have 
exaggerated and hypersensitive HPA-activity in response to novelty or 
contextual cues (Abelson et al., 2007), whereas patients with PTSD may have 
hypoactive HPA-axis responses (Yehuda et al., 1995). Of particular relevance 
for the development of anxiety disorders later in life may be early life 
traumatic events occuring during a developmental period of neuronal 
plasticity. These may cause persistent neuroendocrine changes that sensitize 
the HPA-axis, with predisposition for increased anxiety in adolescence and 
adulthood as a consequence (Bale et al., 2010; Gillespie et al., 2009).  
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2.3.6 TREATMENT 
 
Anxiety disorders are usually treated with anxiolytic medication, 
psychotherapy, or a combination of both. Medication is important for 
keeping many of the physiological and psychological symptoms under 
control, while underlying reasons for the disease are explored in therapy 
where behavioral change is supported.  
 
Pharmacological treatment 
 
The first drugs developed specifically to target symptoms of anxiety were 
barbiturates in 1903 (Durant et al., 2010). They were widely used until the 
1950s and were highly effective, but caused many accidental deaths due to 
respiratory arrest. They were therefore replaced by benzodiazepines in the 
1950s, which are still among the most prescribed drugs for anxiety disorders. 
Both barbiturates and benzodiazepines are now known to potentiate GABA 
receptor function. Examples of commonly prescribed benzodiazepines 
include diazepam, lorazepam, clonazepam, and alprazolam (Pillay and Stein, 
2007). Although benzodiazepines are effective in short term, they are usually 
prescribed only for short periods of time, as they are associated with physical 
and psychological dependence, and tolerance (Atack, 2010). They also have 
side effects such as sedation and cognitive impairment. 
In the 1960s, the anxiolytic effects of antidepressants such as the tricyclics 
imipramine and clomipramine, and monoamine oxidase inhibitors (MAOIs) 
such as phenelzine received attention (Bespalov et al., 2010). These drugs 
increase available levels of both serotonin and norepinephrine (by either 
inhibiting their re-uptake from the synapse or inhibiting the monoamine 
oxidase that degrades them, respectively), but their anxiolytic effects are 
thought to be due to their serotonergic component. However, also tricyclics 
and MAOIs have side effects by influencing physiological processes mediated 
by the autonomic nervous system, interaction with the dietary monoamine 
tyramine (MAOIs) and antihistamine effects (tricyclics). 
The selective serotonin re-uptake inhibitors (SSRI) class of 
antidepressants, such as fluoxetine, sertraline, escitalopram and paroxetine 
(Pillay and Stein, 2007) are considered a safer, more tolerable and efficient 
alternative than tricyclics and MAOIs (Bespalov et al., 2010). They are 
therefore the current recommended first line of treatment for anxiety 
disorder according to US and European treatment guidelines (Bandelow et 
al., 2008). SSRIs are believed to function by increasing levels of serotonin in 
the synaptic cleft by inhibiting its reuptake into the presynaptic cell. A 
disadvantage of SSRIs is that it takes up to several weeks for them to reach 
their full working potential. They also have a range of side effects, such as 
nausea, headache, and disturbances of sexual functioning. In addition to 
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SSRIs, also inhibitors of both serotonin and norepinephrine reuptake 
(SNRIs), such as venlafaxine and duloxetine, are in use.   
 
Cognitive-behavioral therapy 
 
Different types of cognitive-behavioral therapy are the most common type of 
psychotherapy for anxiety disorders. Methods used include exposure 
programs, cognitive restructuring procedures, anxiety management 
techniques, and their combinations (Choi et al., 2010). Cognitive-behavioral 
therapy aims to help people change the thinking patterns that support their 
fears, and to change the way they react to anxiety-provoking situations. For 
instance, PD patients are taught to think that panic attacks do not indicate a 
heart attack, and social phobia patients that they are not constantly judged 
by others. Exposure therapy, where the patient gradually encounters the 
object or situation that is the focus of his/her fear more strongly, is used in 
treatment of phobias. 
 
Combining psychotherapy with medication 
 
In general, it is thought that best results for the treatment of anxiety 
disorders are achieved by a combination of psychotherapy and drug 
treatment. This view is supported by meta-analytic comparisons of 
pharmacotherapy combined with psychotherapy in depressive disorders 
(Cuijpers et al., 2009). However, with regard to anxiety disorders, there are 
also several disappointing large trials that suggest that combined treatment 
provides little benefit compared to either type alone, and that responses to 
combined treatment may vary across the disorder subtypes (Otto et al., 2007; 
Foa et al., 2002). Pharmacological targeting of symptoms alone without 
treating the root source of the disorder may be therefore not be the optimal 
treatment strategy. The possibility to pharmacologically enhance the new 
learning that occurs in psychotherapy has emerged as a promising and more 
efficient strategy (Choi et al., 2010). One notable example of this comes from 
treatment of fear of heights, where D-cycloserine (a partial agonist of the N-
methyl-d-aspartate receptor) treatment significantly accelerated the 
associative learning processes that are a part of fear extinction in patients 
undergoing behavioral exposure therapy (Ressler et al., 2004) 
To summarize, many anxiolytics are available but a large percentage of 
anxiety disorder patients show only partial response or treatment resistance 
(Trivedi et al., 2006). All anxiolytics have complicating side effects. 
Therefore, there is a need to develop safer, more specific and more efficient 
anxiolytics. 
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2.3.7 LINKAGE STUDIES 
 
The evidence suggesting that genetic factors are involved in determining 
anxiety predisposition has spurred numerous attempts at identifying specific 
susceptibility genes. Both studies using clinical dichotomous anxiety 
disorders, as well as quantitative measures of anxiety-related personality 
traits as phenotypes, have been carried out. In addition, both genome-wide 
linkage scans in families, and candidate gene analyses in case-control cohorts 
have been performed. Most recently, following the general trend in genetic 
mapping research, GWA studies have been carried out. The most promising 
findings from gene mapping attempts in anxiety disorders are described in 
the following sections. They are graphically summarized in Figure 7, page 52. 
Few linkage analysis findings in anxiety disorders meet the criteria for 
genome-wide significance, LOD ≥ 3.3. Therefore, both these loci, and loci 
showing suggestive linkage (as defined by Lander and Kruglyak, 1995; LOD ≥ 
1.9) in at least two independent samples are summarized in Table 4. Notably, 
due to the limited number of studies that have been carried out with each 
specific phenotype, solid susceptibility loci are scarce when requiring 
findings to the same phenotype and chromosomal position. Some potentially 
interesting overlaps are observed when anxiety disorders and anxiety-related 
personality traits are considered together. Of particular interest are loci on 7p 
(implicated in PD and neuroticism), 12q (neuroticism and shared genetic risk 
for PD and bipolar disorder), 13q (broadly defined PD syndrome), 14q (OCD, 
neuroticism, trait anxiety and phobias), and 22q (neuroticism and PD 
syndrome). Overall, there has been disappointingly little success in 
identifying specific susceptibility genes under the linkage peaks, and they 
typically harbor a large number of potential candidates. Fine mapping 
attempts also suffer from many of the same limitations as candidate gene 
association studies, described below. 
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Table 4. Genome-wide linkage scans in anxiety disorders and related personality 
traits. Peaks were included if showing significant evidence for linkage (LOD ≥ 3.3) in at least 
one study, or if there was suggestive evidence (LOD ≥ 1.9) in more than one study.   
Linkage 
peak 
position
Maximum 
LOD score/ 
P-value
Phenotype
Subjects
(N subjects/families)
Population Reference
1p21 2.16 OCD 35/3 Costa Rica Ross et al., 2011
1p22 3.25 EPQ neuroticism 561 sibpairs England Fullerton et al., 2003
2p22 3.3 PD 992/120c USA Logue et al., 2009
2q37 4.6 PD + bipolar disorder risk 992/120c USA Logue et al., 2009
3q27.3 2.9 OCD/compulsive hoarding 919/219a USA Samuels et al., 2007
3q27-28 2.67 OCD 649/219a USA Shugart et al., 2006
4q31 3.15 EPQ neuroticism subscale 561 sibpairs England Fullerton et al., 2003
4q31-4q34 4.3x10-4 Anxiety disorders 219/19b Connecticut Kaabi et al., 2006
7p14 3.18 EPQ neuroticism 561 sibpairs England Fullerton et al., 2003
7p14.1 2.23 PD or panic attacks 113/23 US Midwest Crowe et al., 2001
7p15.1 2.45 PD 368/23c USA Knowles et al., 1998
9q31.1 4.18 PD 67/25 Iceland Thorgeirsson et al., 2003
10p14-15.3 2.0 EPQ/NEO neuroticism 5069 sibpairs
Australia and 
Netherlands
Wray et al, 2008
10p15 2.43d OCD 121/26 USA Hanna et al., 2007
12q23 3.6 PD + bipolar disorder risk 992/120c USA Logue et al., 2009
12q23.1 3.95 EPQ neuroticism 561 sibpairs England Fullerton et al., 2003
12q24.3 2.13 EPQ neuroticism 714 sibpairs Ireland Kuo et al., 2007
13q32 4.2 PD syndrome 476/34c USA Weissman et al., 2000
13q32.1-q32.3 3.57 PD syndrome 587/60c USA Hamilton et al., 2003
14q13 3.7 Specific phobia 129/14 Connecticut Gelernter et al., 2003
14q31.3 3.66 OCD/compulsive hoarding 919/219a USA Samuels et al., 2007
14q32.1 2.6 EPQ/NEO neuroticism 5069 sibpairs
Australia and 
Netherlands
Wray et al, 2008
14q32.2 3.4 State Trait Anxiety Inventory 2188/566 Netherlands Middeldorp et al., 2008 
16p12.1 1.9 PD or panic attacks 113/23 US Midwest Crowe et al., 2001
16p13.3-p13.2 3.13 PD syndrome 587/60c USA Hamilton et al., 2003
21q22 3.42d NEO neuroticism
221 descendants of 
20 related couples
Netherlands Amin et al,. 2011
22q11 3.07 NEO neuroticism
221 descendants of 
20 related couples
Netherlands Amin et al,. 2011
22q12.3-q13.1 4.11 PD syndrome 587/60c USA Hamilton et al., 2003
a, b, c Partially overlapping families
d Non-parametric LOD
Chr = chromosome; EPQ = Eysenck Personality Questionnaire; LOD = logarithm of the odds; NEO = Neuroticism-
Extraversion-Openness Personality Inventory; OCD = obsessive-compulsive disorder; PD = panic disorder; PD
syndrome = PD with bladder/renal conditions, serious headaches, thyroid problems and/or mitral valve 
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2.3.8 CANDIDATE GENE STUDIES 
 
Selection of genes for examination in candidate gene association studies of 
anxiety disorders has primarily been based on prior assumptions about the 
underlying biology. The most studied candidates are genes encoding proteins 
involved in neurotransmitter metabolism and signaling, proteins targeted by 
anxiolytics, neuropeptides and genes of the stress response. Among the 
single most studied genes are COMT (catechol-O-methyltransferase) and 
SLC6A4 (serotonin transporter). COMT degrades dopamine, epinephrine 
and norepinephrine and thereby influences neurotransmitter levels, whereas 
SLC6A4 is responsible for the uptake of serotonin from the synaptic cleft. 
Due to the large number of association studies carried out and the high 
probability that some published associations are spurious, strict criteria are 
needed to identify the most likely true susceptibility genes. Genes showing 
evidence for association with P ≤ 0.01 in at least two independent studies of 
anxiety disorders or anxiety-related personality traits are summarized in 
Table 5. Yet stricter criteria would be requiring that the same allele of the 
same variant has been associated with the same phenotype in at least two 
studies. Such level of evidence has been obtained for COMT (in PD and 
OCD), HTR2A (5-hydroxytryptamine [serotonin] receptor 2A; in PD), DRD2 
(dopamine receptor D2; in PTSD) and FKBP5 (FK506-binding protein 5; in 
PTSD). However, it is important to note that the majority of published 
studies for the listed genes are in fact negative (Smoller et al., 2009).  
Meta-analyses of the three most studied individual variants, Val158Met in 
COMT, the promoter length repeat polymorphism (5-HTTLPR) in SLC6A4 
and Val66Met in BDNF (brain-derived neurotrophic factor) exist. They 
suggest that COMT Val158Met is a susceptibility factor for PD, but the risk 
allele shows ethnic heterogeneity and effects female-specificity (Domschke et 
al., 2007). Meta-analyses of 5-HTTLPR and neuroticism/harm avoidance 
show conflicting results, suggesting that its effect, if any, is minor (Munafo et 
al., 2009b; Sen et al., 2004). Overall, Met-carriers of BDNF Val66Met have 
lower neuroticism scores, but there was no association between the variant 
and anxiety disorders (Frustaci et al., 2008). Taken together, it is difficult to 
make solid claims regarding links between the most popular candidate genes 
for neuropsychiatric disorders and susceptibility to anxiety. However, animal 
evidence supporting their involvement in regulation of anxiety-like behavior 
should not be forgotten (e.g., Papaleo et al., 2008; Holmes et al., 2003). 
Lately, it has been increasingly acknowledged that gene x environment 
(GxE) interactions play an important role in determining individual variation 
in stress resilience and vulnerability to mental disorders (Wermter et al., 
2010). Several studies have thus examined genetic variation for effects in 
modulating disease predisposition in interaction with the environment.  The 
environmental factors most studied in the context of anxiety are childhood 
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adverse life events, which are known strong risk factors for anxiety disorders 
later in life (Green et al., 2010). Again, the length polymorphism of SLC6A4 
has received the most attention after the initial finding that it modulates the 
effect of stressful life events on depression, depressive symptoms and 
suicidality (Caspi et al., 2003). This finding is supported by the largest meta-
analysis of the interaction to date, in particular with childhood maltreatment 
as the stressor (Karg et al., 2011). Interactions between SLC6A4 and early life 
stress in influencing anxiety sensitivity and PTSD diagnosis were also seen 
(Xie et al., 2009; Stein et al., 2008). Recent GxE findings in anxiety further 
include interaction of FK506-binding protein 5 (FKBP5), a regulator of 
glucocorticoid receptor sensitivity, with early life stress in modulating risk for 
PTSD symptoms and diagnosis (Xie et al., 2010; Binder et al., 2008). 
A likely reason for the many discrepancies in the candidate gene literature 
of anxiety- and other neuropsychiatric disorders is that many studies, 
especially in the early days, were performed with small sample sizes. They 
were underpowered to detect the modest effects now thought to be conferred 
by individual risk variants. The genetic and phenotypic heterogeneity that 
underlie complex mental disorders have further complicated their study, 
increasing the sample size required to observe statistically significant 
evidence for association that survives correction for multiple testing.  
Table 5. Putative susceptibility genes for anxiety disorders and related personality 
traits. Only genes showing evidence for association with P ≤ 0.01 in at least two 
independent human study samples were included in this summary. 
Gene 
symbol
Gene name Phenotype References
ADORA2A adenosine A2a receptor PD, TPQ harm avoidance
Hohoff et al., 2010;
Deckert et al., 1998
BDNF brain-derived neurotrophic factor OCD, phobias, TCI harm avoidance
Xie et al., 2011; Montag et al., 
2010; Hall et al., 2003
CCKBR cholecystokinin B receptor PD
Hösing et al., 2004; Kennedy et 
al., 1999
COMT catechol-O -methyltransferase
PD, OCD, phobic anxiety, TCI harm 
avoidance, genetic susceptibility 
shared by anxiety spectrum 
phenotypes
Hettema et al., 2008; Pooley et 
al., 2007; Kim et al., 2006; Rothe 
et al., 2006; McGrath et al., 2004
DRD2 dopamine receptor D2 PTSD, GAD, social phobia
Sipilä et al., 2010; Lawford et al., 
2006; Young et al., 2002
FKBP5 FK506-binding protein 5 PTSD Xie et al., 2010; Binder et al., 2008
HTR2A 5-hydroxytryptamine receptor 2A PD, OCD
Maron et al., 2005; Meira-Lima et 
al., 2004; Inada et al., 2003
MAOA monoamine oxidase A PD, GAD, phobias
Samochowiek et al., 2004; Tadic 
et al., 2003; Deckert et al., 1999
RGS2
regulator of G-protein signaling 2, 
24kDa
PD, PTSD symptoms, behavioral 
inhibition
Otowa et al., 2011; Amstadter et 
al., 2009;Smoller et al., 2008
SLC6A4
solute carrier family 6 
(neurotransmitter transporter, 
serotonin), member 4
PD, OCD, STAI, anxiety and/or MD, 
neuroticism 
Costas et al., 2010; Wray et al., 
2009; Strug et al., 2010; Bloch et 
al., 2008
GAD = generalized anxiety disorder; MD = major depression; OCD = obsessive-compulsive disorder; PD = panic disorder;
PTSD = post-traumatic stress disorder; STAI = State Trait Anxiety Inventory; TCI = Temperament and Character Inventory;
TPQ = Tridimensional Personality Questionnaire  
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2.3.9 GENOME-WIDE ASSOCIATION STUDIES 
 
As previously noted, hypothesis-free GWA studies are now commonplace in 
the study of complex disorders. A limited number of such studies have 
examined anxiety-related phenotypes, and only one has reported genome-
wide significant results (P < 5 x 10-8; defined by Risch and Merikangas, 
1996). All studies performed to date that have reported at least suggestive 
associations (P < 10-4) are summarized in Table 6. 
 
Table 6. Genome-wide association studies in anxiety disorders and related 
personality traits. SNP findings are ranked from most to least significant evidence for 
association. 
Implicated 
chromosomal 
position
Implicated 
gene
Most 
significant 
P-valuea
Phenotype
Subjects
(cases/
controls)a
Population Reference
12p13 ANO2  (anoctamin 2) 3.7x10-9 PD 200/200 Japan
Otowa et al., 
2009
1q32 PKP1 (plakophilin 1) 4.6 x 10-8 PD 200/200 Japan
Otowa et al., 
2009
13q32 GPC6 (glypican 6) 1.0x10-7 b
EPQ 
neuroticism 
2235 
subjects
Switzerland
Calboli et al., 
2010
12q24.33
TMEM132D (transmembrane 
protein 132D)
1.2x10-7 PD 909/915 Germany
Erhardt et al., 
2011
17q25 SDK2  (sidekick homolog 2) 2.1x10-7 PD 200/200 Japan
Otowa et al., 
2009
13q32 - 3.1x10-7 PD 200/200 Japan
Otowa et al., 
2009
12q13
CALCOCO1 (calcium binding and 
coiled-coil domain 1)
3.3x10-7 PD 200/200 Japan
Otowa et al., 
2009
6q21
NKAIN2  (Na+/K+ transporting 
ATPase interacting 2)
3.4x10-7
EPQ 
neuroticism 
2235 
subjects
Switzerland
Calboli et al., 
2010
6q25
PLEKHG1 (pleckstrin homology 
domain containing, family G)
4.9x10-7 PD 200/200 Japan
Otowa et al., 
2009
8p21 CLU  (clusterin) 6.8x10-7 PD 200/200 Japan
Otowa et al., 
2009
14q21.3
MDGA2  (MAM domain containing 
glycosylphosphatidylinositol anchor 2)
6.9x10-7
EPQ 
neuroticism 
3107 
subjects
USA
van den Oord 
et al., 2008
6q14.1 LCA5  (Leber congenital amaurosis 5) 7x10-7 Hoarding
3410 
subjects
Caucasian
Perroud et al., 
2011
15q26.3 ARRDC4  (arrestin domain containing 4) 1.5x10-6
EPQ 
neuroticism 
2235 
subjects
Switzerland
Calboli et al., 
2010
5q11.2 - 2x10-6 Hoarding
3410 
subjects
Caucasian
Perroud et al., 
2011
5q12
PDE4D  (phosphodiesterase 4D, 
cAMP-specific)
2x10-6
EPQ 
neuroticism 
3500 
subjects
England
Shifman et al., 
2008
20p12-p11.2
SNAP25 (synaptosomal-associated 
protein, 25kDa )
5x10-5
NEO 
neuroticism 
7012 
subjects
Sardinia, USA 
and Netherlands
Terracciano et 
al., 2010
a Based on inclusion of replication samples, where applicable
b P-value for interaction with age
EPQ = Eysenck Personality Questionnaire; Hoarding = acquisition of items in pathological excess, and failure to discard
them - a manifestation of obsessive-compulsive disorder; NEO = Neuroticism-Extraversion-Openness Personality
Inventory; PD = panic disorder
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One general implication from GWA studies in anxiety-related phenotypes 
has been that the effect sizes of individual common risk variants on the 
phenotype are small, as in most other complex disorders (Bodmer and 
Bonilla, 2008). For instance, SNPs reported to influence neuroticism explain 
less than 1% of the total genetic variation in the trait (Shifman et al., 2008; 
van den Oord et al., 2008). Therefore, there is a call for studies performed by 
international collaborative networks with the larger sample sizes that are 
likely required to identify any putative common variants with small sample 
sizes. Such studies have already been performed in other psychiatric 
disorders, and are currently ongoing in anxiety disorders. 
Another general implication from the GWA studies performed to date is 
that there is little specific overlap with the linkage studies performed with the 
corresponding phenotypes. Notable and potentially interesting overlaps 
when considering clinical anxiety disorders and anxiety-related personality 
traits together include the 13q32 region, for which strong genetic linkage 
(LOD = 4.2) with a broadly defined PD syndrome was reported (Weissman et 
al., 2000), along with GWA associations with PD and neuroticism (Calboli et 
al., 2010; Otowa et al., 2009). However, no specific candidate genes have 
been conclusively identified in the region so far. 
Another interesting position may be the 12q23-24 reqion, which was 
implicated in linkage studies of neuroticism and shared genetic risk factors 
for PD/bipolar disorder (Logue et al., 2009; Kuo et al., 2007; Fullerton et al., 
2003). This region also showed significant association in a GWA study of PD 
(Erhardt et al., 2011). Extension of the study with two replication samples 
confirmed the observed associations with PD in the TMEM132D 
(transmembrane protein 132D) gene, but also showed that it associated with 
anxiety symptoms in a broader sense. The authors further demonstrated that 
anterior cingulate cortex expression levels of Tmem132d were positively 
correlated with anxiety-like behavior in a mouse models of extremes of trait 
anxiety, and a that a SNP from the gene associated with anxiety-related 
behavior. Taken together, TMEM132D is one of the more promising 
candidate genes to have been identified by the GWA approach, but its 
function in general, and in anxiety, is not well characterized yet. It is a 
membrane protein that could be involved in neural interconnection and 
signaling (Erhardt et al., 2011). 
Two other candidate genes first identified by GWA approaches have 
subsequently shown evidence for association in other independent studies, 
MDGA2 (MAM domain containing glycosylphosphatidylinositol anchor 2) 
and PDE4D (phosphodiesterase 4D). MDGA2 was first identified in a GWA 
of neuroticism in an American sample, and the findings were supported by 
replication in a German sample (van den Oord et al., 2008). A subsequent 
candidate gene study replicated the finding with neuroticism, and extended 
them by also reporting associations between the gene and harm avoidance 
(Heck et al., 2011). Although the function of MDGA2 is not well understood, 
it is expressed in the brain and it encodes an immunoglobulin domain cell 
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adhesion molecule that could regulate neuronal migration and axon 
guidance. PDE4D was identified in the first GWA of neuroticism that was 
published (Shifman et al., 2008), and some nominally significant support 
was obtained for the association in the largest neuroticism GWA to date 
(Calboli et al., 2010). PDE4D may well have behavioural effects relevant for 
anxiety, as it encodes an enzyme that degrades the important second 
messenger molecule cAMP (cyclic adenosine monophosphate). Furthermore, 
mice deficient of Pde4d show reduced depression-like behavior.  
The only two GWA findings meeting strict criteria for genomewide 
significance (P < 5 x 10-8) are from a study of PD in the Japanese population 
(Otowa et al., 2009). The two implicated genes were PKP1 (plakophilin 1) 
and ANO2 (anoctamin 2). Of these, PKP1 participates in desmosome 
formation, and ANO2 is a calcium-activated chloride channel. However, 
these findings have so far not been replicated in independent samples. 
Taken together, the GWA studies performed in anxiety disorders and 
related personality traits so far have identified a few new promising 
candidate genes. The hypothesis-free genome-wide scans have an important 
role in that they may lead to discoveries beyond the “usual suspect” 
candidate genes heavily studied in anxiety disorders. However, additional 
replication and functional studies are essential for confirming their 
involvement in susceptibility to anxiety. Figure 7 graphically summarizes the 
most promising results from human linkage studies, and candidate gene and 
genome-wide association studies, to date. 
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Figure 7 The genomic landscape of anxiety disorders and anxiety-related personality 
traits. Figure based on Tables 4, 5 and 6. Please refer to them for specifc references and full 
gene names. Linkage findings with either LOD ≥ 3.3 in one study, or LOD ≥ 1.9 in at least 
two independent studies, are shown on the right side of each chromosome. Candidate genes 
showing evidence for association with P ≤ 0.01 in at least two studies are shown in italics on 
the left side of each chromosome. The most promising gene findings from genome-wide 
association studies are shown in underlined italics on the left side of each chromosome. 
Cytogenetic map by courtesy of David Adler (www.pathology.washington.edu/ 
research/cytopages/idiograms/human/). 
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2.3.10 GENE EXPRESSION PROFILING STUDIES 
 
In addition to evaluations of differences in DNA-level variations between 
anxiety disorder patients and controls, gene expression profiling studies have 
also been carried out. Such studies aim to identify transcripts that are either 
up- or downregulated in high anxiety conditions. As expression levels are 
functional mediators of gene function, global gene expression profiling can 
lead to identification of regulatory networks and biological pathways that are 
dysregulated in disease states. Such studies have the additional advantage 
that they can be carried out on samples from the tissue most relevant for the 
investigated disease, such as post-mortem samples of specific brain regions. 
However, for practical reasons, most profiling studies done in human anxiety 
disorders so far were done using peripheral lymphoblasts as source material. 
The total number of performed gene expression studies is also limited. 
Two studies have examined gene expression profiles in panic-related 
phenotypes. The first compared lymphoblastoid transcriptomes of 16 PD 
patients and 17 controls, and identified ~3000 transcripts with either up- or 
downregulation in all patient cell lines (Philibert et al., 2007). 
Disappointingly, no enriched functional pathways were found among the 
differentially regulated transcripts. The second study used panic attacks 
induced in 31 healthy subjects by CCK-4 injections as an experimental model 
(Maron et al., 2010). Sixty-one transcripts were differentially expressed 
between subjects who responded to the CCK-4 challenge with a panic attack, 
and those who did not panic. Many of them were involved in immune 
response or related to the clinical phenotypes of disorders comorbid with PD, 
such as asthma, diabetes or coronary artery disease. Three transcripts were 
dysregulated in both of the aforementioned studies, namely SREBF2 (sterol 
regulatory element binding transcription factor 2), ARHGEF1 (Rho guanine 
nucleotide exchange factor 1) and EPSTI1 (epithelial stromal interaction 1), 
and in particular these should be further examined in PD susceptibility. 
All other gene expression profiling studies in anxiety have examined 
subjects with PTSD following trauma exposure. They were carried out with 
limited sample sizes and show little overlapping results (Sarapas et al., 2011; 
Zieker et al., 2007; Segman et al., 2005). The largest study to date (40 
subjects) examined survivors of the 9/11 World Trade Center attacks, and 
found distinct expression profiles associated with PTSD risk, resilience and 
symptom recovery (Sarapas et al., 2011). More specifically, the study 
identified MHC class II and FKBP5 (also showing GxE interactions in 
modulating PTSD symptoms; Xie et al., 2010) as state markers of PTSD with 
lower expression in subjects with active or remittent disease. 
To summarize, gene expression studies may result in identification of 
biomarkers or risk profiles for anxiety, but larger studies are needed. 
Moreover, the relevance of gene expression findings in peripheral blood for 
CNS pathology remains poorly examined in anxiety-related phenotypes. 
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2.3.11 ANIMAL MODELS 
 
In general, animal models offer advantages such as access to biomaterial 
from specific brain regions, minimized genetic heterogeneity in inbred 
strains and possibilities to control environmental effects and administer 
specific compounds. As discussed earlier, anxiety is an evolutionarily 
conserved response, and many of the biological mechanisms identified in for 
instance rodents are likely to be relevant also for human anxiety. A large 
variety of behavioral paradigms have been developed for the measurement of 
anxiety-like behavior in rodents, and pharmacologically validated with 
anxiolytic drugs. The most commonly used ones include the elevated plus 
maze (Lister, 1987), light/dark box (Crawley and Goodwin, 1980), and open 
field tests (Hall and Ballachey, 1932), which are all based on the approach-
avoidance conflict, or the choice a rodent has when exposed to a novel 
environment: to either explore the potentially threatening but also 
interesting surroundings, or stay in a more sheltered area. Other paradigms 
are based on social interaction or social defeat (Björkqvist, 2001; File and 
Hyde, 1978). Rodent paradigms likely model aspects of human anxiety, but 
no single optimal model exists for particular human anxiety disorders. 
There are a number of different experimental approaches that make use 
of animal models to either identify genes that influence anxiety, or to study 
the function of specific candidate genes. Examples of animal model-based 
approaches that have lead to important insight into mechanisms underlying 
anxiety, and identification of novel potential candidate genes, are given in the 
following sections. 
 
Mapping of quantitative trait loci (QTL) for anxiety 
 
More than a hundred different inbred mouse strains have been produced for 
laboratory use, such as C57BL/6, DBA/2, and BALB/c. They have different 
behavioral characteristics, including differential levels of innate anxiety, as a 
consequence of the genetic background. Quantitative trait locus (QTL)- 
mapping makes use of this to identify loci that influence a trait. The principle 
is to cross two inbred strains with extreme behavior (e.g., high and low 
anxiety). The F1 (filial 1) offspring will all have the same heterozygous 
genome, but when they are crossed with each other to produce the F2 
generation the result is genetically and phenotypically unique offspring. 
Finally, behavioral phenotyping of the F2 individuals is combined with 
genotyping of markers spread throughout the genome. The final analysis is a 
genome-wide linkage scan for loci influencing the trait of interest, followed 
by fine mapping efforts. Nowadays, panels of recombinant inbred mice with 
genomes that are random mosaics of founder haplotypes from parental 
inbred strains (typically two strains) are available, and offer an easier start 
for QTL-mapping studies (Flint et al., 2005). Efforts like the Collaborative 
Cross that aim to create recombinant inbred strains that are mosaics of up to 
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eight different inbred mouse strains are ongoing. Such efforts would allow for 
much greater mapping resolution, which would be important as the main 
disadvantage of QTL-mapping is that the identified QTLs are typically large 
(10-20 cM) and contain many polymorphisms in several potential candidate 
genes. 
Multiple QTL-mapping efforts focusing on murine anxiety have been 
published (Henderson et al., 2004; Turri et al., 2001). The corresponding 
chromosomal regions have subsequently been tested for linkage or 
association to PD, anxiety proneness and behavioral inhibition in human 
study samples (Smoller et al., 2001; Smoller et al., 2001). The only true 
success story in QTL-mapping of anxiety-related phenotypes is identification 
of the Rgs2 (regulator of G-protein signaling 2) gene. A QTL for emotionality 
was first identified on chromosome 1 (Flint et al., 1995), and subsequently 
finemapped to a narrow 0.8 cM interval in the 58th generation of mice 
originally descending from 8 inbred mouse strains (Talbot et al., 1999). A 
quantitative complementation approach finally identified the gene 
responsible for the signal as Rgs2 (Yalcin et al., 2004). Today, genetic 
variation in RGS2 has been associated with human PD, PTSD symptoms and 
behavioral inhibition (Otowa et al., 2011; Amstadter et al., 2009; Smoller et 
al., 2008b). Remarkably, a SNP in RGS2 was estimated to explain 10-15% of 
the variation in amygdala and insular cortex activation in response to 
emotional faces (Smoller et al., 2008b). 
 
Gene expression and proteomics-based approaches for identification of 
genes influencing anxiety 
 
Global gene expression and proteomic profiling approaches have also been 
used in animal models to identify genes and biochemical pathways important 
for anxiety. In one study particularly relevant for the work presented in this 
thesis, Hovatta et al. used inbred mouse strains that differ in their innate 
levels of anxiety-like behavior as a model, and performed gene expression 
profiling of seven brain regions involved in the regulation of anxiety (Hovatta 
et al., 2005). They found 17 genes with an expression pattern that correlates 
with anxiety, suggesting that they may modulate the trait. Due to its 
relevance for the candidate gene selection of this thesis, the work of Hovatta 
et al. is described in more detail in the Materials and Methods (section 4.2).  
Other laboratories have used selective breeding schemes to produce 
mouse strains with high or low anxiety-like behavior (HAB and LAB, 
respectively) from outbred strains. Recently, two independent studies 
comparing brain region transcription profiles of such HAB and LAB strains 
were published (Czibere et al., 2011; Virok et al., 2011). Czibere et al. 
identified four genes with large (> 500%) expression changes between the 
strains in all examined brain regions, namely Abca2 (ATP-binding cassette, 
sub-family A member 2), Ctsb (cathepsin B), Enpp5 (ectonucleotide 
pyrophosphatase /phosphodiesterase 5) and Ttbk1 (tau tubulin kinase 1). Of 
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these, Ctsb emerged as the most promising novel candidate for influencing 
emotionality, as Ctsb-deficient mice showed increased anxiety-like behavior. 
Virok et al. identified both previously known and novel functional gene 
networks among the gene sets differentially regulated between HAB and LAB 
mice. One of the most prominent findings was alterations of neuropeptide-
encoding genes and members of neuropeptidergic signaling, such as NPY, 
neurotrophin 3, neurotensin and angiotensinogen. 
Similarly, proteomic comparisons of brain tissues from HAB and LAB 
mice have been made to identify changes in protein levels potentially 
relevant for anxiety. Enolase-phosphatase 1 (Enoph1) and glyoxalase 1 (Glo1) 
were identified by 2D polyacrylamide gel electrophoresis combined with 
mass spectrometry as protein markers of anxiety (Ditzen et al., 2010; Krömer 
et al., 2005). HAB and LAB mice have different isoforms of Enoph1, a 
member of the methionine salvage biochemical pathway, with the HAB strain 
isoform having relatively lower enzyme activity (Ditzen et al., 2010). HAB 
mice also have lower levels of Glo1, an antioxidative and detoxification 
enzyme that protects agains oxidative stress (Krömer et al., 2005). 
Downregulation of Glo1 in the brain of anxious mice was also observed 
among the 82 differentially expressed proteins discovered by a separate 
laboratory using a similar selective breeding approach (Szego et al., 2010). In 
contrast, upregulation of Glo1 in more anxious inbred mouse strains was 
observed in the gene expression profiling work mentioned above (Hovatta et 
al., 2005). Moreover, local overexpression of Glo1 in the cingulate cortex 
increased anxiety-like behavior, whereas silencing decreased it, further 
supporting a causal role between Glo1 levels and anxiety. It has now become 
evident that the difference in Glo1 expression between inbred mouse strains 
is due to a copy number variant, the presence of which correlates positively 
with anxiety-like behavior (Williams et al., 2009). These findings, combined 
with observations of reduced Glo1 expression in human patients with active 
depression or bipolar disorder (Fujimoto et al., 2008), underscore the need 
for further studies of the gene as a potential susceptibility factor for 
psychiatric disorders.  
In recent years, the importance of miRNAs as functionally important 
post-transcriptional regulators of gene expression has been realized. miRNAs 
bind to complementary sequences on target mRNA transcripts, typically 
conferring translational repression or target degradation and thereby gene 
silencing. Attempts to identify specific disease-associated miRNAs have been 
made. So far, no large scale studies have been made in anxiety-related 
phenotypes. One study looked for hippocampal miRNA expression 
differences between four inbred mouse strains, and reported 11 miRNAs with 
expression patterns that correlated significantly with different behavioral 
measures (Parsons et al., 2008). Of these, the most relevant for anxiety were 
miR-34c and miR-323. Later on, it was shown that lentiviral-mediated 
overexpression of miR-34c in the central amygdala induces anxiolytic 
behavior (Haramati et al., 2011). 
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To summarize, some promising candidate genes for influencing anxiety 
have first been identified by animal-model based identification strategies 
such as QTL-mapping and global expression/proteomic approaches. For 
some genes (e.g., Rgs2 and Glo1), there has been some subsequent evidence 
demonstrating also potential relevance for human psychiatric disorders. 
 
Genetically modified animal models 
 
Transgenic models are an important tool for understanding how a specific 
gene functions and influences behavior. A large number of knockout mouse 
strains have been assessed for differences in anxiety-like behavior. It is also 
possible to make conditional models, with the gene deficiency or 
overexpression specific to a certain tissue or developmental time point. A 
general feature of studies of anxiety-related phenotypes in genetically 
modified animals has been that results are not always consistent between 
studies, or different behavioral paradigms within the same study. Potential 
reasons for this include different genetic background of the animals, slightly 
different protocols for behavioral testing between laboratories and that 
different paradigms may measure different aspects of anxiety-like behavior. 
There are also commonly other mechanisms that are able to compensate for 
the introduced gene deficiency, and thereby rescuing the phenotype of the 
transgenic animal. 
The most studied models are mice that lack genes functioning in 
neurotransmitter systems regulating anxiety, such as norepinergic, 
serotonergic and GABAergic genes, or genes involved in function of the HPA-
axis (reviewed in Finn et al., 2003). Some of the most solid (in more than one 
behavioral test) reported anxiety-related phenotypes are from mice lacking 
Slc6a4, Htr1a, Gabrg2 (GABAA receptor, subunit γ2) or Gad65 (glutamic 
acid decarboxylase, 65 kDa isoform). All of the above show increased anxiety-
like behavior. Examples of knockout mice showing decreased anxiety-related 
behaviour include mice deficient for the glucocorticoid receptor (N3rc1), 
Htr1b or Crhr1 (corticotropin releasing hormone receptor 1). 
In addition, transgenic mouse models that overexpress desired genes of 
interest have been made. Examples include mice that overexpress human 
variants of COMT and show alterations in cognitive and affective functions 
relevant for anxiety (Papaleo et al., 2008), and mice that overexpress the 
neurotrophin-3 receptor TrkC in the brain and show increased anxiety-like 
behavior and enhanced panic reaction as a consequence (Dierssen et al., 
2006). 
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3 AIMS OF THE STUDY 
The aim of the present study was to extend knowledge on the genetic basis of 
human anxiety disorders by examining whether there is predisposing genetic 
variation in selected novel and previously implicated candidate genes.  
 
The following specific aims were addressed in the studies included in this 
thesis:  
 
1. To investigate whether any of the human homologues of 13 murine 
anxiety candidate genes, selected based on up- or downregulated 
expression in inbred mouse strains with higher innate anxiety, 
predisposes to human anxiety disorders in the Finnish population-
based Health 2000 anxiety disorder study sample (Study I). 
 
2. To investigate whether the genes encoding the asthma susceptibility 
factor neuropeptide S receptor 1 (NPSR1) and its ligand neuropeptide 
S (NPS) are involved in anxiety susceptibility in three independent 
samples from Finland, Spain and Sweden (Study II). 
 
3. To investigate whether genetic variation in any of 16 putative anxiety 
susceptibility genes, selected based on previously reported 
associations with human anxiety disorders or anxiety-related 
personality traits, predisposes to anxiety disorders in the Health 2000 
anxiety disorder study sample (Study III). In addition, we aimed to 
test whether any of the studied candidate polymorphisms interacted 
with childhood adverse life events in modulating the risk for anxiety 
disorders. 
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4 MATERIALS AND METHODS 
All methods used in this study have been described in detail in the original 
publications (I-III). An overview of the methods is presented here (Table 7) 
and their use is explained in the following sections.  
 
Table 7. Overview of the methods used in the present study 
Method Reference Publication(s)
Experimental procedures
5'-nuclease cleavage assay (TaqMan) 
genotyping
Applied Biosystems, Foster City, CA, USA III
DNA extraction Gentra Systems, Minneapolis, MN, USA I, II, III
Electrophoretic mobility shift assay (EMSA) Cold Spring Harbor Laboratory Press, 2005 II
Immobilization stress Buynitsky and Mostofsky, 2009 II
Polymerase Chain Reaction (PCR) I, II, III
RNA extraction
Molecular Research Center, Cincinnati, 
OH, USA
II
Sequenom MassARRAY iPLEX and iPLEX 
Gold SNP genotyping
Sequenom, San Diego, CA, USA I, II, III
SNPlex multiplex genotyping Applied Biosystems, Foster City, CA, USA II
Quantitative Real-Time PCR with SYBR 
Green chemistry
Applied Biosystems, Foster City, CA, USA II
Statistical methods and analysis software
Genetic Power Calculator Purcell et al., 2003 I, II
Haploview Barret et al., 2005 I, II, III
Inverse-variance meta-analysis Borenstein et al., 2009 III
Likelihood-Ratio Test for Case-Control 
Material
Terwilliger and Hiekkalinna,
 unpublished software
I, II, III
Locusview
Petryshen, Kirby and Ainscow, 
unpublished software
I, II, III
Logistic regression modelling of gene x 
environment interactions
Caspi et al., 2003 III
MEGA Tamura et al., 2007 II, III
Pedcheck O'Connell and Weeks, 1998 I, II, III
SNPInspector and MatBase Genomatics, Munich, Germany II
Tagger deBakker et al., 2005 I, II, III
Typer Analyzer Sequenom, San Diego, CA, USA I, II, III
Unphased Dudbridge et al., 2003 I, II, III
Databases and online resources
dbSNP www.ncbi.nlm.nih.gov/projects/SNP I, II, III
Ensembl www.ensembl.org I, II, III
HapMap http://hapmap.ncbi.nlm.nih.gov/ I, II, III
Patrocles http://patrocles.org/ I
SNPper http://snpper.chip.org/ I, II, III
UCSC Genome Browser http://genome.ucsc.edu I, II, III  
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4.1 STUDY SAMPLES 
Four different case-control study samples with different properties and from 
four different countries were used in the original publications of this study. 
Their characteristics are summarized in Table 8, and they are described in 
more detail in the following sections.  
 
The Finnish Health 2000 anxiety disorder study sample (I, II and III) 
 
The core sample of all three studies was an anxiety disorder sample derived 
from the population-based epidemiological Health 2000 Study, carried out 
in 2000-2001 by investigators of the National Public Health Institute 
(currently the Institute for Health and Welfare). Its aim was to assess major 
public health problems, functioning, and their determinants in adult Finns 
(≥ 30 years of age; Heistaro, 2008). The 12-month prevalence of DSM-IV 
mental disorders was estimated in a representative sample (N = 6986) of the 
Finnish general adult population by structured psychiatric interview (Munich 
Composite International Diagnostic Interview; M-CIDI; Pirkola et al., 
2005b). No ethnic groups were excluded during the recruitment, but only 
approximately 2% of the Finnish population was of foreign descent at the 
time of the study, and the interview was conducted in Finnish, excluding all 
non-fluent language speakers. The assessed mental disorders were: major 
depressive disorder (MDD), dysthymia, GAD, PD with or without 
agoraphobia, agoraphobia, social phobia and alcohol abuse and dependence. 
Among the total number of reliably performed mental health interviews (N = 
6005), the prevalence of DSM-IV anxiety disorders was 4.1%. As lifetime 
prevalences were not assessed, OCD and PTSD were not diagnosed, and M-
CIDI dropouts had somewhat higher scores in the Beck Depression Inventory 
and General Health Questionnaire-12 (indicating increased depressive 
symptoms and psychic distress, respectively) this figure is an underestimate 
of the true prevalence of anxiety disorders in the Finnish population.  
We used the Health 2000 cohort to form an anxiety disorder sample for 
genetic analyses according to the following. We first selected all individuals 
meeting the criteria for a DSM-IV anxiety disorder diagnosis during the 
previous year (N = 295). In addition, we further broadened the definition of 
anxiety disorder subjects to include individuals meeting the criteria for DSM-
IV sub-threshold diagnoses (N = 40). We subsequently selected two control 
individuals per case, matched based on sex, age (± 1 year), and university 
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Table 8. Main characteristics of the four human study samples used in the present study 
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hospital catchment area (5 in the entire country; each with approximately 1 
million inhabitants). Controls lacked anxiety or major mental disorders and 
had explicit negative diagnoses for all symptoms of anxiety. The majority 
replied negatively to all questions of the General Health Questionnaire-12, 
further indicating absence of psychic distress. The final sample size after 
accounting for DNA availability was 974 (321 cases with specific diagnoses as 
detailed in Table 9, and 653 controls). Some SNPs in study II were genotyped 
in an extended control sample totaling 1317 controls, with the age matching 
criterion relaxed to ± 2 years. 
Table 9. Characteristics of the Health 2000 anxiety disorder study sample (N =974) 
Diagnostic group Core
Sub-
threshold
Total Controls Total Men Women
Mean age 
± SD
Any anxiety disordera 282 39 321 653 974 357 (36.7%) 617 (63.3%) 49.8 ± 12.7
Panic disorder with or 
without agoraphobia
108 0 108 218 326 106 (32.5%) 220 (67.5%) 46.7 ± 11.3
Generalized anxiety 
disorder
73 30 103 206 309 122 (39.5%) 187 (60.5%) 50.6 ± 12.6
Social phobia 58 7 65 133 198 99 (50.0%) 99 (50.0%) 45.4 ± 10.2
Agoraphobia without a 
history of panic disorder
31 15 46 94 140 60 (42.9%) 80 (57.1%) 52.8 ± 13.0
Phobia, not otherwise 
specified
58 0 58 121 179 54 (30.2%) 125 (69.8%) 54.6 ± 13.3
Cases
a Includes subjects with any of the diagnoses listed below. Note that 41 individuals met criteria for more
than one anxiety disorder.  
 
Disease comorbidities are important to acknowledge in any study sample. 
35.9% of the identified anxiety disorder cases met the criteria for a comorbid 
depressive disorder (MDD and/or dysthymia), and 22.4% had a comorbid 
alcohol use disorder (alcohol abuse and/or dependence). Among the anxiety 
disorders, the most frequent comorbidity was between panic disorder and 
social phobia (N = 18; 6.4%). Altogether 41 subjects (14.5%) met the criteria 
for more than one anxiety disorder. 
We performed genetic power calculations with an online tool (Purcell et 
al., 2003) to demonstrate the power of the sample to detect associations. 
They indicated > 80% power to detect a genotypic relative risk of 1.48-2.62 
with disease allele frequencies of 1-60%. 
In study II, we evaluated the comorbidity of asthma and specific DSM-IV 
anxiety disorders in the whole Health 2000 sample (N = 6005). For this 
purpose, we used consensus diagnoses of asthma that were made based on 
physicians’ clinical examination, spirometry, and register data on use of 
health care services and reimbursed asthma medication. 
In study III, we used information on the subjects’ early childhood (≤ age 
16) social environment in GxE models testing for interactions between 
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genetic polymorphisms and the number of childhood adversities in 
predicting onset of anxiety disorders. Childhood adversities were assessed 
with an 11-item self-report questionnaire that subjects completed in their 
own homes (Table 10; Pirkola et al., 2005a). They were instructed to choose 
“no”, “yes”, or “cannot say” in reply to the questions and only “yes” answers 
were coded positive. The highest observed sum score was 9, and the 
correlation between responses to individual questions was moderate 
(Crombach’s alpha = 0.67; Kananen et al., 2010). In order to have 
approximately equal sample sizes in each group, subjects were categorized 
into three groups based on the number of experienced childhood adversities: 
0 (N = 360), 1 (N = 216), and ≥ 2 (N = 281). This partition was the best one 
available, because the distribution of sum scores was highly left-skewed as 
most subjects reported no experienced childhood adversities (Figure 8).  
Table 10. Self-report questionnaire for assessment of childhood adversities in the 
Health 2000 study sample 
Choose “no”, “yes”, or “cannot say” in response to the following questions.
 “When you think about your growth years, i.e., before you were aged 16, …”
1. Did your family have long-term financial difficulties?
2. Was your father or mother often unemployed although they wanted to work?  
3. Did your father or mother suffer from some serious disease or disability?
4. Did your father have alcohol problems?
5. Did your mother have alcohol problems?
6. Did your father have any mental health problem, e.g., schizophrenia, other psychosis, 
or depression?
7. Did your mother have any mental health problem, e.g., schizophrenia, other psychosis, 
or depression?
8. Were there any serious conflicts within your family?
9. Did your parents divorce?
10. Were you yourself seriously or chronically ill?
11. Were you bullied at school?
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Figure 8 Distribution of childhood adversity sum scores in the Health 2000 sample. As 
the distribution was highly left-skewed, a categorized grouping of subjects (0, 1 and ≥ 2 
experienced childhood adversities) was chosen for the gene x environment interaction 
analyses in study III. 
Barcelona panic disorder sample (II) 
 
In study II, we sought for a replication sample in which to follow up on 
association findings in the genes NPSR1 and NPS that were observed in 
primary analyses done in the Health 2000 anxiety disorder sample. We 
established collaboration with the group of Xavier Estivill in Barcelona, 
Spain. Estivill and colleagues had collected a PD sample, consisting of 188 
adult (> 18 years of age) Spanish Caucasians from the Psychiatry outpatient 
unit in Hospital del Mar, Barcelona (Table 8, page 61). As controls, they used 
315 ethnicity-matched blood donors recruited from the Blood and Tissue 
Bank of the Catalan Health Service. Notable differences between the 
Barcelona sample and the Health 2000 sample are: exclusion of subjects 
with current comorbid DSM-IV axis disorders apart from other anxiety 
disorders, exlusion of subjects with lifetime history of mood disorder, 
psychiatrically unscreened controls, and the nature of recruitment (clinical 
vs. population-based). 
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The Swedish BAMSE cohort (II) 
 
In study II, we also turned our attention to a Swedish population-based birth 
cohort (BAMSE), in which some of the same SNPs from our candidate genes 
of interest (NPSR1 and NPS) had been genotyped (Table 8, page 61). The 
BAMSE birth cohort originally included 4089 children from the central and 
north-western parts of Stockholm (Melen et al., 2005; Wickman et al., 
2002). For our study, we used phenotypic information collected in 
conjunction with a clinical examination performed when children were 8 
years old. After exclusion of subjects with incomplete questionnaire 
information, or no DNA available, our study sample consisted of 2020 
children (49% of the original birth cohort size). 
Our interest in the BAMSE sample was to evaluate the epidemiological 
comorbidity between asthma and anxiety, and to further test for genetic 
associations between the NPSR1 and NPS genes and anxiety. The asthma 
phenotype was defined as at least four episodes of wheezing during the last 
12 months, or at least one episode of wheezing during the same period if the 
child was receiving inhaled steroids (Ostblom et al., 2008). Unfortunately, no 
information from specific anxiety symptom questionnaires was available to 
us. We therefore used a question from the parent-completed EuroQol (EQ-
5D) questionnaire (The EuroQol Group, 1990) to assess anxiety/depression 
in the BAMSE children. Parents were asked: “Indicate which statement best 
describes your child’s health condition today”, and the reply options were: 1) 
is not anxious or depressed; 2) is moderately anxious or depressed; or 3) is 
extremely anxious or depressed. Only 0.1% of the children were extremely 
anxious or depressed and we therefore combined them with moderately 
anxious or depressed. We thus used a dichotomous assessment of parent-
reported anxiety/depression (N positive = 138; N negative = 1882) as a 
phenotype in the genetic analyses of the BAMSE sample.  
The most notable differences between the BAMSE sample and the other 
samples used in this study are the age of the subjects, and the unspecificity of 
the anxiety phenotype. We nevertheless thought that analysis of the EQ-5D 
anxiety/depression question had some additional value for two reasons: 1)  
Parent-reported emotional problems (anxiety, shyness, and withdrawal) in 8-
year olds are specifically associated with a 2.6-fold risk for an anxiety 
disorder in early adulthood (Sourander et al., 2007), and 2) although the EQ-
5D question in itself is unspecific in nature, it showed considerable overlap 
with the specific diagnoses of agoraphobia, GAD, and social phobia in the 
Health 2000 sample (in which the EQ-5D questionnaire had also been 
included).      
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The Virginia Adult Twin Study of Psychiatric and Substance Use Disorders 
(III) 
 
In study III, we again first conducted a primary genetic association analysis 
in the Health 2000 sample. Using meta-analytic methods, we subsequently 
combined our positive association findings in the glutamate decarboxylase 1 
(GAD1) gene with data from the study in which prior evidence for association 
to the gene was originally reported (Hettema et al., 2006). In the prior study, 
GAD1 SNPs were examined in a sample derived from the Virginia Adult Twin 
Study of Psychiatric and Substance Use Disorders (VATSPSUD; Table 8, page 
61). VATSPSUD is a population-based study consisting of 9270 twin subjects, 
all Caucasian and born in Virginia, USA. In that cohort, a multivariate 
genetic analysis was performed to identify a latent phenotype reflecting 
shared genetic susceptibility across a broad range of anxiety and mood 
phenotypes: GAD, PD, agoraphobia, social phobia, neuroticism, and MDD. 
This genetic risk factor was then used to create a case-control sample by 
selecting one member of each twin pair as a case or control based upon 
scoring above the 80th or below the 20th percentile, respectively, of the 
genetic risk factor. The resulting sample consisted of 1128 subjects (589 cases 
and 539 controls). The cases had the following frequencies of mental 
disorders: MDD 80.1%, GAD 53.8%, PD 20.5%, agoraphobia 14.1%, and 
social phobia 17.5%, whereas the controls lacked any of the listed.  
Notable differences between the VATSPSUD and the Health 2000 
samples is the nature of the phenotype (derived from genetic risk factor 
modeling), the use of lifetime diagnoses compared to 12-month ones, the 
high MDD prevalence (more than twice the Health 2000 one), and a large 
difference in sex distribution among cases (59% males, compared to 37% in 
Health 2000). Nevertheless, when pooling association data from the Health 
2000 sample with the VATSPSUD sample, we had the opportunity to study a 
combined sample of 1985 individuals (871 cases and 1114 controls) in 
analyses reflecting effects of genetic susceptibility across a broad range of 
internalizing disorders.   
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4.2 CANDIDATE GENE SELECTION 
Througout this study, a total of 30 potential susceptibility genes for anxiety 
disorders were examined for disease-predisposing genetic variation 
represented by a total of 333 SNP markers (Table 11). The rationale for 
studying the genes was different in each of the original publications (I-III), 
and as described in the following sections.  
Table 11. Candidate genes for anxiety disorders examined in the present study 
Gene 
symbol
Gene name
Total N 
SNPs 
examined
Publi-
cation(s)
ACE angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 2 III
ADORA2A adenosine A2a receptor 6 III
ALAD aminolevulinate, delta-, dehydratase 18 I
BDNF brain-derived neurotrophic factor 3 III
CCKBR cholecystokinin B receptor 3 III
CDH2 cadherin-2, type 1, N-cadherin (neuronal) 23 I
COMT catechol-O-methyltransferase 5 III
CPSF4 cleavage and polyadenylation specificity factor 4, 30kDa 4 I
CREM cAMP responsive element modulator 2 III
CRH corticotropin releasing hormone 4 III
DYNLL2 dynein, light chain, LC8-type 2 7 I
EPB41L4A erythrocyte membrane protein band 4.1 like 4A 44 I, III
EPHX1 epoxide hydrolase 1, microsomal (xenobiotic) 13 I
GAD1 glutamate decarboxylase 1 (brain, 67kDa) 8 III
GLO1 glyoxalase I 15 I
GSR glutathione reductase 22 I
HTR2A 5-hydroxytryptamine (serotonin) receptor 2A 2 III
NPS neuropeptide S 16 II
NPSR1 neuropeptide S receptor 1 43 II
NPY neuropeptide Y 10 III
PDE4D phosphodiesterase 4D, cAMP-specific 6 III
PLXNA2 plexin A2 11 III
PSAP
prosaposin (variant Gaucher disease and metachromatic 
leukodystrophy)
19 I
PTGDS prostaglandin D2 synthase 21kDa (brain) 10 I
RGS2 regulator of G-protein signaling 2, 24kDa 2 III
S100A10 S100 calcium binding protein A10 5 I
SCN1B sodium channel, voltage-gated, type I, beta 5 I
SLC15A2 solute carrier family 15 (H+/peptide transporter), member 2 12 I
SLC6A3
solute carrier family 6 (neurotransmitter transporter, dopamine), 
member 3
11 III
SLC6A4
solute carrier family 6 (neurotransmitter transporter, serotonin), 
member 4
2 III
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Murine anxiety candidate genes (I) 
 
In study I, we focused on a set of candidate genes that had been identified 
using inbred mouse strains that differ in their innate levels of anxiety-like 
behaviour as a model (Hovatta et al., 2005). Iiris Hovatta and colleagues had 
combined behavioural testing of six inbred mouse strains with gene 
expression profiling of seven brain regions involved in the regulation of 
anxiety to identify genes with an expression level that might regulate anxiety-
like behavior (Figure 9). Their strategy was to look for genes with an 
expression profile that correlated (either positively or negatively; Pearson 
correlation ≥ 0.75 or ≤ -0.75) with a behavioural vector representing anxiety 
levels across the six chosen mouse stains. An additional criterion used to 
prioritize genes with the potentially largest phenotypic effects, was that the 
fold difference in gene expression between the least and the most anxious 
strains (C57BL/6J and FVB/NJ vs. A/J and DBA/2J) had to be at least 50%. 
 
 
Figure 9 A strategy combining behavioural testing with gene expression profiling for 
identification of anxiety candidate genes in the mouse. First, inbred mouse strains with 
different innate characteristics are phenotyped by behavioural testing and ranked according 
to their order of relative anxiety (A). Second, gene expression profiling of brain regions 
relevant for anxiety is carried out to identify genes with expression levels that correlate with 
the anxiety phenotype (B). Potential candidate genes are either expressed at a higher level 
in more anxious strains than in strains with lower anxiety levels, or vice versa. Figure based 
on (Hovatta et al., 2005).     
 69 
With the strategy described above, 17 genes were identified. The most 
convincing proof-of-principle that the approach was able to identify mouse 
genes relevant for anxiety came from subsequent functional studies on two of 
the 17 genes, glyoxalase 1 (Glo1) and glutathione reductase (Gsr). These 
genes encode important antioxidant enzymes involved in cellular defense 
against oxidative stress. By overexpressing or silencing them in the mouse 
cingulate cortex with lentivirus-mediated gene transfer, the anxiety-like 
behaviour of mice could be altered (Hovatta et al., 2005). This functionally 
demonstrated that the expression level of Glo1 and Gsr regulates anxiety in 
mice. 
For my own study in humans (I), we selected the 13 known human 
homologues of the 17 anxiety candidate genes identified in the mouse (Table 
11). We considered them excellent previously unexamined candidate genes 
for human anxiety disorders based on the link between their expression level 
and anxiety in the mouse model, and the supporting functional evidence 
described above. 
 
Asthma-related candidate genes (II) 
 
In study II, we examined the genes encoding a previously identified asthma-
susceptibility factor (neuropeptide S receptor 1; NPSR1) and its ligand 
(neuropeptide S; NPS) as potential candidate genes for anxiety disorders. 
Although the G-protein coupled receptor encoding NPSR1 (formerly 
GPR154) was originally identified by positional cloning as a susceptibility 
gene for asthma and atopy (Laitinen et al., 2004), later identification of and 
studies on its ligand NPS made it clear that the receptor system is an 
important regulator of neurobiological phenotypes as well. At the time when 
our study was initiated, it was known that Npsr1 is highly expressed in rat 
brain regions regulating arousal, anxiety, learning, and memory (Xu et al., 
2007). Moreover, it was shown that NPS had a unique behavioural profile of 
simultaneously inducing wakefulness/arousal and anxiolysis when 
administered to the rodent brain (Xu et al., 2004). 
Another line of evidence that prompted us to select the NPS-NPSR1 
system for investigation came from epidemiological studies. Comorbidity 
between asthma and anxiety disorders had been observed in numerous 
clinical and community-based samples (e.g., Roy-Byrne et al., 2008; 
Goodwin et al., 2004; Goodwin et al., 2003; Goodwin, 2003). Other studies 
showed that subjects having both an anxiety disorder and asthma had poorer 
asthma control, more functional impairment, and decreased quality of life 
when compared to asthma patients without a psychiatric diagnosis 
(McCauley et al., 2007; Richardson et al., 2006; Lavoie et al., 2005). 
However, the underlying biological mechanisms of comorbidity are poorly 
known and shared genetic vulnerability represented one attractive 
hypothesis. 
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Based on the independent evidence implicating the NPS-NPSR1 system in 
both anxiety and asthma, we reasoned that the system could be a genetic link 
between the disorders and one potential mechanism behind their 
comorbidity. In study II, we therefore assessed the role of NPSR1 and NPS as 
susceptibility genes for human anxiety disorders.  
 
Candidate genes previously implicated in human anxiety (III) 
 
In study III, we chose a set of 15 putative human anxiety susceptibility genes 
for investigation, aiming to replicate previous association findings in them in 
the Health 2000 sample. We performed a MEDLINE literature search for 
published human candidate gene studies reporting associations with anxiety 
disorders or anxiety-related personality traits during the previous 15 years. 
The 15 genes that were selected for investigation represented some of the 
most relevant findings within our field of research. One of the reasons for 
discrepant findings in psychiatric genetics is that most of the published 
studies, in particular in the earlier days of association studies, used small 
sample sizes. They were likely underpowered to detect the small effect sizes 
that are currently believed to be conferred by individual genetic risk variants, 
and consequently many early studies published with loosely defined 
significance criteria may represent spurious false positive findings. 
Therefore, and in general, the keys to evaluating the relevance of genetic 
association findings are replication in independent samples, and functional 
studies demonstrating causality. In particular, well-characterized 
population-based samples are rare within the anxiety disorders. We therefore 
thought that the Health 2000 study sample represented a valuable resource 
in which to attempt replication of some of the previous key findings of the 
field. 
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4.3 MARKER SELECTION 
Throughout this study, SNP markers were used to represent the genetic 
variation of their surrounding genomic regions. The following general 
principles and tools were used to choose SNPs for genotyping: 
 
1) For each gene of interest, we retrieved SNP information using the 
dbSNP database (www.ncbi.nlm.nih.gov/projects/SNP/) and the 
SNPper bioinformatics tool (Riva and Kohane, 2002). For additional 
examination of genes of interest, we also used the Ensembl 
(http://www.ensembl.org) and UCSC Genome Browser 
(http://genome.ucsc.edu) databases. 
 
2) We first selected all non-synonymous SNPs for genotyping, reasoning 
that they would be prime candidates for having functional effects. 
 
3) We then used the Tagger algorithm in Haploview (Barrett et al., 2005; 
de Bakker et al., 2005) to select complementary tagSNPs that would 
most efficiently capture the remaining genetic variation of the loci. We 
used genotype information for the HapMap European-derived 
Caucasian/European ancestry (CEU) population as a basis for the 
selection (The International HapMap Consortium, 2003). The criteria 
for selecting tagSNPs was that they had to have minor allele 
frequencies ≥ 0.05 and capture the genetic variation of as many other 
SNPs with minor allele frequencies ≥ 0.05 as possible by r2 ≥ 0.8. Due 
to the large size of some genes, we had to limit the number of tagSNPs 
selected from them to 1 SNP/exon. 
 
4) In study I, we additionally used the Patrocles database (Hiard et al., 
2010) to select SNPs representing polymorphic microRNA binding 
sites, i.e. SNPs with alleles that create novel or disrupt existing 
microRNA target sites. We considered the identified SNPs good 
potential candidates for influencing gene expression. 
 
5) As study III was a replication attempt of previously published findings, 
we prioritized SNPs that had been genotyped in prior studies in the 
selection. 
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4.4 GENOTYPING 
As a part of the Health 2000 Study, peripheral venous blood samples were 
collected from participants that consented. DNA was extracted from them at 
the DNA extraction core facility of the National Public Health Institute, with 
the majority of samples processed with the Puregene manual DNA extraction 
kit (Gentra Systems, Minneapolis, MN, USA). DNA quality control measures 
included sex-specific polymerase chain reaction to verify that samples were 
not cross-contaminated. The order of case and control samples was 
randomized across all plates, and the plates contained both internal 
duplicate and cross-plate genotyping controls. No template controls were 
also included to verify specific amplification of PCR products. 
Genotyping of all but one SNP in the Health 2000 sample was carried out 
using Sequenom MassARRAY high-throughput genotyping technology with 
either iPLEX, or iPLEX Gold chemistry in accordance with the 
manufacturer’s instructions (Sequenom, San Diego, CA, USA). This 
genotyping technology is based on single-base pair primer extension, in 
combination with matrix-assisted laser desorption/ionization time-of-flight 
mass spectrometry (MALDI-TOF MS) analysis of the extension products 
(Figure 10). Final genotype calls are made from the mass spectrometry 
spectrum, based on the allele-specific masses of the extension products. A 
total of 12.5 – 15 ng of genomic DNA on 384-well plates was used as template 
for the genotyping.  
We used software provided by Sequenom for both assay design (Assay 
Design), and for making preliminary genotype calls (Typer Analyzer). The 
Assay Design software aids combination of the SNPs into multiplex pools by 
designing compatible PCR- and extension primers. The average pool size in 
our study was 22 SNPs. The preliminary genotype calls made by Typer 
Analyzer for all SNPs were further manually verified by two independent 
investigators who verified that genotype clusters were distinguishable and 
unclear genotypes excluded. Routine genotyping quality control procedures 
further included checking no template control samples for absence of allele 
peaks and verifying consistencies in genotype calls of duplicates samples. In 
addition, Mendelian inheritance of marker alleles was verified by separate 
genotyping in a sample of 60 anonymous parent-offspring trios that was 
analyzed with the Pedcheck software (O'Connell and Weeks, 1998). As a 
general principle, marker assays with low success rates (< 85%) or deviation 
from Hardy-Weinberg equilibrium (P < 0.05) in the control sample were 
disregarded. Furthermore, all genotype data for individuals with genotype 
calls for less < 75% of the analyzed markers was excluded from the analysis. 
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Figure 10 Principle of the Sequenom iPLEX genotyping technology. The SNP marker 
regions are first amplified in PCR multiplexes, followed by shrimp alkaline phosphatase 
(SAP) treatment for dephosphorylation of unincorporated dNTPs to prevent them from 
reacting in subsequent steps. In the actual iPLEX single base pair extension reaction, an 
extension primer anneals to each SNP site and addition of only one nucleotide to the primer 
using the SNP site as a template takes place due to the use of terminator ddNTPs 
(dideoxynucleotide triphosphates). Extension products are desalted and dispensed onto 
bioarrays for matrix-assisted laser desorption/ionization time-of-flight mass spectrometry 
(MALDI-TOF MS) analysis. Final genotype calls are made from the mass spectrometry 
spectrum using the Typer Analyzer software, based on the allele-specific masses of the 
extension products. Figure modified from (Oeth et al., 2005). 
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One additional SNP of functional relevance (rs16147) from the 
neuropeptide Y gene was genotyped with the 5’ nuclease cleavage assay 
(TaqMan assay) according to the manufacturer’s instructions (Applied 
Biosystems, Carlsbad, CA, USA). For this purpose 10 ng of DNA template was 
used on 384-well plates. PCR runs for allelic discrimination of the 
fluorescently labeled allele signals (either FAM or VIC) were performed on a 
CFX384 thermal cycling instrument (Bio-rad, Hercules, CA, USA). The Bio-
rad CFX Manager software was used to interpret the fluorescent genotype 
signals, and genotyping quality control was performed as detailed above. 
For the other samples of this study (BAMSE, Barcelona and VATSPSUD), 
DNA was processed according to the routine procedures of the respective 
institutions. In the BAMSE sample, genotyping was performed with 
Sequenom technology at the Karolinska Institute, Stockholm, Sweden. In the 
Barcelona sample, SNPs were genotyped at the Centro Nacional de 
Genotipado, Genoma España, Spain with the SNPlex multiplex genotyping 
system (Applied Biosystems). In the VATSPSUD sample, SNPs were 
genotyped with the 5’ nuclease cleavage assay at the Virginia Institute for 
Psychiatric and Behavioral Genetics, Virginia Commonwealth University, 
Richmond, USA. 
4.5 STATISTICAL ANALYSES 
The statistical procedures used in this study were mainly methods used to 
evaluate genetic associations in case-control samples, both on the level of 
individual SNPs and haplotypes. Moreover, the produced SNP and haplotype 
data was used for purposes of gene x environment interaction modeling and 
meta-analysis. The use of these genetic methods is described in more detail 
in the following sections. In addition, conventional statistical tests such as 
the chi square test, Fisher’s exact test and its Freeman-Halton extension, t-
test and factorial analysis of variance (ANOVA) were used.  
 
Pointwise association analyses 
 
Genetic association analyses of individual SNPs were carried out similarly in 
all studies. We used a 2 x 2 contingency table likelihood-ratio test for case-
control material to test the independence of SNP allele counts in cases and 
controls (J. D. Terwillliger and T. Hiekkalinna, unpublished). The same test 
was extended to a 2 x 3 table to test independence of genotype counts. We 
always performed 10000 permutations of the dataset to compute empirical 
P-values. In most instances, we described results with empiral P ≤ 0.01 as 
showing some evidence for association. The results obtained with the 
likelihood-ratio test were in concordance with those of a conventional chi 
square test.  
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Haplotype association analyses 
 
Haploview (Barrett et al., 2005) and Locusview (T. Petryshen, A. Kirby and 
M. Ainscow, unpublished) softwares were used to examine and illustrate the 
LD structures of the examined genes visually. There is no universally optimal 
gold standard method for definition of haplotype blocks for haplotype 
association analyses. Thus, varying definitions were used throughout this 
study.  
In study I, we performed global haplotype association tests on 2- and 3-
marker sliding windows.  
In study II, we restricted the analysis to regions of relatively stronger LD 
by first defining haplotype blocks with the algorithm of Gabriel et al. (Gabriel 
et al., 2002) in Haploview. This algorithm is based on 95% confidence 
intervals of D’-values, and it creates a block whenever 95% of informative 
SNP comparisons are categorized as being in strong LD. We then tested the 
specific haplotypes within the identified blocks for association. 
In study III, we analyzed haplotype blocks consisting of all genotyped 
SNPs for each gene, and thus spanning the full length of the loci of interest.  
The major reasons for this approach were that many of the prior studies that 
we based our SNP selection on had performed such analyses, and only a 
limited number of SNPs (2-3) were studied for many of the genes. 
In all studies, we used the Unphased software (Dudbridge, 2008) to 
perform the haplotype association analyses. Unphased estimates haplotype 
frequencies from unphased genotype data with an expectation-maximization 
algorithm. In global analyses, Unphased tests the null hypothesis that the 
odds ratios (ORs) of all haplotypes are equal with a likelihood-ratio test. In 
analyses of specific haplotypes, Unphased uses a score test to test whether 
there is a difference in OR between the test haplotype and all others pooled 
together. We always performed 10000 permutations of the dataset to obtain 
empirical P-values. 
 
Phylogenetic analyses 
 
The relation between individual SNP and haplotype associations can be 
better understood by interpreting findings in a phylogenetic context. For 
these purposes, we used the maximum parsimony algorithm in MEGA 
software to determine the most likely haplotype phylogeny (Tamura et al., 
2007). As the amount of SNP information for each gene of interest was 
limited, we reasoned that the relatedness of haplotypes would be best 
explained by the phylogenetic tree that requires the least amount of 
evolutionary change to explain the observed data. The statistical support for 
each node on the phylogenetic trees was evaluated by bootstrapping.  
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Gene x environment interaction modelling 
 
We evaluated GxE interaction effects in the Health 2000 anxiety disorder 
sample in study III. Childhood adversities represent some of the strongest 
known environmental risk factors for anxiety disorders, and this effect has 
been observed also in the Health 2000 sample (Pirkola et al., 2005a). We 
thus had strong prior evidence for main effects of childhood adversities, 
which motivated these analyses.  
We used a binary logistic regression model in PASW Statistics Software 
(SPSS, Chicago, Illinois) to evaluate interactions. The model was based on 
one of the early seminal GxE examinations in mental disorders (Caspi et al., 
2003). We aimed to explain anxiety disorder diagnosis with SNP genotypes, 
childhood adversities, and their interaction as covariates: 
 
Logit[Prob(Any anxiety disorder)] = b0 + b1(SNP genotype) + 
b2(Childhood adversities) + b3(SNP genotype*Childhood adversities), where:  
 
b0 is a constant; b1 is genotype classes of each SNP coded 0, 1, and 2 to reflect 
minor allele dosage; b2 is the number of childhood adversities (categorized to 
groups of 0, 1, and 2 or more adversities to have as equal subgroup sizes as 
possible); and b3 is the product of b1 and b2.  
 
We did not include sex in the models, as it was a criterion for matching cases 
and controls. We also carried out haplotype-based GxE analyses for genes 
implicated by the individual SNP findings by substituting SNP genotype with 
haplotype copy number in the model.  
We decided not to evaluate specific anxiety disorder subdiagnoses 
separately, as the major challenge of these analyses was the limited subgroup 
sample size that resulted from dividing the sample by both number of 
experienced childhood adversities and genotype. To further avoid spurious 
findings caused by limited sample size, and to obtain further statistical 
support for their modulating effects, we also conducted secondary analyses 
for SNPs showing significant interaction effects (P ≤ 0.01). We tested their 
genotype distributions within the three categories of experienced childhood 
adversities (0, 1, ≥ 2) for significant deviations from the expected with either 
a chi square test or the Freeman-Halton extension of Fisher’s exact test for 2 
x 3 contingency tables, when appropriate. 
 
Inverse-variance meta-analysis 
 
In study III, we observed association to the same variants as investigators in 
a previous study of the GAD1 gene (Hettema et al., 2006). This inspired us to 
carry out a meta-analysis to more accurately assess the overall contribution 
of GAD1 to susceptibility to internalizing disorders (e.g., anxiety and mood 
disorders). We combined our genotype data from the Health 2000 sample 
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with data from the VATSPSUD sample, in which the prior study of GAD1 was 
undertaken. Due to some inherent differences between the samples (Table 8, 
page 61), a broadly defined phenotype was chosen for unbiased pooling of 
both samples. We combined the whole Health 2000 sample with the 
VATSPSUD sample in order for the meta-analysis to reflect effects of genetic 
susceptibility shared by a broad range of internalizing disorders. The validity 
of this approach was also supported by models suggesting that comorbidity 
between internalizing disorders is explained, to a large extent, by shared 
genetic factors (Hettema et al., 2006). The final sample size for the joint 
analysis was 871 cases and 1114 controls. 
We used the inverse-variance method (Borenstein et al., 2009) to 
compute weighted means for the effect sizes of risk alleles and and 
haplotypes observed in the two studies. The weighting coefficients for each 
sample were equal to the inverse variance of the observed effect estimates 
(1/variance). Weighted effect size means, and the combined variance, were 
calculated according to the formulas in Figure 11. The null hypothesis that 
the combined effect size is zero was evaluated with a 1 degree of freedom chi 
square test. 
 
 
 
 
 
 
 
 
 
Figure 11 Formulas used for inverse-variance meta-analysis. Weighted combined mean 
effect sizes (M) are calculated by dividing the sum of the products of sample effect size (W) 
multiplied by sample weight (Y = 1 / sample variance) with the sum of the sample weights. 
The variance of the weighted mean effect size (VM) is the reciprocal of the sum of weights, 
and the standard error (SEM) is the square root of the variance (Borenstein et al., 2009).   
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4.6 ELECTROPHORETIC MOBILITY SHIFT ASSAY 
In study II, we tested whether the most significantly associated SNPs in the 
NPSR1 gene influence transcription factor binding to their surrounding DNA 
sequence in an allele-specific manner. These experiments were carried out in 
the research group of Juha Kere at the Karolinska Institute, Stockholm, 
Sweden. We used electrophoretic mobility shift assay (EMSA) for this 
purpose (Cold Spring Harbor Laboratory Press, 2005). This method is used 
to study the DNA-binding properties of proteins, and we used it to determine 
possible sequence-dependent DNA-binding. Briefly, 32P-radiolabeled DNA 
probes specific for each allele were first allowed to bind to a nuclear extract 
from the SH-SY5Y neuroblastoma cell line. The nuclear extract represents a 
total mixture of transcription factor proteins. The DNA-protein complexes 
were subsequently separated on a nondenaturing 6% polyacrylamide gel, and 
visualized by autoradiography. Whenever proteins have bound to the 
radiolabeled probe, its migration is altered on the gel. Thus, possible allele-
specific protein binding can be discerned by comparing gel runs for probes 
corresponding to the different alleles of interest.  
Having identified both qualitative and quantitative differences in DNA-
protein binding for two of our SNPs of interest, we further attempted to 
identify the specific transcription factors involved. We bioinformatically 
predicted likely candidates with SNPInspector and MatBase software 
(Genomatix Software, Munich, Germany) and chose the most promising 
candidates, based on suggested involvement in neuronal function or mental 
disorders, for functional verification. For this purpose, we used a so-called 
“supershift” version of the EMSA, in which DNA-protein complexes are 
further allowed binding to an antibody for the protein of interest. If the 
radiolabeled probe has formed a complex with the hypothesized protein, its 
migration will be further retarded on the gel. 
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4.7 IMMOBILIZATION STRESS AND QUANTITATIVE 
REAL-TIME PCR 
Also in study II, we examined whether gene expression responses are altered 
in immobilization stress-exposed mice deficient of neuropeptide S receptor 1 
(Npsr1-/-). These experiments were carried out in collaboration with the 
research groups of Juha Kere and Harri Alenius at the Karolinska 
Institute/University of Helsinki and Finnish Institute of Occupational 
Health, respectively. We used 12-16 wk old male mice on a heterogeneous 
C57BL/6 x 129/SvEvBrd background (Lexicon Genetics, The Woodlands, 
Texas). The mice were housed in standard cages with access to food and 
water ad libitum.  
We used the immobilization stress paradigm as an inducer of 
physiological and psychological stress responses. Immobilization stress is 
one of the most frequently used methods for this purpose, and it is based on 
restricting the free movement of the test animal for a desired amount of time 
(Buynitsky and Mostofsky, 2009). Although the methods to induce 
immobilization are physical, the paradigm is considered to be a primary 
psychological stressor and thus a good model for psychiatric stress, with any 
physical discomfort the animal experiences being secondary. Physiological 
and molecular effects of immobilization stress include increased ACTH-
response and corticosterone secretion, decreased heart rate, abnormalities in 
blood pressure, increased tumor necrosis factor-α (TNF-α) levels, increased 
c-fos expression, and increased oxidative damage to proteins and lipids 
(Buynitsky and Mostofsky, 2009), which together indicate increased stress. 
Behavioral changes induced by immobilization stress are increased anxiety-
related behavior, reduced activity and exploration, increased pain response, 
increased acoustic startle response, decreased memory retention and 
reconsolidation. As any animal model, the immobilization stress paradigm is 
thought to model some aspects of human stress response, but results are 
difficult to directly extrapolate to human conditions. 
We used an acute (1 h) immobilization stress paradigm, with sacrifice by 
CO2 inhalation either immediately, or after a 1 h recovery period. 
Immobilization stress was carried out in 50 ml conical tubes put into 
darkened plastic boxes.  
We used quantitative real-time PCR (qRT-PCR) to evaluate 
immobilization stress-induced changes in gene expression in Npsr1-/- and 
wild type mice. Brain regions (hypothalamus, cerebellum, hippocampus, 
striatum, cortex, and midbrain) were dissected immediately after sacrifice, 
frozen on dry ice, and stored at -80°C. Total RNA was extracted from them 
with TRI reagent (Molecular Research Center, Inc., Cincinnati, OH), and 
cDNA was synthesized from 500 ng of RNA with SuperScript First-Strand 
Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA). Quantitative RT-
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PCR was performed with ABI Prism 7900 or ABI Prism 7500 Fast 
instruments using either TaqMan probes or self-designed primers (Table 12) 
for SYBR Green assay (Applied Biosystems). PCR amplifications were 
performed with 0.07 nM primer concentrations in the final reaction and a 
protocol consisting of initial denaturation at 95°C for 10 min, followed by 39 
cycles of denaturation at 95°C for 15 s and annealing/extension at 60°C for 1 
min. Expression levels were normalized to the levels of the endogenous 
control genes Gapdh or Rn18s. The genes of interest were, in addition to 
Npsr1 and Nps, either: 
 
1) Putative stress-related downstream target genes of NPS-NPSR1 
signaling (Vendelin et al., 2006); namely Bhlhb2 (basic helix-loop-
helix domain containing, class B2), Egr1 (early growth response 1), 
Fos (FBJ osteosarcoma oncogene), Gal (galanin), Inhba (inhibin 
beta-A), Junb (jun-B oncogene), Klf10 (Kruppel-like factor 10), 
Nab1 (Ngfi-A binding protein 1) and Tac1 (tachykinin 1), or 
2) Genes well known to be involved in stress response; Il1b 
(interleukin 1 beta), Ntf3 (neurotrophin 3) and Tnf (tumor 
necrosis factor) 
 
Table 12. Sequences of self-designed mouse primers for quantitative real-time PCR  
 
 
In addition to the gene expression experiment, we collected blood from the 
mice for serum corticosterone measurement. This was carried out with the 
OCTEIA Corticosterone HS Enzyme immunoassay (Immunodiagnostic 
Systems, Boldon, UK) according to the manufacturer’s instructions. 
Gene 
symbol
Forward primer sequence 
(5'->3')
Reverse primer sequence 
(5'->3')
Bhlhb2 TTGGGTCACTTGGAAAAAGC TTTCTTCCCGACAAATCACC
Egr1 ACCCGTTCGGCTCCTTTC GCAGCATCATCTCCTCCAGTTT
Fos GGAATGGTGAAGACCGTGTCA TCAGGAGATAGCTGCTCTACTTTGC
Gal TGGAGGAAAGGAGACCAGGAAG GCCTCTTTAAGGTGCAAGAAACTG
Inhba AGGCGGCGCTTCTCAAC CCTCTATCTCCACATACCCGTTCT
Junb GGCTTTGCGGACGGTTTT GGCGTCACGTGGTTCATCT
Klf10 GCCTGTCACACCAGTGTCTG GGCTGTAAGGTGGCGTTAAA
Nab1 TCTATGGGCGATTTGACTCC CAGGGCAAAAAGCTCATCTC
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5  RESULTS 
5.1 SIX MURINE ANXIETY GENES MAY INFLUENCE 
SUSCEPTIBILITY TO HUMAN ANXIETY DISORDERS 
(I AND III) 
The human homologues of thirteen candidate genes for modulating murine 
anxiety-like behavior, identified based on their up- or downregulation in 
brain regions of more anxious mouse strains (Hovatta et al., 2005), were 
tested for association to human anxiety disorders. These analyses were 
carried out in the Health 2000 anxiety disorder study sample, which was 
described for the first time in original publication I.  
 
Two-stage association analysis identifies six prime candidates 
 
Pointwise analyses 
 
The association analysis was carried out in two stages, with an initial first 
screening round with less markers/gene (Figure 12). A second stage of fine-
mapping was then done for the top genes from stage I. The criteria for 
including a gene in the stage II analysis were: 1) at least two SNPs with 
empirical P ≤ 0.05 in any of the analyzed diagnostic groups; or 2) a haplotype 
window with empirical P ≤ 0.05 in any of the analyzed diagnostic groups. 
Eight of the thirteen genes were selected for analysis in stage II based on the 
criteria above (Figure 12).  
Finally, data from a total of 144 SNPs from 13 genes was analyzed. We 
tested them for association to both core (only subjects with DSM-IV 
diagnoses), and extended (including DSM-IV subthreshold diagnoses) 
anxiety disorder diagnoses of any anxiety disorder, PD, GAD and social 
phobia. At empirical P ≤ 0.01 in the final association analysis of the 
combined data from stages I and II, five genes showed evidence for 
association in the pointwise SNP analyses: ALAD (δ-aminolevulinate 
dehydratase), CDH2 (cadherin 2), EPB41L4A (erythrocyte membrane 
protein band 4.1 like 4a), PSAP (prosaposin), and PTGDS (prostaglandin D2 
synthase). These individual SNP findings are summarized in Table 13. 
Notably, some of the most significantly associated SNPs either conferred 
amino acid or triplet codon change (in EPB41L4A and PTGDS, respectively), 
or were located in potential regulatory regions (3’-untranslated region [UTR] 
in ALAD and promoter in PSAP).    
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Figure 12 Schematic of results from a two-stage association analysis of 13 murine 
anxiety candidate genes. Eight of 13 genes were examined further after stage I. Finally, six 
genes showed evidence for association by P ≤ 0.01. ALAD = δ-aminolevulinate dehydratase; 
CDH2 = cadherin 2; CPSF4 = cleavage and polyadenylation specificity factor 4; DYNLL2 = 
dynein light chain LC8-type 2; EPB41L4A = erythrocyte membrane protein band 4.1 like 4a; 
EPHX1 = epoxide hydroxylase 1; GLO1 = glyoxalase 1; GSR = glutathione reductase; 
miRNA = microRNA; PSAP = prosaposin; PTGDS = prostaglandin D2 synthase; S100A10 = 
S100 calcium binding protein A10; SCN1B = voltage-gated sodium channel type I beta; 
SLC15A2 = solute carrier family 15 (H+/peptide transporter), member 2. 
Table 13. Murine candidate gene SNPs with P ≤ 0.01 in tests for allelic association 
Gene SNP
SNP 
location/type
Alleles 
[A1/A2]
A1 A2
Allelic LRT 
P-valuec
Allelic OR 
(CI 95%)
Phenotype
ALAD rs818702 3'UTR A/G Cases 0.884 0.116 0.008 2.40 (1.25 - 4.60) SOCPHa
Controls 0.761 0.239
CDH2 rs7240351 Intronic A/G Cases 0.333 0.667 0.006 1.90 (1.21 - 3.00 SOCPHb
Controls 0.488 0.513
EPB41L4A rs7719346 A/G Cases 0.140 0.860 0.008 2.03 (1.17 - 3.54) GADa
Controls 0.248 0.752
rs1464766 Intronic A/G Cases 0.255 0.745 0.010 1.57 (1.09 - 2.27) PD
Controls 0.350 0.651
rs12657885 Intronic C/T Cases 0.918 0.083 0.010 1.98 (1.13 - 3.49) GADb
Controls 0.849 0.151
PSAP rs4746097 C/T Cases 0.729 0.271 0.004 1.68 (1.17 - 2.40) PD
Controls 0.616 0.384
rs11597008 C/T Cases 0.615 0.385 0.008 1.59 (1.13 - 2.22) PD
Controls 0.502 0.498
PTGDS rs4880179 A/G Cases 0.053 0.947 0.010 3.74 (1.36 - 10.27) GADb
Controls 0.015 0.985
a DSM-IV core diagnosis
b DSM-IV extended diagnosis
c Empirical p-values from 10 000 permutations are shown.
Allele frequencies
ALAD = δ-aminolevulinate dehydratase; CDH2 = cadherin 2; CI = confidence interval; EPB41L4A = erythrocyte
membrane protein band 4.1 like 4A; GAD = generalized anxiety disorder; LRT = likelihood-ratio test; OR = odds ratio;
PD = panic disorder; PSAP  = prosaposin; PTGDS  = prostaglandin D2 synthase; SOCPH = social phobia
Non-synonymous 
(Tyr/His)
Synonymous 
(Thr/Thr)
Predicted 
promoter
Predicted 
promoter
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Haplotype analyses 
 
Haplotype analyses of 2- and 3-SNP sliding windows yielded further support 
for associations in ALAD, CDH2 and PSAP. One additional gene not 
implicated by P ≤ 0.01 in the pointwise analyses, DYNLL2 (dynein light chain 
LC8-type 2), reached this level of significance when analyzing haplotypes. 
The results from the sliding window analyses of the six genes with P ≤ 0.01 in 
pointwise and/or haplotype analyses are depicted in Figure 13, which also 
shows their genomic structure. Test statistics for haplotype blocks with 
empirical global P ≤ 0.01 are further detailed in Table 14.  
Sixteen additional SNPs in the large (257 kb) EPB41L4A gene were 
genotyped in study III to increase coverage. The haplotype figures and 
analyses shown here were updated to include all studied SNPs from the gene. 
Table 14. Murine candidate gene 2- or 3-marker haplotype blocks with P ≤ 0.01 in a 
likelihood-ratio test for global haplotype association 
Gene SNPs
Empirical 
global 
P-valuec
Haplo-
types
Cases Controls
Haplotype-
specific
P-value
OR (CI 95%) Phenotype
ALAD 0.006 C-A-C 0.014 0.002 0.002 8.12 (1.72 - 38.36)
C-C-C 0.578 0.607 0.246
C-C-T 0.408 0.391 0.505
0.0009 A-C-A 0.036 0.000 0.005 N/A SOCPHa
A-C-C 0.848 0.766 0.079
G-C-C 0.116 0.234 0.010
CDH2 rs1041985-rs7240351 0.001 C-G 0.317 0.160 0.0006 2.44 (1.45 - 4.09) SOCPHb
C-A 0.333 0.487 0.006
T-G 0.350 0.353 0.956
DYNLL2 0.009 A-G-C 0.131 0.061 0.004 2.31 (1.30 - 4.12) GADb
A-G-T 0.621 0.717 0.017
G-A-C 0.248 0.222 0.480
PSAP 0.008 C-C-C 0.612 0.552 0.014 1.28 (1.05 - 1.56)
C-C-T 0.100 0.116 0.298
C-T-T 0.197 0.259 0.003
T-T-T 0.091 0.073 0.185
rs7092990 - rs4746097 0.008 C-C 0.729 0.616 0.004 1.68 (1.17 - 2.40) PD
C-T 0.196 0.310 0.002
T-T 0.075 0.074 0.975
a DSM-IV core diagnosis
b DSM-IV extended diagnosis
c Empirical p-values from 10 000 permutations are shown.
ALAD = δ-aminolevulinate dehydratase; CDH2 = cadherin 2; CI = confidence interval; DYNLL2 = dynein light
chain LC8-type 2; SOCPH = social phobia; GAD = generalized anxiety disorder; OR = odds ratio; PD = panic
disorder; PSAP  = prosaposin
Haplotype 
frequencies
rs818702 - rs11789221 - 
rs8177822 
rs11789221 - rs8177822 - 
rs818708
rs7092990 - rs4746097 - 
rs11597008
rs10132 - rs9900038 - 
rs9902118 
Any anxiety 
disordera
Any anxiety 
disorderb
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Figure 13 Results from haplotype analyses of sliding SNP windows, and genomic 
structure, for murine anxiety candidate genes with P ≤ 0.01 in pointwise and/or 
haplotype analyses. Plots show –log of the P-value for each analyzed haplotype block, 
identified by a running number from left to right.The solid horizontal line corresponds to P = 
0.01, and the dotted line to P = 0.05. Results are shown for the analysis type (either 2- or 3-
marker sliding window) and phenotypes that each gene was most significantly implicated in 
(social phobia for ALAD and CDH2, generalized anxiety disorder for DYNLL2, EPB41L4A 
and PTGDS, and panic disorder for PSAP). Individual SNPs with P ≤ 0.01 are shown bold 
and underlined. Haplotype windows with P ≤ 0.01 are circled, and their marker composition is 
identified with the corresponding number under the gene structure.  
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Trend analysis further supports EPB41L4A findings 
 
Since we had conducted a total of 1008 statistical tests when analyzing the 
individual SNPs (7 phenotypes x 144 SNPs), our results did not survive a 
Bonferroni-based multiple testing correction. Therefore, to provide further 
support for relevance, we performed a supplementary analysis to examine if 
any of the investigated genes was overrepresented among the top findings 
across all tests. We ranked all obtained P-values from most to least 
significant (1 – 1008) and divided them into four classes: top decile, second 
decile, second quintile and bottom 60%. For each gene, we then compared 
the observed distribution of P-values across the classes to that expected 
under the null hypothesis of randomly distributed P-values. We also 
performed the same analysis minimized across all tests for each marker, i.e. 
including only the smallest observed P-value for each SNP when taking all 7 
analyzed phenotypes into account. The reason for the minimized analysis 
was that we wanted to acknowledge that the 7 analyzed phenotypes are in 
fact not independent as for instance the core and extended diagnostic groups 
include largely the same subjects. The statistical significances of deviations 
from the expected P-value distribution were evaluated with a 3 df likelihood-
ratio test.   
Both the analysis of all ranked P-values and the minimized analysis 
indicated that EPB41L4A SNPs were overrepresented among the top findings 
(Pall = 0.0003; Pminimized = 0.008; Figure 14). When comparing only the most 
relevant class of findings, i.e. the top quintile of P-values, to the remainder 
with a 1-tailed likelihood-ratio test, the significance of EPB41L4A further 
increased (Pall = 9.46 x 10-6; Pminimized = 0.002). The trend analysis thus 
highly supported that SNPs in EPB41L4A yield more significant P-values 
than expected by chance, further suggesting relevance for the gene in anxiety 
disorder predisposition. 
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Figure 14 Trend analysis comparing the distribution of ranked P-values across classes 
representing top and bottom findings. The significance of overrepresentation of a gene 
among the top 20% of findings was evaluated with a likelihood-ratio test, and P-values for 
genes with P ≤ 0.05 are shown. The same analysis was carried out using all obtained P-
values for each SNP (A), and minimized by including only the smallest observed P-value for 
each SNP to elimate redundancy (B). Both analyses most significantly implicated EPB41L4A 
as being overrepresented among the top findings, compared to a random distribution of P-
values.   
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Summary of results 
 
Of 13 candidate genes identified based on their differential expression level 
between non-anxious and anxious mouse strains, we found that six showed 
some evidence for involvement in susceptibility to specific human anxiety 
disorders (Table 15). The most significant evidence for association was for a 
haplotype block in the 3’-UTR of ALAD with social phobia (P = 0.0009). A 
role for EPB41L4A in anxiety predisposition was further supported by 
overrepresentation of SNPs from this gene among the most significant 
associations.  
 
Table 15. Summary of murine and human results for the six identified novel anxiety 
disorder candidate genes 
Gene
Expression in more 
anxious mouse strains
Average 
fold 
changeb
Associated diagnostic 
group(s)
Most significant 
association 
P-value
ALAD
↑ in hippocampus, 
periaqueductal grey
2.17
Social phobia, 
any anxiety disorder
0.0009
CDH2 ↑ in pituitary 1.72 Social phobia 0.001
DYNLL2 ↑ in periaqueductal grey 1.85 GAD 0.009
EPB41L4A ↑ in pituitary 3.98 PD, GAD, social phobia 0.006
PSAP ↑ in periaqueductal grey 1.73 PD, any anxiety disorder 0.004
PTGDS
↓ in bed nucleus of 
stria terminalis, 
periaqueductal grey
-2.67 GAD 0.01
a Data from Hovatta et al., 2005
Mice
a Humans
ALAD = δ-aminolevulinate dehydratase; CDH2 = cadherin 2; EPB41L4A = erythrocyte
membrane protein band 4.1 like 4A; GAD = generalized anxiety disorder; PD = panic
disorder; PSAP  = prosaposin; PTGDS  = prostaglandin D2 synthase
b Average fold change for comparison between the two most anxious (DBA/2J and A/J) vs.
the two least anxious (C57BL/ 6J and FVB/NJ) mouse strains. In cases of multiple brain
regions with differential expression, an average of them is shown.
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5.2 NEUROPEPTIDE S AND ITS RECEPTOR 
PREDISPOSE TO PANIC DISORDER (II) 
We aimed to evaluate the potential role of the asthma-predisposing NPS-
NPSR1 signaling system in susceptibility to anxiety disorders. Genetic 
variation in the NPSR1 and NPS encoding genes was tested for association 
with anxiety disorders in adults, and parent-reported anxiety/depression in 
children. The association analyses were done in three different study samples 
(Table 8, page 61): the population-based Health 2000 anxiety disorder 
sample from Finland, a clinical PD replication sample from Spain, and a 
Swedish birth cohort (BAMSE). In the two epidemiological samples, we also 
aimed to confirm previously reported comorbidity between asthma and 
anxiety. We further wanted to provide evidence for functional relevance of 
the most significantly associated SNPs, and carried out EMSA experiments to 
examine whether they might influence transcription factor binding to their 
surrounding genomic region. We also tested whether gene expression 
responses are altered in Npsr1-deficient mice exposed to acute stress. 
 
Comorbidity of asthma and anxiety 
 
We confirmed previously reported comorbidity between anxiety and asthma 
in both the adults (≥ 30 years) of the Health 2000 study, and in the 8-year 
old children of the BAMSE birth cohort. All anxiety disorders pooled did not 
significantly associate with asthma in the Health 2000 sample, but we found 
that subjects with agoraphobia had asthma significantly more often than 
expected by chance (14.1% of subjects with agoraphobia had asthma, 
compared to 4.0% in subjects without agoraphobia; χ2 = 20.1, df = 1, P =3.0 x 
10-4). In a logistic regression model of determinants of asthma, the only 
significant predictors were female sex (P = 0.001; OR = 5.17, CI95% 2.23 – 
12.00) and agoraphobia (P = 1.20 x 10-5; OR = 1.64, CI95% 1.24 – 2.17). 
In the BAMSE sample, 11.3% of children with asthma were reported by 
their parent as being anxious or depressed. The corresponding frequency 
among children without asthma was 6.5%. Anxiety was a significant 
predictor of asthma in a logistic regression model (unadjusted P = 0.026, P = 
0.049 when adjusted for sex, heredity for allergic diseases, maternal smoking 
during pregnancy and/or at childbirth and maternal age at study 
enrollment). 
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Genetic associations with panic disorder and anxiety/depression 
 
Primary association analysis in the Health 2000 sample 
 
In an initial examination in the Health 2000 sample, we found that 17 of the 
examined 43 NPSR1 SNPs, and 3 of the 16 examined NPS SNPs showed 
evidence for association at P ≤ 0.05 with either PD (including both PD with 
and without agoraphobia), or its subdiagnosis category PD without 
agoraphobia (summarized in Figures 15 and 16). Analyses of PD with 
agoraphobia were not given great emphasis, as the size of this diagnostic 
subgroup was limited (N = 30). However, they suggest that associations in 
NPSR1 cannot be directly attributed to any subtype of PD, whereas NPS is 
more specifically associated with the subdiagnosis PD with agoraphobia. 
We further identified eight haplotype blocks in NPSR1 and NPS, and 
examined specific haplotypes within them for association to PD. We found 
risk haplotypes for either PD or PD without agoraphobia within three of the 
blocks (P ≤ 0.05; Figures 15C-D and 16C). The potentially functionally most 
relevant finding in NPSR1 was for a haplotype carrying a common and well-
studied gain-of-function amino acid substitution (rs324981; Asn107Ile). The 
Ile-allele, which we found associated with PD (empirical P = 0.03), is known 
to increase the sensitivity of the NPSR1 receptor for NPS by 10-fold 
(Reinscheid et al., 2005).  
In NPS, we found one specific risk haplotype that accounted for all the 
individual SNP findings and spanned the entire small locus of the gene 
(empirical P = 0.015). Notably, it was tagged by the Leu-allele of a non-
conservative amino acid substitution (rs990310; Ser14Leu) in the signal 
peptide motif of the NPS precursor protein. 
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Figure 15 Graphical summary of genetic association findings in the NPSR1 gene in the 
Finnish Health 2000 study sample. (A) Plot showing the –log association P-value of each 
individual SNP tested. Results are shown for panic disorder (PD), and its subdiagnoses PD 
with and without agoraphobia. The solid horizontal line corresponds to P = 0.01, and the 
dotted line to P = 0.05. (B) Genomic structure of NPSR1, and positions of the analyzed 
SNPs. (C and D) Detailed structure of blocks containing haplotypes showing evidence for 
association with either any PD (C) or PD without agoraphobia (D). Risk alleles of individual 
SNPs also implicated by P ≤ 0.05 in either any PD or PD without agoraphobia are shaded 
grey. Spans of haplotype blocks shown in (C) and (D) are indicated in panels (A) and (B) with 
their corresponding letter. 
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Figure 16 Graphical summary of genetic association findings in the NPS gene in the 
Finnish Health 2000 study sample. (A) Plot showing the –log association P-value of each 
individual SNP tested. Results are shown for panic disorder (PD), and its subdiagnoses PD 
with and without agoraphobia. The solid horizontal line corresponds to P = 0.01, and the 
dotted line to P = 0.05. (B) Genomic structure of NPS, and positions of the analyzed SNPs. 
(C) Detailed structure of a locus-spanning haplotype block showing evidence for association 
with any PD. Risk alleles of individual SNPs also implicated by P ≤ 0.05 in either any PD or 
PD with agoraphobia are shaded grey. The span of the haplotype shown in (C) is shown in 
panels (A) and (B).  
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Replication attempt in the Barcelona panic disorder sample 
 
We subsequently aimed to replicate the observed associations with PD in a 
Spanish sample of PD outpatients (Table 8, page 61). No significant evidence 
for association to NPSR1 was observed, but two NPS SNPs, representing the 
same S14L-haplotype as in the Finnish sample, associated with PD without 
agoraphobia (P ≤ 0.05, summarized in Figure 17). However, the risk alleles 
were opposite compared to the Finnish sample. No haplotype associations 
with empirical P ≤ 0.05 were found in the Spanish sample. 
 
 
 
Figure 17 Graphical summary of NPSR1 (A) and NPS (B) genetic association findings in 
three independent samples. Results (-log P-values for each individual SNP) are shown for 
the Finnish Health 2000 sample, the Spanish panic disorder (PD) sample, and the Swedish 
BAMSE birth cohort. The shown P-values are minimized from analyses of any PD and PD 
without agoraphobia in the Finnish sample, and any PD and its subdiagnoses PD with or 
without agoraphobia in the Spanish sample. Marker regions where evidence for association 
(P ≤ 0.05) overlaps between at least two of the samples are circled. Note that although the 
same two NPS SNPs are implicated in Finland and Spain, the risk alleles are different.  
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Further associations between NPSR1 SNPs and parent-reported 
anxiety/depression 
 
Twenty-six SNPs from NPSR1 and two from NPS had been genotyped in 
children of the Swedish BAMSE birth cohort. Based on our findings with PD, 
we evaluated their association with a parent-repored measure of 
anxiety/depression from the EQ-5D questionnaire. Five NPSR1 SNPs 
associated with this phenotype (P ≤ 0.05, Figure 17). Three of them, and a 
fourth proxy for one of the Swedish SNPs, were also implicated in PD in the 
Health 2000. No haplotype associations with empirical P ≤ 0.05 were found. 
 
Potential functional relevance of NPSR1 SNPs 
 
We aimed to show that the NPSR1 SNPs with evidence for association might 
have functional consequences. We selected five SNPs, all with P ≤ 0.01 in 
either the Health 2000 sample or in the BAMSE sample, and tested them for 
allele-specific binding to nuclear proteins in EMSAs. Alleles of two of the 
SNPs, rs2530548 and rs2530566, showed both qualitative and quantitative 
differences in protein binding. As nuclear extracts are rich in transcription 
factors (TFs), they might be the proteins involved in the allele-specific 
binding. We therefore attempted to identify the specific TFs responsible for 
the DNA-protein interactions. According to bioinformatic predictions, 
rs2530548 might affect binding of SOX-5 (sex determining region Y-box 5), 
whereas rs2530566 might influence binding of a number of TFs like growth 
factor independent 1 transcription repressor (GFI1), OVO-like 1 (OVOL1), 
homeobox transcription factors A9 and B9 (HOXA9, HOXB9) and runt-
related transcription factor 2 (RUNX2). We prioritized SOX-5 and RUNX2 
for functional testing, as they had the clearest prior evidence for suggested 
involvement in neuronal function and mental disorders (Kwan et al., 2008; 
Benes et al., 2007). However, antibodies for these two TFs did not shift the 
gel migration of the DNA-protein complexes in supershift EMSAs, and they 
are thus unlikely the proteins involved in the interactions.  
 
Npsr1-deficiency alters molecular stress responses in mice 
 
We evaluated immobilization stress-induced gene expression changes in 
Npsr1-/- mice and wild types. Altogether, we tested whether 14 genes were 
differentially regulated in response to stress due to Npsr1-deficiency. 
Expression changes of these genes were evaluated in at least one of four brain 
regions (cortex, hippocampus, hypothalamus, and striatum). The treatment 
groups consisted of mice killed immediately after 1 h immobilization stress, 
mice subjected to 1 h restraint stress and killed after a 1 h recovery period, 
and unstressed controls killed immediately after home cage removal. Results 
from factorial ANOVA analyses evaluating main effects of stress treatment, 
Npsr1 genotype, and their interaction are shown in Table 16, page 96.  
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We found experiment-wide significant (P ≤ 0.0019 [0.05/26 hypotheses 
tested]) main effects of stress treatment for serum corticosterone levels and 
the expression of six genes in at least one brain region (Egr1, Fos, Il1b, JunB, 
Klf10 and Tnf; Figure 18). This was an expected result, as these genes were 
mainly immediate early genes already previously linked to stress response. 
However, together with the significant increase in serum corticosterone, 
these findings indicated that our stress treatment was valid and working. 
Our main interest was rather in identifying genes that showed main 
effects of Npsr1 genotype or genotype x stress treatment interactions. Such at 
least nominally significant effects were observed for Nps, Fos, JunB in the 
cortex, for Il1b in the cortex and hypothalamus, and for Ntf3 in the cortex 
and striatum (Figures 18 and 19). The experiment-wide significant, and thus 
most relevant, results were for Il1b and Ntf3. Il1b was upregulated in the 
cortex of Npsr1-/- mice after stress exposure as compared to wild types (1.9 
fold immediately after immobilization and 2.7 fold after a 1 h recovery; P = 
0.0005). Npsr1-deficient mice further lacked the stress-following induction 
of Ntf3 that was seen in the striatum of wild types (7.5 fold immediately after 
immobilization and 2.5 fold after a 1 h recovery; P = 0.0006). 
 
 
Figure 18 Serum corticosterone, and brain gene expression levels of genes showing 
experiment-wide significant effects (P ≤ 0.0019) of immobilization stress treatment in 
Npsr1
-/-
 and wild type mice. Units are ng/ml for corticosterone, and expression relative to 
either Gapdh or Rn18s for the genes. Please refer to Table 16 for test statistics, and full gene 
names. Note that Fos, Il1b and Junb also show nominally significant main effects of Npsr1 
genotype. Significant post-hoc comparisons (P ≤ 0.05) between genotypes in Student’s T-
test are indicated (*). Cx = cortex; hp = hippocampus. 
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Figure 19 Brain gene expression levels of genes showing at least nominally significant 
(P ≤ 0.05) effects of Npsr1 genotype, or stress treatment x Npsr1 genotype 
interactions. Units are expression relative to either Gapdh or Rn18s. Please refer to Table 
16 for test statistics, and full gene names. Note that Fos and Junb, plotted in Figure 18, also 
show nominally significant main effects of Npsr1 genotype. Significant post-hoc comparisons 
between genotypes in Student’s T-test are indicated (* P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001). 
Cx = cortex; ht = hypothalamus; st = striatum. 
Summary of results 
 
We replicated prior epidemiological findings of comorbidity between anxiety 
and asthma in both adults and children. SNPs and haplotypes within both 
NPSR1 and NPS were associated with PD in adults. NPSR1 SNPs were also 
associated with parent-reported anxiety/depression in children. Evidence 
from three human study samples thus supports a role for the NPS-NPSR1 
system in modulating anxiety predisposition. 
We further suggest that the associated NPSR1 polymorphisms may 
influence transcription factor binding to an intronic region. This might 
influence the expression level of NPSR1 if it affects a regulatory element. 
However, the specific transcription factors involved remain to be identified. 
Finally, Npsr1-deficient mice differ from wild types most significantly 
regarding the induction of two known stress-related genes, Il1b and Ntf3. 
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Table 16. Serum corticosterone levels [ng/ml], and relative brain expression levels of genes related to stress and anxiety in Npsr1
-/-
 and wild type 
mice after immobilization stress. Results are shown for controls killed after home cage removal, mice killed after 1 h stress exposure (Immobilized), and 
mice killed after 1 h stress and a 1 h recovery (1 h after immobilization). Mean values are based on three – six animals per treatment group. P-values ≤ 0.05 
are highlighted in bold. 
Gene/hormone Symbol Tissue M ±SD M ±SD M ±SD M ±SD M ±SD M ±SD F df=1 P F df=2 P F df=2 P
Corticosterone N/A Serum 80.2 50.4 471.9 30.7 316.0 68.6 83.6 60.9 460.3 19.9 234.3 26.0 2.31 0.148 141.0 6.92 x 10-11 1.62 0.228
Basic helix-loop-helix domain 
containing, class B2
Bhlhb2 Ht 1.45 0.05 1.36 0.14 1.31 0.25 2.14 0.53 1.36 0.18 2.06 1.29 3.85 0.069 1.40 0.278 0.99 0.396
Egr1 Cx 0.52 0.18 1.17 0.42 1.77 0.14 0.64 0.30 0.94 0.14 1.99 0.66 0.04 0.849 29.45 2.11 x 10-6 0.64 0.540
Hp 1.19 0.34 1.47 0.31 1.32 0.31 1.05 0.20 1.10 0.14 2.00 0.78 0.01 0.936 3.79 0.042 3.31 0.060
Ht 1.45 0.68 5.83 1.13 9.20 3.90 0.85 0.07 4.72 0.79 15.56 8.43 0.97 0.337 17.45 6.12 x 10-5 2.36 0.123
Fos Cx 1.40 0.81 7.06 1.78 7.33 2.12 2.94 2.46 7.96 2.15 10.11 1.51 5.13 0.036 27.47 3.40 x 10-6 0.52 0.605
Hp 1.16 0.30 2.54 0.62 3.03 1.33 1.15 0.34 3.11 1.32 4.02 1.13 1.10 0.307 22.47 1.28 x 10-5 0.47 0.633
Ht 0.80 0.32 8.03 2.33 6.34 2.94 1.00 0.28 8.92 2.33 4.52 1.12 0.08 0.788 24.95 5.31 x 10-5 0.85 0.451
Galanin Gal Ht 2.97 4.88 0.42 0.17 0.45 0.27 1.04 1.18 0.52 0.16 0.31 0.02 0.16 0.692 2.69 0.095 0.34 0.716
Il1b Cx 1.23 0.28 1.97 0.59 0.78 0.20 1.58 0.47 3.76 1.20 2.10 0.75 17.62 0.0005 12.43 0.0004 2.42 0.118
Ht 0.32 0.14 0.50 0.39 0.65 0.28 0.44 0.21 1.15 0.36 0.52 0.18 3.74 0.069 5.14 0.017 4.15 0.033
Inhibin beta-A Inhba Cx 3.21 0.54 2.37 0.38 2.14 0.50 3.16 0.93 2.36 0.56 2.33 0.54 0.04 0.852 5.83 0.011 0.09 0.913
Hp 1.76 0.79 1.76 0.40 1.68 0.40 1.88 0.30 1.50 0.14 1.83 0.54 0.02 0.884 0.26 0.773 0.63 0.542
Ht 1.48 0.50 1.14 0.18 1.87 1.11 1.38 0.23 1.22 0.20 1.74 0.47 0.02 0.877 2.56 0.105 0.07 0.933
Jun-B oncogene Junb Cx 1.74 0.55 3.60 0.83 3.28 0.75 2.42 1.05 3.73 0.67 4.39 0.38 4.51 0.048 13.87 0.0002 0.87 0.434
Hp 0.90 0.20 1.17 0.20 2.23 1.28 1.08 0.22 1.72 0.66 2.79 0.89 3.78 0.068 14.01 0.0002 0.10 0.903
Ht 0.97 0.59 3.11 0.77 1.83 1.11 0.92 0.17 3.42 0.94 4.03 5.09 0.37 0.553 8.27 0.003 0.08 0.922
Klf10 Hp 1.12 0.04 1.22 0.09 1.50 0.13 1.35 0.43 1.33 0.18 1.95 0.33 4.22 0.056 8.14 0.003 0.44 0.651
Ht 1.28 0.64 0.76 0.20 0.99 0.18 1.06 0.22 0.99 0.19 2.08 2.39 0.62 0.443 0.84 0.452 0.50 0.617
Nab1 Hp 1.50 0.89 1.09 0.37 1.13 0.23 1.23 0.46 1.18 0.47 1.33 0.33 0.00 0.980 0.46 0.639 0.50 0.617
Ht 0.75 0.07 0.59 0.13 0.77 0.06 0.90 0.19 0.83 0.16 0.84 0.19 3.68 0.058 1.11 0.354 0.54 0.592
Neuropeptide S Nps Cx 0.41 0.37 0.38 0.25 2.28 1.83 0.22 0.29 0.58 0.72 0.17 0.14 1.03 0.331 0.23 0.799 8.17 0.006
Neuropeptide S receptor 1 Npsr1 Cx 3.47 0.42 3.59 0.11 3.44 0.16 0.00 0.00 0.00 0.00 0.00 0.00 N/A N/A 0.32 0.730 N/A N/A
Neurotrophin 3 Ntf3 Cx 6.15 1.45 10.15 1.90 10.36 0.35 9.56 3.04 11.39 1.96 7.95 1.22 0.98 0.335 5.04 0.018 5.09 0.018
St 3.06 1.73 7.51 5.11 2.10 1.24 2.87 2.20 1.00 0.51 0.84 0.19 14.96 0.0006 2.65 0.088 4.25 0.024
Tachykinin Tac1 Cx 4.80 0.49 4.38 0.81 4.65 0.52 4.84 0.81 5.03 2.26 5.05 0.84 0.63 0.439 0.04 0.962 0.15 0.865
Tumor necrosis factor Tnf Cx 1.18 0.37 0.38 0.10 0.58 0.26 1.01 0.17 0.61 0.12 0.55 0.20 0.01 0.914 17.13 6.82 x 10-5 1.58 0.233
Mean values shown are based on three-six animals per experimental group. P-values ≤ 0.05 were highlighted in bold.
Early growth response 1
FBJ osteosarcoma oncogene
Interleukin 1 beta
Kruppel-like factor 10
Ngfi-A binding protein 1
ANOVA = analysis of variance; Cx = cortex; Hp = hippocampus; Ht = hypothalamus; M = mean; N/A = not applicable; SD = standard deviation; St = striatum. 
Wild type Npsr1 -/- Factorial ANOVA test statistics
Controls Immobilized 1 h after immobilization Controls Immobilized 1 h after immobilization Genotype main  effects Treatment main effects Genotype x treatment effects
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5.3 GLUTAMATE DECARBOXYLASE 1 AND 
NEUROPEPTIDE Y MODULATE ANXIETY 
SUSCEPTIBILITY (III) 
We analyzed 92 SNPs from 15 putative susceptibility genes for anxiety 
disorders or anxiety-related traits, aiming to replicate some of the most 
relevant findings within the field in the Health 2000 sample. Childhood 
adversities are known strong risk factors for anxiety disorders, and GxE 
interactions may be important in explaining why some individuals are more 
stress resilient than others. Therefore, we further examined whether any of 
the studied genetic variants modulates the effect of the number of 
experienced childhood adverse life events on anxiety disorder risk. 
 
Primary analysis implicates GAD1 in susceptibility to phobias 
 
We tested SNPs for association to any anxiety disorder, PD, GAD, and 
phobias (combining social phobia, agoraphobia, and phobia not otherwise 
specified into one phenotype in this study). We also chose to focus our 
analyses only on the subjects with DSM-IV core diagnoses, excluding 
subjects with subthreshold diagnoses. The only gene showing evidence for 
association at empirical P ≤ 0.01 was glutamate decarboxylase 1 (GAD1), in 
which three SNPs associated with phobias (Table 17). An additional 9 genes 
were implicated with P ≤ 0.05, and these findings are summarized in Table 
18. Although these 9 genes only showed modest evidence for genetic 
association, the results are shown here as the purpose of the investigation 
was to replicate prior findings and they may therefore be of some relevance. 
On the haplotype level, the only gene showing evidence for association at 
empirical P ≤ 0.01 was similarily GAD1 with phobias. In fact, the three 
individual SNP findings in the gene were not independent, as they all 
represented the same specific risk haplotype (Figure 20, page 99). 
Table 17. Genetic associations (P ≤ 0.01) in the GAD1 gene with phobias  
SNP
SNP
type
Alleles 
[A1/A2]
A1 A2
Allelic LRT 
P-valuea
Allelic OR 
(CI 95%)
rs769407 Intronic C/G Cases 0.385 0.615 0.0005 1.79 (1.30-2.48)
Controls 0.259 0.741
rs3791851 Intronic G/A Cases 0.390 0.610 0.0009 1.64 (1.21-2.23)
Controls 0.280 0.720
rs769395 3'-UTR C/T Cases 0.388 0.612 0.002 1.64 (1.21-2.22)
Controls 0.278 0.722
a Empirical p-values from 10 000 permutations are shown.
Allele frequencies
CI = confidence interval; LRT = likelihood-ratio test; OR = odds ratio
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Table 18. Genetic associations with P ≤ 0.05 in 9 putative susceptibility genes for 
anxiety disorders  
Gene SNP
SNP
type
Alleles 
[A1/A2]
A1 A2
Allelic 
LRT
P-valuea
Phenotype
Previously associated with 
(references)
ADORA2A rs1003774 5'-UTR G/T Cases 0.583 0.417 0.028 GAD
Controls 0.473 0.527
rs5751876 C/T Cases 0.479 0.521 0.014 GAD
Controls 0.603 0.397
rs1041749 3'-UTR C/T Cases 0.478 0.522 0.012 GAD
Controls 0.609 0.391
BDNF rs6265 A/G Cases 0.120 0.880 0.030 Phobias
Controls 0.177 0.823
COMT rs737865 Intronic A/G Cases 0.774 0.226 0.038
Controls 0.816 0.184
Cases 0.774 0.226 0.026 Phobias
Controls 0.837 0.163
rs1544325 Intronic A/G Cases 0.416 0.584 0.044 PD
Controls 0.498 0.502
CRH rs11997416 3'-UTR C/T Cases 0.945 0.055 0.037 GAD
Controls 0.887 0.113
NPY rs16135 Intronic C/T Cases 0.939 0.061 0.023 PD
Controls 0.885 0.115
PDE4D rs35305 Intronic G/T Cases 0.530 0.470 0.039 Phobias
Controls 0.604 0.396
PLXNA2 rs12094123 Intronic A/T Cases 0.495 0.505 0.030 PD
Controls 0.581 0.419
SLC6A3 rs27072 3'-UTR A/G Cases 0.224 0.776 0.044 PD
Controls 0.160 0.840
rs403636 Intronic G/T Cases 0.840 0.160 0.027 GAD
Controls 0.913 0.087
SLC6A4 rs6354 5'-UTR A/C Cases 0.776 0.224 0.049 PD
Controls 0.838 0.162
a Empirical p-values from 10 000 permutations are shown.
ADORA2A = adenosine A2a receptor; BDNF = brain-derived neurotrophic factor; COMT = catechol-O-
methyltransferase; CRH = corticotropin releasing hormone; GAD = generalized anxiety-disorder; LRT =
likelihood-ratio test; MD = major depression; NPY = neuropeptide Y; OCD = obsessive-compulsive disorder; PD
= panic disorder; PDE4D = phosphodiesterase 4D, cAMP-specific; PLXNA2 = plexin A2; PTSD = post-traumatic
stress disorder; SLC6A3 = solute carrier family 6 (neurotransmitter transporter, dopamine), member 3; SLC6A4 
= solute carrier family 6 (neurotransmitter transporter, serotonin), member 4; SOCPH = social phobia
Allele 
frequencies
Non-
synonymous 
(Met/Val)
Synonymous 
(Tyr/Tyr)
PD, caffeine-induced 
anxiety, harm avoidance 
(Hamilton et al., 2004; 
Childs et al., 2008; Deckert 
et al., 1998)
OCD, neuroticism, harm 
avoidance (Montag et al., 
2010; Frustaci et al., 2008)
PD, OCD, anxiety and/or 
MD, neuroticism, trait 
anxiety (Wray et al., 2009; 
Costas et al., 2010; Strug et 
al., 2010) 
PTSD, GAD, SOCPH 
(Rowe et al., 1998; Segman 
et al., 2002)
Anxiety disorders, 
neuroticism, psychological 
distress, anxiety severity 
(Wray et al., 2007; Coric et 
al., 2010)
Neuroticism
(Calboli et al., 2010; 
Shifman et al., 2008)
Anxiety disorders, harm 
avoidance (Zhou et al, 
2008)
Behavioral inhibition
(Smoller et al., 2005; 
Smoller et al., 2003)
PD, genetic susceptibility 
shared by anxiety 
spectrum phenotypes, 
harm avoidance, phobia, 
low extroversion (Hettema 
et al., 2008)
Any 
anx.dis.
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Figure 20 Genomic structure of GAD1, and haplotype association finding with phobias 
in the Finnish Health 2000 study sample. (A) Genomic structure of GAD1 and positions of 
the analyzed SNPs. SNPs associating with phobias with P ≤ 0.01 are highlighted in bold. (B) 
Detailed structure of a locus-spanning haplotype block. One specific risk haplotype (H3) 
associates with phobias and accounts for the individual SNP findings. Risk alleles of 
individual SNPs also implicated by P ≤ 0.01 are shaded grey. The span of the haplotype 
block is shown in (A). 
Meta-analysis suggests involvement of GAD1 in susceptibility to a broad 
range of internalizing disorders 
 
The GAD1 risk haplotype we discovered was the same one that was 
associated with genetic susceptibility shared by anxiety disorders, MD and 
neuroticism in a prior study (Hettema et al., 2006) done in the VATSPSUD 
sample (Table 8, page 61). We therefore used meta-analytic methods to 
incorporate the VATSPSUD findings with ours, with the aim to obtain a more 
accurate cross-study assessment of the contribution of GAD1 to susceptibility 
to internalizing disorders. As there were several inherent differences between 
the Health 2000 sample and the VATSPSUD one (please refer to section 4.1 
for details), our best option for unbiased pooling of the samples was to 
combine the entire samples with each other. Four of the same GAD1 SNPs 
had been genotyped in both samples. In the resulting combined analysis (N = 
1985) of a broad phenotype reflecting shared genetic susceptibility across a 
range of internalizing disorders and neuroticism, significance of the 
aforementioned specific risk haplotype increased compared to the analysis of 
either sample alone (Table 19). Altogether, this haplotype increased the risk 
for internalizing disorders by an OR = 1.3 (CI 95% 1.11 – 1.52). 
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Table 19. Meta-analysis of GAD1 risk alleles and haplotypes with a broad phenotype 
reflecting shared genetic susceptibility across internalizing disorders and neuroticism  
SNP(s)
Risk
allele/
haplotype
Risk 
allele 
freq.
OR (CI 95%)
 P-
value
Risk 
allele 
freq.
OR (CI 95%)
 P-
value
OR (CI 95%)
 P-
value
rs2241165 A 0.746 1.04 (0.82-1.32) 0.765 0.748 1.37 (1.12-1.68) 0.001 1.22 (1.05-1.42) 0.011
rs769407 C 0.288 1.19 (0.94-1.50) 0.160 0.236 1.27 (1.05-1.53) 0.008 1.23 (1.07-1.43) 0.005
rs3791851 G 0.308 1.13 (0.91-1.40) 0.264 0.238 1.24 (1.02-1.49) 0.013 1.19 (1.03-1.37) 0.019
rs3791850 C 0.761 0.98 (0.77-1.24) 0.878 0.749 1.41 (1.15-1.72) 0.0006 1.21 (1.04-1.41) 0.014
rs2241165-rs769407-
rs3791851-rs3791850
A-C-G-C 0.221 1.27 (1.00-1.61) 0.044 0.200 1.32 (1.08-1.62) 0.007 1.30 (1.11-1.52) 0.0009
a 282 cases with PD, GAD, social phobia, agoraphobia and phobia not otherwise specified, and 575 controls 
Combined sample 
(N = 1985)
Health 2000 sample 
(N = 857)a
VATSPSUD sample 
(N = 1128)b
CI = confidence interval; GAD = generalized anxiety disorder; GAD1 = glutamate decarboxylase 1; MDD = major
depressive disorder; OR = odds ratio; PD = panic disorder; VATSPSUD = Virginia Adult Twin Study of Psychiatric
and Substance Use Disorders 
b 589 cases and 539 controls scoring at the extremes of a genetic risk factor reflecting shared susceptibility to
MDD, GAD, PD, agoraphobia, social phobia, and neuroticism  
 
Anxiety-predisposing effects of NPY are conditional on early life stress 
exposure 
 
Of all examined genes in the Health 2000 sample, only NPY showed solid 
gene x environment interaction effects. Three SNPs in this gene, representing 
two phylogenetically related risk haplotypes hereafter referred to as H3 and 
H4 (Figure 21), modulated the effect of childhood adverse life events on 
susceptibility to anxiety disorders (P ≤ 0.01; Table 20 and Figure 22). The 
most significant GxE effect was observed when analysing the related H3 and 
H4 jointly to increase subgroup sample size, thus comparing subjects with 
any other haplotype configuration to H3/- or H4/- heterozygotes, and a 
pooled group of H3/H3, H4/H4 homozygotes and H3/H4 compound 
heterozygotes (b = 0.47, SE = 0.16, P = 0.003; Figure 22F). Among subjects 
who had experienced at least two childhood adversities, the H3 or H4 
heterozygotes had a 3.76-fold risk for an anxiety disorder compared to 
subjects with other haplotype configurations, whereas the corresponding risk 
for individuals homozygous for H3 or H4, or compound heterozygotes, was 
6.00-fold.  
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Figure 21 Genomic structure of NPY, and haplotype phylogeny and structure of the 
locus in the Finnish Health 2000 study sample. (A) Genomic structure of NPY and 
positions of the analyzed SNPs. SNPs showing gene x environment (GxE) interaction effects 
with childhood adversities in influencing anxiety susceptibility (P ≤ 0.01) are highlighted in 
bold. (B) Maximum parsimony-based phylogeny analysis for the seven haplotypes spanning 
the NPY locus (designated H1 – H7, in order of population frequency). Particular support was 
obtained for relatedness of H3 and H4, and H5 and H6. (C) Detailed structure of the locus-
spanning haplotype block. Risk alleles of individual SNPs showing GxE interactions are 
shaded grey. Only one haplotype (H3) carries all three risk alleles, whereas its closest 
relative H4 carries two of them. The span of the haplotype block is shown in (A). 
Table 20. Logistic regression analysis of gene x environment interactions between 
NPY and childhood adversities in influencing susceptibility to anxiety disorders. 
Results shown for SNPs and haplotypes with interaction effects with P ≤ 0.01. 
SNP/haplotype b SE P-value b SE P-value b SE P-value
rs16142 0.498 0.111 7.22 x 10-6 -0.333 0.206 0.105 0.427 0.151 0.005
rs2023890 0.903 0.119 3.42 x 10-14 0.321 0.204 0.115 -0.427 0.148 0.004
rs17374047 0.580 0.101 8.87 x 10-9 -0.246 0.263 0.351 0.519 0.201 0.010
H3 0.584 0.102 1.10 x 10-8 -0.344 0.279 0.218 0.586 0.210 0.005
H4 0.657 0.102 1.24 x 10-10 -0.267 0.289 0.355 0.239 0.211 0.258
H3+H4 0.504 0.114 9.22 x 10
-6
-0.341 0.212 0.108 0.468 0.156 0.003
Childhood adversities
SNP genotype/ 
haplotype copy 
number
Childhood adversities 
x SNP genotype
b  = regression coefficient; SE = standard error of b
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Figure 22 Probability of anxiety disorder diagnosis as a function of the number 
experienced childhood adversities, and NPY genotype. (A-C) Three SNPs in NPY 
showed significant effects (P ≤ 0.01) in logistic regression analysis of gene x environment 
(GxE) interactions. (D-F) Haplotype copy number-based analyses of two phylogenetically 
related haplotypes, H3 and H4 (as designated in Figure 21), supported the individual SNP 
findings. Haplotype H3 was tagged by rs17374047 (C) and thus yielded a similar result. 
Analysis of H4 alone was non-significant, while pooled analysis of H3 and H4 to achieve the 
largest subgroup sample size possible yielded the most significant observed GxE interaction. 
Sample sizes for the subcategories of experienced childhood adversities were: 0 (N = 360), 1 
(N = 216), and ≥ 2 (N = 281). 
Summary of results 
 
Although the most significant findings in the GAD1 gene were obtained with 
a phobia phenotype, it also appeared to contribute to susceptibility to 
internalizing disorders in a broad sense. These effects are mainly due to to 
one specific common risk haplotype. We also observed that genetic variation 
in NPY, attributable to two related risk haplotypes, interacts with childhood 
adverse life events to influence susceptibility to anxiety disorders. No main 
effects of NPY SNP genotype or haplotype were observed, indicating that its 
anxiety-predisposing effects are conditional on childhood stress exposure in 
our sample. 
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6 DISCUSSION 
6.1 GENERAL IMPLICATIONS 
The work presented in this study has lead to the identification of altogether 
ten potential susceptibility genes for anxiety disorders at the P ≤ 0.01 
significance level (Table 21). For seven of the ten implicated genes, our 
findings can be considered the first report of involvement in human anxiety. 
The identified genes encode proteins representing four different main 
categories: four enzymes catalyzing biochemical reactions important for 
brain functioning (ALAD, GAD1, PSAP and PTGDS), two neuropeptides and 
one neuropeptide receptor (NPY, NPS and NPSR1), two structural proteins 
involved in neuronal morphology and signaling (CDH2 and EPB41L4A) and 
a regulator of dynein complex assembly involved in axonal retrograde 
transport (DYNLL2). Although the 30 genes examined throughout this study 
naturally only represent a biased subset of all human genes, these findings 
illustrate the genetic and functional heterogeneity that likely underlies 
anxiety disorders. 
 
The multiple testing problem and defining a true finding 
 
Upfront, it should be acknowledged that some of the findings likely are 
statistical type I error false positives caused by limited sample size of the 
analyzed anxiety disorder subdiagnosis groups, in combination with the 
multiple statistical tests performed. We chose a permutation-based approach 
to correct for small sample deviations from chi-square assumptions in the 
association analyses. This should reduce the chance for spurious genetic 
associations. In addition, we explored the use of multiple testing corrections 
based on the total number of performed statistical tests (Bonferroni-
correction; Bonferroni, 1932), or less conservatively, based on the actual 
efficient number of statistical tests as our SNPs were typically in LD and 
therefore not independent (Nyholt, 2004). However, it became clear that the 
penalty conferred by testing a large number of SNPs in multiple phenotypes 
is such that no multiple testing correction method would support the 
findings. Corrections based on the concept of false discovery rate (FDR; the 
rate by which significant features at a given threshold are truly false) are also 
advocated by many as proving a good and easily interpreted balance between 
the number of true and false positive findings (Storey and Tibshirani, 2003). 
We did not perform FDR-analyses, but they could have been helpful for 
critical interpretation of our findings. Unfortunately, there is no gold 
standard methodology for multiple testing correction in datasets like ours, 
and the development of such standard guidelines is one of the current major 
challenges of genetic epidemiology. Even the question on what an 
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appropriate threshold for a genome-wide significant finding is remains 
somewhat unresolved, but the order of magnitude for Western populations 
seems to be in the range of 5-7 x 10-8 (Dudbridge and Gusnanto, 2008; Risch 
and Merikangas, 1996). Some argue that almost equally stringent criteria 
should be applied also in candidate gene studies by correcting for all the 
statistical tests that were not performed in reality – after all, had we not 
discovered anything, we would have moved on to another genomic position 
to look further (Joseph D. Terwilliger, personal communication).  
Table 21. Summary of genes showing evidence for association (P ≤ 0.01) with 
anxiety disorders. 
Gene 
symbol
Gene name Function
Most 
significant 
P-value
Phenotype
GAD1
glutamate decarboxylase 1 
(brain, 67kDa)
Enzyme synthesizing GABA 0.0005a
Phobias 
(social phobia, 
agoraphobia, 
phobia NOS)
ALAD
aminolevulinate, delta-, 
dehydratase
Enzyme of heme 
metabolism
0.0009b
Social phobia, any 
anxiety disorder
CDH2
cadherin-2, type 1, N-
cadherin (neuronal)
Neural cell-cell adhesion 0.001b Social phobia
NPSR1 neuropeptide S receptor 1 Receptor for NPS 0.001a PD
NPY neuropeptide Y
Regulation of emotional 
homeostasis, stress 
coping, cognitive 
processes, food- and 
ethanol intake and sexual 
behavior 
0.003b
Any anxiety 
disorder (GxE 
interaction with 
childhood 
adversities)
PSAP
prosaposin (variant 
Gaucher disease and 
metachromatic 
leukodystrophy)
Neurotrophic factor, repair 
of neural injury and 
enzyme for hydrolysis of 
sphingolipids
0.004a
PD, any anxiety 
disorder
EPB41L4A
erythrocyte membrane 
protein band 4.1 like 4A
Interactions between 
plasma membrane and 
cytoskeleton
0.008a
Social phobia, 
GAD, PD
NPS neuropeptide S
Regulation of arousal and 
anxiety, food and ethanol 
intake and immunological 
phenotypes
0.007a PD
DYNLL2
dynein, light chain, 
LC8-type 2
Axonal retrograde 
transport, dynein complex 
assembly
0.009b GAD
PTGDS
prostaglandin D2 synthase 
21kDa (brain)
Enzyme for synthesis of 
prostaglandin D2, a 
neuromodulator and 
neurotrophic factor
0.01a GAD
a Pointwise
b Haplotype-based
GxE = gene x environment; GABA = gamma-aminobutyric acid; GAD = generalized anxiety
disorder; NOS = not otherwise specified; PD = panic disorder
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It is clear based on the above that the threshold we chose as a criterion for 
evidence for association (P ≤ 0.01) is an arbitrary one, used primarily to 
identify the most relevant SNPs or genes from a larger dataset. Therefore, 
extreme caution is needed in interpreteting them as true findings. The best 
way to obtain further confidence in the findings would be to replicate them in 
independent samples and preferably in the strictest sense (same allele, same 
phenotype). Moreover, the many hypotheses and questions that the genetic 
variation showing evidence for association raise should be experimentally 
evaluated. For instance, among the associated variation are synonymous 
SNPs, non-synonymous SNP, SNPs in promoter regions, SNPs in 3’-UTRs, 
intronic SNPs that potentially influence transcription factor binding and 
haplotypes spanning the entire loci of the investigated genes. Functional 
experiments could be designed to evalute the effects of these alleles on gene 
expression, and protein structure and function, in vitro and in vivo. Genetic 
imaging studies to assess whether the identified genetic variants influence 
responses in brain regions relevant for anxiety would be an important 
addition. Finally, transgenic animal models with either overexpression or 
silencing of the identified genes, preferably in relevant brain regions, would 
be important for understanding their potential impact on behavior.  
To summarize, a combination of replication and functional approaches is 
needed before our gene findings can be considered true. Encouragingly, for 
some of our top candidate genes (e.g., GAD1, NPY, NPS and NPSR1) there is 
already published functional evidence from various sources that supports 
their role in modulating the same phenotypes that we found associated with 
the genes. These specific findings are discussed in sections to come. 
 
Common versus rare variants in anxiety disorder susceptibility 
 
We identified 15 risk variants showing evidence for association with P ≤ 0.01 
in pointwise SNP tests. Of these, 13 can be considered common (frequency > 
0.05) and 2 rare (frequency < 0.05). The average OR was 1.79 for the 
common risk variants, and 3.15 for the rare variants. This is a sensible result, 
as we had very limited statistical power to detect variants with smaller effects 
with the sample sizes available to us. Moreover, being common was a 
selection criterion for many of the investigated SNPs (i.e., all tagSNPs). The 
ORs and risk allele frequencies observed by us are also in line with those 
reported in other candidate gene studies of anxiety disorders (e.g., Hohoff et 
al., 2010; Hettema et al., 2008; Wray et al., 2007). Our limited data from a 
few candidate genes does not allow for any conclusions regarding whether 
the CD-CV, or the CD-RV hypothesis is more appropriate for explaining 
genetic susceptibility to anxiety disorders. The most likely answer is that 
anxiety, as other complex diseases, is influenced by a spectrum of allelic 
variation that includes both common and rare variants (Smoller, 2011; 
Bodmer and Bonilla, 2008). One factor that could influence this allelic 
spectrum, and in which subjects with anxiety disorders differ from patients 
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with some other psychiatric diseases, is that they may not have as 
dramatically reduced fecundity as in e.g. schizophrenia or autism (Bundy et 
al., 2011; Reichenberg et al., 2006). This would imply less negative selection 
keeping frequencies of anxiety risk variants low in the population. 
 
Shared or disorder-specific genetic susceptibility and the phenotype 
problem 
 
Whether the clinical DSM-IV grouping of anxiety disorders accurately 
reflects their underlying biology and genetics is a matter of ongoing debate. 
The best answer is “yes and no“, as on one hand DSM-IV defined anxiety 
disorders exhibit familial aggregation and are heritable entities (Smoller et 
al., 2008a). On the other hand, the genetic boundaries between disorders are 
blurry and anxiety-proness phenotypes transcend the categorical DSM-IV 
boundaries. Multivariate structural equation models based on a large twin 
sample suggest that there are both genetic susceptibility factors that are 
shared between many anxiety disorders, and disorder-specific factors 
(Hettema et al., 2005). In this thesis work, we had the opportunity to 
examine both a pooled sample of many anxiety disorders, as well as some of 
the most common anxiety disorders separately. Most of the associations 
discovered were to specific anxiety disorder diagnoses rather than to the 
group of all anxiety disorders pooled, supporting the existence of disorder-
specific risk factors. This is somewhat surprising, as we clearly had the 
largest power to detect associations in the pooled sample. A likely 
explanation is that the “any anxiety disorder” group we used in the analyses 
was too phenotypically heterogeneous to be optimal for detection of 
susceptibility genes.  
It remains unresolved what the optimal way would be to pool different 
types of anxiety disorders together to obtain the larger sample sizes needed 
to identify genetic risk variants with small effects. When studying a complex 
phenotype, a compromise between too modest subgroup sample size and 
excess phenotypic heterogeneity is necessary. In this thesis, we tried to 
extend subgroup sample sizes by both pooling anxiety disorders based on 
symptom level similarity, and by using extended anxiety disorder definitions 
(e.g., including subjects with DSM-IV subthreshold diagnoses). Grouping 
disorders with phobic symptoms (social phobia, agoraphobia, phobia NOS) 
yielded the most significant observed association of the study, namely for 
GAD1. Symptom level classification might thus be a good option for future 
biological and genetic studies of anxiety disorders, as the diagnostic 
classifications were in fact primarily made for clinical grouping purposes. 
 On the other hand, we had hypothesized that DSM-IV subthreshold 
cases, showing some signs of anxiety symptoms but not sufficiently for a full 
diagnosis, share the same underlying genetic susceptibility to anxiety as core 
cases. In our data, it was clearly not universally true that inclusion of the 
subthreshold subjects made associations stronger. This could reflect the 
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blurry line between what is  considered “normal” and what “pathological” 
anxiety, and the difficulty of where to place a subject with a subtreshold 
diagnosis in that phenotypic spectrum. 
To summarize, both susceptibility gene identification attempts using 
clinical diagnosis entities of anxiety, as well as attempts using phenotypes 
that transcend DSM-IV boundaries, likely provide clues about the 
mechanisms underlying anxiety-like behavior.  
 
Implications due to inherent characteristics of the Health 2000 sample 
 
The discovery sample featured in all studies of this thesis, the Health 2000, 
has several characteristics that should be considered when interpreting the 
results. For instance, the study did not actively exclude individuals of foreign 
descent. This raises the question whether population stratification may be a 
source of spurious associations. We do not believe that this is the case, as the 
Finnish population in general is genetically homogeneous and only 2% of it 
was of foreign descent at the time of the study, and proficiency in Finnish 
was a prerequisite for a successful mental health interview.  
It is notable that the methodology of the Health 2000 was not designed to 
assess lifetime diagnoses of anxiety disorders, and we have therefore likely 
not identified subjects that are in remission. Likewise, we have missed 
subjects with OCD and PTSD diagnoses as these phenotypes were not 
assessed. Also, the fact that dropouts from the mental health interview had 
personality inventory scores indicating poorer psychosocial functioning 
suggests that some subjects with more severe forms of anxiety disorders may 
inadvertently have been excluded from the study. The consequence of all the 
exlusions above is likely reduced signal from true findings and therefore 
lower power to detect them. 
Finally, the availability of a measure of experienced childhood stress is 
one considerable asset of the Health 2000 sample. Its limitation is its self-
reported nature. It is possible that anxiety disorder subjects recall their 
childhood in a different light than healthy individuals, seeking an 
explanation for their symptoms. The large age range of the study subjects 
(30-87 years) also makes it possible that there is a cohort effect present in the 
sample. A further limitation is that some severe stressors, such as childhood 
abuse and parental death were not assessed. However, such traumatic events 
may represent strong individual triggers of anxiety disorders on their own. 
The events we did assess are relatively more mildly linked causally to the 
onset of anxiety disorders, and therefore perhaps even better suited for the 
analysis of additive effects in GxE interactions.   
In the following sections, I will focus on some of the more specific 
conclusions and implications that result from the data presented in this 
thesis. I will also highlight biological mechanisms that could explain how the 
identified susceptibility genes might influence anxiety. 
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6.2 A CROSS-SPECIES APPROACH FOR 
IDENTIFICATION OF ANXIETY-PREDISPOSING 
GENES 
Traditional selection of candidate genes for influencing a trait, which are 
then experimentally evaluated, is typically based on earlier linkage 
information and/or prior presumptions about the physiology and molecular 
biology that underlies the trait of interest. Although such selections are 
scientifically sound, and have lead to the identification of genetic variation 
relevant for disease susceptiblity, the limitation is that this may lead to an 
“information bottleneck” (Zhu and Zhao, 2007) that hampers understanding 
of the biology of the studied trait. This may be particularly relevant in 
psychiatric disorders, where the underlying molecular and genetic 
mechanisms are extremely complex in nature, and we acknowledge that our 
knowledge of them is incomplete. Based on prior assumptions, most 
candidate gene studies in anxiety disorders have examined genes involded in 
neurotransmitter metabolism and signaling, genes encoding proteins 
targeted by anxiolytics, and genes involved in stress response.  
With current technology, there are now ways to circumvent information 
bottlenecks. Global hypothesis-free approaches for the examination of whole 
genomes, transcriptomes, or proteomes in disease susceptibility have become 
available. Cross-species approaches using such methodological tools in 
animal models, and subsequently applying the gained knowledge to the study 
of human disease phenotypes may be particularly beneficial. The benefits of 
cross-species approaches here is that animal models provide access to 
sample material from the tissue most relevant for the disease for e.g. 
functional genomics studies. Moreover, a human complex trait such as 
anxiety is influenced by marked genetic and environmental heterogeneity. 
Both of these can be minimized when studying the trait in animals: genetic 
heterogeneity by using inbred animals that are genetic clones, and 
environmental exposures by equalizing conditions across animals. The main 
limitation of cross-species approaches is that the animal findings may not 
translate directly to the human disease due to the species difference. 
However, an evolutionarily strongly conserved phenotype, such as anxiety-
related behavior, for which pharmacologically validated animal paradigms 
also exist, may be particularly suitable for cross-species studies.  
 In study I of this thesis, we carried out an investigation in which 
candidate gene selection was based on a cross-species approach, unbiased by 
previous knowledge. Of 13 genes differentially expressed between anxious 
and non-anxious mice (Hovatta et al., 2005), six showed some evidence for 
association with anxiety disorders at P ≤ 0.01. These findings necessarily 
require replication in other independent samples to be appropriately 
evaluated, as our study is the first one to directly link the identified genes 
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(ALAD, CDH2, DYNLL2, EPB41L4A, PSAP and PTGDS) to anxiety 
phenotypes. Functionally, all of them can be imagined to be very important 
genes for proper functioning of the brain (Table 21, page 104). However, the 
most important consequence of study I has been to further narrow down the 
list of interesting candidate genes derived from a gene expression study in 
mice to a subset that may be most relevant for human anxiety. This will in 
the future lead to prioritization of the six top candidate genes  for functional 
studies that aim to unravel their mechanistic link to anxiety.  
Others have also taken advantage of a variety of cross-species approaches 
for the identification of anxiety candidate genes. There have been one human 
linkage study and a few association studies that have examined human 
chromosomal loci syntenic to murine QTLs for anxiety (Fullerton et al., 
2007; Smoller et al., 2001; Smoller et al., 2001). The linkage study provided 
suggestive evidence for linkage (LOD ≥ 1.9) with PD/agoraphobia or anxiety 
proness on 10q, 12q13 and 1q (Smoller et al., 2001). A family-based 
association analysis of behavioral inhibition examined four candidate genes 
(GAD2 [glutamate decarboxylase 2, the adenosine receptor encoding genes 
ADORA1 and ADORA2A, and PENK [preproenkephalin]),  selected based on 
murine QTL-data or functional evidence from mouse models with features of 
the phenotype (Smoller et al., 2001). The only gene that showed suggestive 
evidence for association (P = 0.05) was GAD2, a GABA synthesizing enzyme. 
However, the most promising candidate gene to have emerged from cross-
species approaches is RGS2, that was originally identified from a murine 
QTL for emotionality (Yalcin et al., 2004). The gene has now been associated 
with human PD, PTSD and behavioral inhibiton (Otowa et al., 2011; 
Amstadter et al., 2009; Smoller et al., 2008b). A genetic imaging study has 
demonstrated that a SNP in RGS2 has a strong effect on amygdala and 
insular cortex activation in response to emotional faces (Smoller et al., 
2008b), and studies addressing the functional link between anxiety and 
RGS2 are ongoing (e.g., Salim et al., 2011). 
Among other animal-model based approaches for identification of anxiety 
susceptibility factors are transcription profiling, proteomics and 
metabolomics experiments in mouse strains selectively bred for high- or low 
anxiety-related behavior. These have already resulted in the identification of 
several potential biomarkers for anxiety, with Glo1 expression and protein 
levels emerging as one prime candidate (Czibere et al., 2011; Filiou et al., 
2011; Hovatta et al., 2005; Krömer et al., 2005). So far, attempts to establish 
relevance for findings from these global profiles in human anxiety disorders 
have been limited. This should be one focus of future research, and in the 
present study we add to this field by reporting suggestive associations (0.01 < 
P < 0.05) between SNPs in GLO1 and “any anxiety disorder”.  
The availability of genome-wide genotype data and different types of 
global functional profiles are now spurring large-scale integrative approaches 
that combine animal and human datasets with the aim to identify the most 
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relevant genes and functional pathways for a trait. In anxiety disorders, three 
notable recent studies were carried out. 
The first study used a pharmacogenomic mouse model, in which global 
gene expression changes in response to treatment with an anxiogenic 
(yohimbine) or an anxiolytic (diazepam) drug where evaluated in anxiety-
regulating brain regions and in blood (Le-Niculescu et al., 2011). The new 
data was integrated with published human (association/linkage findings, 
expression evidence) and animal data (expression evidence, QTLs, data from 
transgenics) in a translational strategy for cross-matching and prioritizing 
findings. The identified top set of anxiety-relevant pathways included cAMP-, 
glucocorticoid receptor-, and CRH-signaling. Interestingly, PTGDS and 
DYNLL2, linked to anxiety by our human association findings and gene 
expression evidence, emerged among the top candidate genes. 
In another study, a systems biological approach was used to identify 
molecular pathways that are stably enriched in anxiety- and depression-
related phenotypes (Gormanns et al., 2011). For this purpose, the authors 
combined data from a large number of publicly available human and mouse 
phenomes and  transcriptomes, and reported that the most significantly 
dysregulated pathways in anxiety were related to carbohydrate metabolism, 
tight junction signaling and phosphatidylinositol signaling.  
Finally, a third recent study systematically combined genome-wide rodent 
and human data to select a set of candidate genes for association testing in a 
large human sample (Hettema et al., 2011). First, a GWA analysis was used to 
identify QTLs for fear-related behavior in heterogeneous stock mice. 
Findings were priority-ranked based on murine linkage and knockout 
studies, a meta-analysis of human linkage scans and a human GWA of 
anxiety. The top-ranked regions were finally examined in subjects with 
anxiety disorders, high neuroticism and MDD. Evidence for association was 
found in PPARGC1A (peroxisome proliferator-activated receptor gamma 
coactivator 1alpha), which plays a role in energy expenditure and 
neuroprotection. Ppargc1a-/- mice show GABAergic dysfunction, making the 
gene a promising novel candidate for modulating anxiety-related traits. 
To summarize, global hypothesis-free cross-species approaches can give 
important clues about regulatory pathways important for anxiety. The 
present study examined murine candidate genes, selected based on gene 
expression profiling in brain regions of inbred mouse strains, in a human 
sample. We implicated novel candidate genes for anxiety disorders beyond 
the usual suspect genes directly involved in neurotransmitter metabolism 
and signalling or stress response. Ours, and other studies, suggest that cross-
species approaches represent a potentially effective strategy to identify 
molecular pathways that influence a trait. 
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6.3 THE NEUROPEPTIDE S SYSTEM IN PANIC 
DISORDER 
Our interest in the genes of the neuropeptide S signaling system, NPS and 
NPSR1, arose due to the link between the G-protein coupled receptor NPSR1 
and asthma predisposition (Melen et al., 2005; Laitinen et al., 2004), 
accompanied by epidemiological comorbidity between asthma and anxiety 
(Roy-Byrne et al., 2008; Goodwin, 2003). As there was also rodent evidence 
that NPS, the 20 amino acid neuropeptide ligand of NPSR1, has a unique 
behavioral profile of inducing anxiolysis while increasing wakefulness and 
arousal (Xu et al., 2004), we aimed to examine whether the system 
represents a biological link between anxiety and asthma.   
We confirmed that asthma is comorbid with anxiety in adults of the 
Health 2000 sample, and children of the BAMSE study. Several explanations 
for such a comorbidity have been proposed, e.g., that increased anxiety is due 
to living with a chronic potentially life threatening condition like asthma, 
shared respiratory abnormalities, misinterpretation of asthma symptoms as 
panic attacks, shared genetic susceptibility, or anxiogenic effects of asthma 
medication (Goodwin et al., 2003). Agoraphobia was the only specific anxiety 
disorder that co-occurred with asthma in our study. A specific asthma-
agoraphobia link was previously seen in adolescents, and suggested to be due 
to fear conditioning by previous asthma episodes in a public place, or 
parental overprotection of a child with asthma (Katon et al., 2007). 
Unfortunately, no longitudinal data was available to us, and we could not 
assess whether asthma or agoraphobia was the primary diagnosis in our 
subjects. A bidirectional link between the two disorders could have given 
more support to the theory that they share some biological risk factors. 
The genetic part of our study supported the hypothesis that the NPS-
NPSR1 system could influence susceptibility to not only asthma, but also 
anxiety. Both NPSR1 and NPS associated with PD diagnosis, while NPSR1 
also associated with parent-reported anxiety/depression in children. It is 
particularly noteworthy that we unbiasedly set out to investigate several 
subtypes of anxiety disorders, and then observed the most significant 
findings with PD. First, NPSR1 is located under one of the few PD linkage 
peaks (7p14-15) seen in more than one sample (Crowe et al., 2001; Knowles 
et al., 1998). Second, of the anxiety disorders, PD is the one most frequently 
comorbid with asthma (Katon et al., 2004; Goodwin et al., 2003). PD and 
asthma also share symptoms related to respiratory function, such as 
sensations of choking or suffocation and shortness of breath caused by 
hyperventilation (Zaubler and Katon, 1996). Intriguingly, it was shown that 
NPS-signaling regulates respiration via a CNS-mediated pathway, as central 
NPS increased respiratory rate while decreasing tidal volume in mice (Zhu et 
al., 2011). Such changes are hallmarks of the fight-or-flight response and 
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could cause the sensations of shortness of breath seen in asthma- and panic 
attacks. However, the NPSR1 haplotypes that we found associated with PD 
were not the same ones that had been previously associated with asthma 
(Kormann et al., 2005; Melen et al., 2005; Laitinen et al., 2004), at least not 
in the part of the gene that had been examined in all studies. Therefore, we 
cannot directly conclude that asthma and anxiety share the same genetic 
susceptibility in a strict sense, although our results implicate a neuropeptide 
system that clearly could have biological relevance for both respiratory 
abnormalities and anxiety responses.  
In parallel with our work, there was rapid progress in characterizing the 
physiological and neurobiological functions of the NPS-system (Guerrini et 
al., 2010; Pape et al., 2010; Reinscheid, 2008). Although NPS administration 
also has other behavioral consequences, such as reward-like effects (Cao et 
al., 2011), enhanced long-term memory (Okamura et al., 2011), and 
decreased food- and ethanol intake (Badia-Elder et al., 2008; Smith et al., 
2006), a major role for it in fear processing is supported. Neuroanatomically, 
Nps and its only known receptor Npsr1 are expressed in brain regions 
relevant for anxiety (Xu et al., 2007; Xu et al., 2004). Neural circuitry 
responsible for NPS action was identified, demonstrating that NPS-signaling 
modulates afferent and intrinsic glutamatergic and GABAergic transmission 
in the amygdala (Jungling et al., 2008; Meis et al., 2008). Amygdalar NPS 
injections block fear-potentiated startle responses and accelerate fear 
extinction (Fendt et al., 2010; Jungling et al., 2008). NPS also stimulates 
HPA-axis activity, increasing ACTH and corticosterone levels (Smith et al., 
2006). Behavioral studies of Npsr1-/- mice have so far yielded inconsistent 
results, with mice on a 129S-background showing some signs of increased 
anxiety-like behavior (Duangdao et al., 2009), while mice on the C57BL/6 
background show little or no anxiety-related alterations (Fendt et al., 2011). 
We have thus far not evaluated the anxiety-like behavior of our genetically 
heterogeneous Npsr1-/- mice, but we found that they differ from wild types 
regarding the induction of two stress-related genes, Il1b and Ntf3. 
Upregulation of the cytokine IL1B after stress may reflect an increased 
proinflammatory response due to lack of protective NPS-NPSR1 signaling. 
Lack of induction of the neurotrophic factor NTF3 suggests that Npsr1-/- 
mice have reduced capability to maintain neuroplasticity and brain integrity 
under stress. A further important function of NPS signaling may thus be to 
activate molecular pathways that counteract stress-induced brain damage. 
A number of particularly exciting recent human genetic studies directly 
support the associations we observed between the NPS-NPSR1 system and 
PD. Much research was conducted on a functional SNP in NPSR1 (rs324981; 
A/T, Asn107Ile), of which the T-allele (Ile) increases NPSR1 expression and 
the sensitivity of the receptor for NPS by about 10-fold, leading to more 
active NPS-signaling (Bernier et al., 2006; Reinscheid et al., 2005). In a 
study concurrent with ours, the T-allele was associated with PD in two 
German case-control samples (Domschke et al., 2011). The same allele was 
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also associated with the dimensional trait anxiety sensitivity in patients. 
Healthy volunteers carrying the T-allele of rs324981 also evaluate their fear 
reactions to a conditioned stimulus predicting an electrical shock as stronger 
than A/A homozygotes (Raczka et al., 2010). We observed association 
between only one of three haplotypes carrying the T-allele and PD, whereas 
the variant did not show any evidence for association in pointwise analyses. 
A possible reason for this is that there may be other modulating variants in 
LD with rs324981 in the Finnish population that are also functionally 
important. 
Behavioral tests and functional magnetic resonance imaging (fMRI) 
studies are now also shedding light on how rs324981 could influence anxiety 
phenotypes. PD patients carrying the T-allele have increased heart rate and 
anxiety symptom intensity during a stressful behavioral avoidance test 
(Domschke et al., 2011). T-allele carriers also show decreased activation of 
cortical regions involved in cognitive processing of threat-related stimuli (the 
dorsolateral prefrontal, lateral orbitofrontal and anterior cingulate cortex), 
and increased responsiveness of the basolateral amygdala, during emotional 
processing of fearful faces (Dannlowski et al., 2011; Domschke et al., 2011). 
In addition, they have increased activation of the rostral dorsomedial 
prefrontal cortex (involved in conscious assessment of threat) in response to 
conditioned stimuli predicting pain (Raczka et al., 2010). Taken together, we 
are now beginning to understand the neurocircuitry and autonomous 
responses that are influenced by genetic variation in NPSR1.   
All of the above supports that genetic variation in the NPS-NPSR1 system 
could influence its function and PD susceptibility. These effects are likely 
mediated by hyperresponsiveness of the amygdala, overinterpretation and 
distorted processing of stimuli that predict threat, and increased autonomic 
arousal and HPA-axis activity (Figure 23). Individuals that are genetically 
susceptible to increased or more sensitive NPS-signaling may have an innate 
tendency for increased arousal, and for cognitively misinterpreting responses 
to arousing or aversive stimuli (e.g., shortness of breath, palpitations) or 
situations/places in which such symptoms have occurred, as predicting 
threat (Dannlowski et al., 2011; Domschke et al., 2011; Raczka et al., 2010). 
This may lead to a vicious cycle of anxious arousal that manifests as a panic 
attack in a susceptible individual. The theory that increased NPS-signaling is 
associated with PD might at first appear contradictory with the anxiolytic yet 
arousal-provoking effects of NPS administration in rodents (Xu et al., 2004). 
However, PD is to large extent thought to be caused by a state of increased 
arousal (Blechert et al., 2007a). High NPS levels early in development could 
have detrimental effects for shaping neuroendocrine responses and later 
anxiety predisposition, while a dose or increase of NPS later in life could 
primarily have beneficial anxiolytic effects (Dannlowski et al., 2011). Our 
data suggests that some of the NPSR1 SNPs most significantly associated 
with PD alter transcription factor binding and thereby possibly influence 
NPSR1 expression. Such alterations represent one further possible 
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mechanism for innately more active NPS-signaling, in addition to the 
functional Asn107Ile polymorphism described above. 
 
 
Figure 23 Hypothetical model of how genetic susceptibility to increased or more 
sensitive NPS-NPSR1 signaling could increase susceptibility to panic disorder. ACTH 
= adrenocorticotrophic hormone; CRH = corticotrophin-releasing hormone; HPA = 
hypothalamus-pituitary-adrenal; NPS = neuropeptide S; NPSR1 = neuropeptide S receptor 1 
In summary, we implicated the NPS system in predisposition to PD. 
Concurrent and subsequent studies have supported our findings, and a wide 
variety of functional evidence further suggests that NPS-NPSR1 signaling 
plays a role in mediating anxiety predisposition. The possibility of using 
theurapeutic agents that target the system in treatment of anxiety disorders 
should be explored. Several synthetic antagonists of NPSR1 were already 
identified (Dal Ben et al., 2011). In rats, intranasal application of NPS has 
anxiolytic effects, and such a mode of application of the peptide could be 
feasible also in humans (Lukas and Neumann, 2012). However, at least two 
major problems need to be addressed first: 1) Given the widespread functions 
of the NPS-NPSR1 system, one would except a range of undesired side effects 
related to e.g. increased autonomic and behavioral arousal or apetite; 2) NPS 
could be a potent anxiolytic in subjects without a history of pathological 
anxiety, but would NPS administration actually rather trigger panic attacks 
by increasing arousal in sensitized PD patients? 
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6.4 REPLICATION OF GLUTAMATE DECARBOXYLASE 
1 FINDINGS IN THE FINNISH POPULATION 
In study III, we examined 15 putative susceptibility genes for anxiety, 
selected based on some of the most relevant findings from human samples, 
for association to anxiety disorders in the Finnish population. The only gene 
that showed evidence for association with P ≤ 0.01 was GAD1 in the analysis 
of phobias (social phobia, agoraphobia and phobia NOS). One specific locus-
spanning GAD1 risk haplotype (out of six common haplotypes present in the 
population) increased risk for phobias by about 1.3-fold. Interestingly, the 
same haplotype was previously associated with genetic susceptibility shared 
by anxiety disorders, MD and neuroticism in an American sample from 
Virginia (Hettema et al., 2006); VATSPSUD. Of the specific anxiety disorder 
diagnoses in the VATSPSUD, the haplotype showed suggestive association 
with agoraphobia, supporting our observations in subjects with phobias. 
Although our finding cannot be considered as a replication by its strictest 
definition (same allele, same phenotype) as similar phenotype measurements 
were not available for the Health 2000 and VATSPSUD, we provide the first 
independent support for GAD1 as a susceptibility gene for anxiety disorders. 
The fact that the same haplotype has now been associated with anxiety in two 
samples supports that it has true biological relevance. 
By combining effects observed in the Finnish and American samples with 
a meta-analytic approach, we showed that the GAD1 risk haplotype also 
associated with a broad phenotype reflecting shared genetic susceptibility 
across internalizing disorders and neuroticism. The subjects included in the 
broad phenotype had PD, GAD, social phobia, agoraphobia, MDD (in the 
Health 2000 only as comorbid with anxiety disorders), neuroticism (assessed 
only in the VATSPSUD) and phobia NOS (assessed only in Health 2000). 
Thus, although GAD1 may particularly strongly modulate susceptibility to 
phobias, an observable effect remained when considering anxiety and mood 
phenotypes as a whole. Therefore, GAD1 might be an example of a risk factor 
that is shared by multiple psychiatric disorders and anxious personality (see 
Figure 5, page 36). This would not be surprising, given the widespread and 
important role of the enzyme encoded by the gene in the CNS. 
The GAD enzyme synthesizes GABA from glutamate, and is essential for 
the balance between the main excitatory neurotransmitter (glutamate) and 
the main inhibitory neurotransmitter (GABA) of the CNS. In general, there is 
a large body of evidence supporting a role for GABAergic neurotransmission 
in modulation of anxiety. Boosting GABA-signaling with agonists of the 
GABAA-receptor (such as benzodiazepines) has anxiolytic effects, while 
attenuating it with inverse agonists (such as FG7142) has anxiogenic effects 
(Durant et al., 2010). Reduced GABA levels were seen in at least some brain 
regions of PD and social phobia patients (Pollack et al., 2008; Chang et al., 
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2003). In social phobia, these levels were normalized after pharmacological 
treatment (Pollack et al., 2008). It was proposed that a disturbance in GABA 
metabolism is present in PD, and that it may be a consequence of GAD 
enzyme dysfunction (Goddard et al., 2004).  
 The two isoforms of the GAD enzyme, GAD67 and GAD65, are encoded 
by two separate genes (GAD1 and GAD2, respectively). GAD67 is found 
throughout neurons while GAD65 is mainly found in axon terminals 
(Kaufman et al., 1991). GAD67 produces more than 90% of the basal GABA 
(Kash et al., 1999), but there are some brain-region specific differences in the 
relative expression of the isoforms (Feldblum et al., 1993). Gad1-/- mice have 
not been behaviorally studied, as they die after birth due to cleft palate 
(Asada et al., 1997), but Gad2-/- mice show increased anxiety-like behavior 
and reduced response to anxiolytics (diazepam and pentobarbital) that 
facilitate GABAergic neurotransmission (Kash et al., 1999). They also show 
impairments in threat estimation, fear memory consolidation and fear 
extinction (Sangha et al., 2009; Bergado-Acosta et al., 2008; Stork et al., 
2003). Mice selectively bred for high anxiety-like behavior have increased 
amygdalar Gad1 mRNA and protein levels, reflecting an attempt to boost 
GABA release in compensation for the high anxiety state (Tasan et al., 2011). 
Less maternal care during early development increases methylation of the 
Gad1 promoter in the rat hippocampus, reducing its expression (Zhang et al., 
2010). This indicates that environmental factors can have an impact on the 
development of the GABA system. 
In humans, subjects with neuroticism or mood disorders show decreased 
plasma GAD activity (Kaiya et al., 1982). Reduced expression of GAD1 is one 
of the more solid findings in post-mortem brain studies of schizophrenia 
patients (Torrey et al., 2005). Candidate gene studies have tested variants in 
GAD1 for association to a range of psychiatric disorders, such as autism, 
bipolar disorder, depression and schizophrenia. The most solid findings are 
from studies examining schizophrenia-related phenotypes in three 
independent family-based samples (Straub et al., 2007; Addington et al., 
2005). In those studies, allelic variation in GAD1 also associated with 
cognitive measures and cortical grey matter volume loss in schizophrenia 
patients, and with activation of the prefrontal cortex during a working 
memory task in healthy individuals. Unfortunately, direct comparisons 
between our findings and these previously published ones are difficult to 
make as not all of the same SNPs were genotyped.  
As we observed the strongest associations between phobias and GAD1 in 
the Health 2000 sample, it is interesting to note an observation from a 
neurological disorder called stiff-person syndrome (SPS) that supports this 
link. SPS is characterized by autoantibodies against the GAD enzyme, which 
results in reduced levels of GABA in the brain and cerebrospinal fluid (Ameli 
et al., 2005; Henningsen and Meinck, 2003). Patients with SPS have phobias 
as a frequent non-motor symptom, to the extent that subjects are often 
misdiagnosed with a primary psychiatric disorder such as agoraphobia. 
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Human autoantibodies against GAD also induce anxiogenic-like behavior 
when passively transferred into rats (Geis et al., 2011). 
To summarize, one attractive hypothesis is that genetic variation reducing 
GAD1 activity may have profound effects on neurotransmission by reduction 
of GABA levels (Figure 24). Future studies should experimentally address 
whether the GAD1 risk haplotype now identified in two independent samples 
is associated with decreased GAD activity in plasma or post-mortem brain. It 
should be evaluated whether such a change is accompanied by altered GABA 
levels, as reduced GABAergic neurotransmission is one hallmark of anxiety 
disorders and other psychiatric diseases. Targeting of GABAergic 
metabolism, combined with better knowledge of GABAA receptor function, 
are important research fields within the development of novel anxiolytics 
(Durant et al., 2010; Uusi-Oukari and Korpi, 2010; Pillay and Stein, 2007). 
 
 
Figure 24 Hypothetical model for involvement of GAD1 in neuropsychiatric disorders. 
Decreased GAD1 activity, caused by a number of potential factors, could reduce GABA 
levels. Alterations of GABAergic neurotransmission, in combination with other genetic and 
environmental modulatory factors, could have widespread effects in the brain. Such effects 
manifest as a variety of behavioral changes that are hallmarks of specific psychiatric 
disorders. GAD1 could therefore be involved in partially determining predisposition to a wide 
spectrum of more or less severe psychiatric disorders or influence personality. Figure based 
on references cited in the text and (Leppä et al., 2011; Stork et al., 2000). GABA = γ-
aminobutyric acid; GAD1 = glutamate decarboxylase 1.  
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6.5 INTERACTION OF NEUROPEPTIDE Y WITH THE 
ENVIRONMENT IN MODULATING RISK FOR 
ANXIETY DISORDERS 
We turned our attention to GxE interactions in attempt to gain better 
understanding of the joint effects of environmental and genetic factors on 
anxiety disorder susceptibility. More specifically, we explored whether any of 
the SNPs genotyped in the Health 2000 sample modulated anxiety disorder 
onset in interaction with childhood adversities. We had a particularly good 
prior justification for such analyses, as stressful events early in life are 
acknowledged to be some of the strongest known environmental risk factors 
for later anxiety disorders (Green et al., 2010). In particular, adversities of 
the so-called maladaptive family functioning cluster (parental mental illness, 
substance abuse disorder, criminality, violence, physical/sexual abuse and 
neglect) are strong predictors of anxiety disorders. Examinations of possible 
interactions between such well established and strong environmental risk 
factors and genetic variants may shed light on why some individuals are 
more stress resilient than others.  
Of all the SNPs examined in the Health 2000 sample, the only ones 
robustly showing evidence for GxE interaction effects with childhood 
adversities in modulating anxiety disorder susceptibility were from the NPY 
gene. The effects could further be attributed to two phylogenetically related 
risk haplotypes spanning the whole gene locus. In general, the analyses were 
complicated by the limited subgroup sample size that resulted from 
partitioning the sample by both the number of experienced childhood 
adversities and SNP genotype. Some potential effects of SNPs with low MAFs 
may therefore have remained undiscovered, and much larger sample sizes 
would be needed for their reliable assessment. 
Nevertheless, it is particularly interesting that NPY was identified as the 
most promising candidate gene for GxE effects out of all the ones examined. 
NPY is a highly evolutionarily conserved 36-amino acid neuropeptide and 
one of the most abundant peptides of the CNS. It is involved in regulation of 
a wide variety of processes, such as stress response and stress resilience, 
emotional homeostasis, cognitive processes, food- and ethanol intake, energy 
balance, sleep regulation, inflammatory processes, tissue growth and 
remodelling, and sexual behavior (Wu et al., 2011; Thorsell, 2008; Eaton et 
al., 2007). NPY-signaling is mainly anxiolytic and counteracts physiological, 
cellular, and behavioral effects of stress-promoting signals. Accordingly, 
higher NPY levels are associated with stress-resilience in both rodents and 
humans (Morgan et al., 2002; Thorsell et al., 2000). In mammals, five G-
protein coupled receptors for NPY have been identified (Y1, Y2, Y4, Y5 and 
y6), and their signaling inhibits cAMP synthesis via inhibitory G-proteins 
(Wu et al., 2011; Berglund et al., 2003). The Y5 receptor was specifically 
suggested to be responsible for an anxiety disorder linkage peak on 4q31-34 
(Domschke et al., 2008; Kaabi et al., 2006) 
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There is evidence from both animal and human studies suggesting that 
NPY, and genetic variation in it, modulates the effects of environmental 
stress on anxiety proneness. Transgenic rats overexpressing Npy performed 
similarly to controls in the elevated plus maze under baseline conditions, but 
lacked the anxiogenic response seen in wild types when the test was preceded 
by restraint stress (Thorsell et al., 2000). Of macaques exposed to social 
separation stress, carriers of a specific NPY promoter variant had lower CSF 
NPY levels, but higher arousal and alcohol consumption upon later stress 
(Lindell et al., 2010). In humans, haplotypes of NPY predict its mRNA levels 
in lymphoblasts and in post-mortem cerebellum, and plasma NPY levels 
(Zhou et al., 2008). Furthermore, lower NPY expression predicted higher 
emotion-induced activation of the amygdala, and reduced stress resilience. 
The same study reported that one promoter SNP (rs16147) accounted for a 
considerable proportion of the expression differences between different NPY 
haplotypes.  
The functional rs16147 SNP was later examined for GxE interaction 
effects, and shown to interact with childhood adversities in influencing 
symptoms of anxiety and depression (Sommer et al., 2010). It also 
modulated risk for GAD in interaction with exposure to a natural disaster 
(hurricanes; Amstadter et al., 2010). Although both of the mentioned human 
GxE studies support involvement of NPY variation in determining stress 
resilience in interaction with the enviroment, they reported different risk 
genotypes (C/C in the former, vs. T/T in the latter study). The SNP also 
influences HPA-axis responsiveness to acute psychosocial stress, with T/T 
carriers exposed to high early childhood adversity showing the lowest ACTH 
and cortisol stress responses (Witt et al., 2011). 
There are discrepancies regarding which of the alleles of rs16147, C or T, 
is associated with higher expression and protein levels of NPY, with most 
studies supporting that the C-allele is the high expressing one (Sommer et al., 
2010; Shah et al., 2009; Zhou et al., 2008; Buckland et al., 2005; Itokawa et 
al., 2003). This has raised the question whether rs16147 is the actual causal 
variant, or simply in varying degree of LD with other functional variants. In 
our examination, we found no evidence of GxE effects for rs16147, but the 
risk haplotypes we observed carried its T-allele. The most likely scenario is 
that other genetic variation besides rs16147 influences NPY levels, and we 
suggest that only a subset of the T-allele carrying haplotypes confer increased 
risk for anxiety disorders in the Finnish population. Based on the majority of 
reports, they might be accompanied by reduced NPY expression and protein 
levels. Such a finding would be consistent with the decreased 
brain/CSF/plasma NPY levels observed in subjects with PTSD, depression, 
bipolar disorder and suicide victims (Wu et al., 2011). Genetic predisposition 
to reduced NPY levels offers one explanation for the reduced stress resilience 
(assessed by us as predisposition for any anxiety disorder under conditions of 
high early life stress) we observed in subjects with specific risk haplotypes 
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spanning the NPY locus. A hypothetical link between NPY levels and stress 
resilience is illustrated in Figure 25. 
In summary, our findings provide further support that genetic variation in 
NPY, a neuropeptide system crucial for regulation of stress responses, 
modulates stress resilience in interaction with environmental factors. 
Knowledge of such effects is particularly important for understanding why 
some individuals get an anxiety disorder, while others do not, even under 
stressful life conditions. Targeting of the NPY system might offer a novel 
means of treatment for anxiety, mood- and stress-related disorders. 
Investigations of the effects of intranasal NPY administration in humans are 
underway, with no apparent reported side effects, but also no clear evidence 
yet that it enters the brain (Wu et al., 2011; Lacroix et al., 1996). 
 
 
 
Figure 25 A hypothetical link between neuropeptide Y (NPY) and stress resilience. 
Normally, NPY is upregulated in response to stress to counteract the stress-promoting 
effects of increased CRH (corticotrophin-releasing hormone) release and restore emotional 
homeostasis. On a behavioral level, this terminates the stress response. Higher NPY levels 
are consequently associated with better coping under stress. Conversely, innately reduced 
NPY levels could be associated with impaired downregulation of neuroendocrine stress 
responses, and increased risk for anxiety disorders. Programming of neuroendocrine stress 
responses during early development influences later stress-responsiveness. ACTH = 
adrenocorticotropic hormone. 
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7 CONCLUDING REMARKS AND FUTURE 
PROSPECTS 
The field of human genetics has moved forward with tremendous pace since 
it was proclaimed that the human genome sequence had been completed. We 
are living in an era of genomics where the main focus is shifting from first 
understanding the structure of genomes to understanding the biology of 
genomes, and finally to understanding the biology of disease (Green et al., 
2011). There is hope that genomics will live up to its great expections in years 
to come by advancing the field of medicine and improving healthcare. 
Routine analysis of the whole genome of any individual will become 
commonplace soon – but are we ready to understand what the output is 
telling us? Thorough understanding of the biology of a trait will require 
adding additional layers of information to the genome sequence data, such as 
understanding of the regulatory mechanisms of genes (e.g., epigenetic 
mechanisms, post-transcriptional regulation by non-coding RNAs and 
alternative splicing of mRNAs), gene x gene and gene x environment 
interactions, and protein interactions. Technical developments within the 
large-scale “omic” -methods such as as transcriptomics, proteomics and 
metabolomics are now making such integrative approaches to understanding 
human disease-related biological pathways possible. Next-generation 
sequencing based methods will play an important role in the following years 
for not only sequencing of genomes, but also for analyzing quantitatively 
global profiles of mRNA and non-coding RNA expression. 
 Again, the field of genetic mapping of human disease genes is finding 
itself in a transition between current “trendy” methodological approaches 
(GWA => exome sequencing => whole-genome sequencing). Such shifts are 
inevitable, driven by curiosity and desire to improve human quality of life, 
and fueled by technical progress. However, with each new wave of studies 
performed using the concurrent “trendy” genetic mapping method, we have 
had to revise at least some of our basic hypothesis for explaning disease 
susceptibility. The present study was conducted during a time period that 
witnessed the research community rush into the era of GWA studies with 
great enthusiasm, as they became technically and economically feasible. We 
also witnessed many researchers, most of them psychiatric geneticists, 
disembark from their GWA project with considerably less enthusiasm than 
when it started. It became evident that the Finnish anxiety disorder sample 
that this thesis is based on would not be nearly large enough to genome-wide 
significantly detect the small effects now thought to be conferred by each of 
the hundreds or thousands of genetic variants that collectively influence 
susceptibility to a trait as complex as anxiety. Is there then a place for small 
candidate gene studies in this era of large hypothesis-free genome-wide 
studies and omics? 
Concluding remarks and future prospects 
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First, one main significance of this work has been to demonstrate that a 
focused human candidate gene study can at least be used to refine the 
information provided by one global hypothesis-free approach, namely gene 
expression profiling in mice. This combined approach lead to the 
identification of potential novel biological pathways that might not otherwise 
have received attention in concurrent anxiety research.  
Second, by forming a hypothesis about a neuropeptide system (NPS-
NPSR1) that could influence both susceptibility to asthma and anxiety, we 
discovered an intriguing biological link between PD and respiratory 
phenotypes. Later functional studies focusing on genes of the same system 
have been crucial for supporting our findings, and understanding the 
mechanisms involved.  
Third, by a candidate gene replication finding, we support involvement of 
the GAD1 gene in anxiety susceptibility. Solid candidate gene findings are 
scarce in anxiety disorders, and any findings that help to identify the most 
relevant susceptibility genes are valuable in that they provide important clues 
about disease etiology about what the focus of research into novel therapeutic 
agents could be. 
Fourth, with a candidate gene finding in the NPY, we highlight the 
importance of understanding GxE interactions in susceptibility to psychiatric 
disorders. Demonstrating that such effects are indeed present, and disease-
relevant, is an important step in explaining the “missing heritability” 
(Manolio et al., 2009) of complex diseases that remains unresolved by GWA 
studies, and that is particularly pronounced in mental disorders. 
Thus, well-justified and well-designed candidate gene studies in 
comprehensively characterized samples, combined with functional 
experiments, should perhaps not yet be drowned in the omic sea. However, 
the genetic risk variants that were identified in this study conform to the 
same discussion as many of the results of the GWA studies performed to 
date: Will there be a clinical utility, when it comes to prediction of disease 
risk and treatment response, for risk variants with modest or small effect 
sizes?  Will the novel knowledge about the biological mechanisms that they 
provide result in development of novel medications? Hopefully, future 
studies focusing on the top candidate genes identified in this study will help 
answer these questions. 
Current research on the genetics of anxiety disorders should flourish, as 
all the ingredients are there: heritability, better knowledge of  neurocircuitry 
and the molecular basis than in many other psychiatric phenotypes, well-
validated animal models for discovery and validation of candidate genes, and 
an enormous importance for public health (Smoller, 2011). However, 
problems encountered include difficulties in drawing the line between 
normal and pathological anxiety, fuzzy boundaries between the anxiety 
disorders, combined with large genetic heterogeneity. Therefore, genetic 
studies in anxiety have been relatively scarce and a “fear of anxiety genetics” 
has prevailed (Smoller, 2011). The good news is that there is a light in sight. 
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The field is starting to bring anxiety research to the level of other major 
psychiatric disorders, making use of a variety of innovative approaches and 
methodologies.  
In the future, exome and eventually genome-wide sequence data, will 
enable assessment of rare variants also in susceptibility to anxiety disorders. 
Anxiety disorders may be relatively more strongly influenced by 
environmental factors and early life experiences that modulate development 
of neural pathways than many other psychiatric disorders. Thus, stressful or 
traumatic life events likely have profound effects on later stress resilience 
and fear responses. I therefore envision that large-scale epigenetic studies 
and gene expression profiles, combined with attempts to understand GxE 
interactions will play a key role in explaining mechanisms behind anxiety 
susceptibility. Imaging genetics will continue to be important for 
understanding how sequence variation modulates brain function on a neural 
circuit level. Moreover, induced pluripotent stem cell technologies will enable 
human patient cell lines of the most relevant type for molecular studies. 
Sequence-based profiles of mRNA and miRNA transcription, and more 
efficient proteomics approaches should be pursued to obtain the most 
comprehensive view yet of regulatory networks and biological pathways 
relevant for anxiety. This will be a rich and crucial source of information for 
drug development.  
Exciting times lay ahead for geneticists and anxiety researchers. It is my 
hope that the work presented in this thesis will have some part in the 
transition taking anxiety research to the next level, eventually leading to 
improved treatment of pathological anxiety.  
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